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Background: There has been no randomised controlled trial (RCT) of fluid bolus therapy in paediatric
sepsis in the developed world despite evidence that excess fluid may be associated with harm.
Objectives: To determine the feasibility of the Fluids in Shock (FiSh) trial – a RCT comparing restricted fluid
bolus (10 ml/kg) with current practice (20 ml/kg) in children with septic shock in the UK.
Design: (1) Qualitative feasibility study exploring parents’ views about the pilot RCT. (2) Pilot RCT over a
9-month period, including integrated parental and staff perspectives study.
Setting: (1) Recruitment took place across four NHS hospitals in England and on social media. (2) Recruitment
took place across 13 NHS hospitals in England.
Participants: (1) Parents of children admitted to a UK hospital with presumed septic shock in the previous
3 years. (2) Children presenting to an emergency department with clinical suspicion of infection and shock
after 20 ml/kg of fluid. Exclusion criteria were receipt of > 20 ml/kg of fluid, conditions requiring fluid
restriction and the patient not for full active treatment (i.e. palliative care plan in place). Site staff and
parents of children in the pilot were recruited to the perspectives study.
Interventions: (1) None. (2) Children were randomly allocated (1 : 1) to 10- or 20-ml/kg fluid boluses
every 15 minutes for 4 hours if in shock.
Main outcome measures: (1) Acceptability of FiSh trial, proposed consent model and potential outcome
measures. (2) Outcomes were based on progression criteria, including recruitment and retention rates,
protocol adherence and separation between the groups, and collection and distribution of potential
outcome measures.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
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v
ABSTRACT
viResults: (1) Twenty-one parents were interviewed. All would have consented for the pilot study.
(2) Seventy-five children were randomised, 40 to the 10-ml/kg fluid bolus group and 35 to the 20-ml/kg
fluid bolus group. Two children were withdrawn. Although the anticipated recruitment rate was achieved,
there was variability across the sites. Fifty-nine per cent of children in the 10-ml/kg fluid bolus group and
74% in the 20-ml/kg fluid bolus group required only a single trial bolus before shock resolved. The volume
of fluid (in ml/kg) was 35% lower in the first hour and 44% lower over the 4-hour period in the 10-ml/kg
fluid bolus group. Fluid boluses were delivered per protocol (volume and timing) for 79% of participants
in the 10-ml/kg fluid bolus group and for 55% in the 20-ml/kg fluid bolus group, mainly as a result of
delivery not being completed within 15 minutes. There were no deaths. Length of hospital stay, paediatric
intensive care unit (PICU) transfers, and days alive and PICU free did not differ significantly between the
groups. Two adverse events were reported in each group. A questionnaire was completed by 45 parents,
20 families and seven staff were interviewed and 20 staff participated in focus groups. Although a
minority of site staff lacked equipoise in favour of more restricted boluses, all supported the trial.
Conclusions: Even though a successful feasibility and pilot RCT were conducted, participants were not as
unwell as expected. A larger trial is not feasible in its current design in the UK.
Future work: Further observational work is required to determine the epidemiology of severe childhood
infection in the UK in the postvaccine era.
Trial registration: Current Controlled Trials ISRCTN15244462.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 51.
See the NIHR Journals Library website for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 51Plain English summary
Usual treatment when a child arrives at a hospital emergency department with a severe infection andshock is to give liberal amounts of fluid via an injection into a vein (fluid bolus therapy). However, this
is based on weak evidence. A group of doctors and researchers came together and proposed the Fluids in
Shock (FiSh) trial, which aimed to find out whether or not giving less fluid is beneficial.
Before a large trial is carried out, it is important to answer the question, ‘can this trial be done?’. The FiSh
feasibility study aimed to do this. First, we conducted an interview study asking parents for their views on
the proposed trial and the acceptability of research without prior consent (RWPC), that is, delaying the
research discussion and consent seeking until after their child has been given emergency trial treatments –
an approach that has been used successfully in previous studies. Second, we conducted a pilot trial
(a small version of the FiSh trial) to test important factors, such as number of children recruited and if
doctors and nurses followed the trial protocol properly. Hospital staff and parents of children who
participated in the pilot were interviewed for feedback.
In the initial interview study, the 21 parents interviewed supported both the FiSh trial and the use of
RWPC. In the pilot trial, 75 children were recruited from 13 hospitals in England. Children were randomly
allocated to receive either liberal (currently recommended volume) or smaller fluid boluses. Recruitment
was close to the expected level (one patient per hospital per month) and hospitals usually gave the correct
volume of fluid in each group. However, participants were a lot less sick than expected, with only a
minority needing intensive care and most requiring only one fluid bolus to show improvement. Overall,
parents and hospital staff supported the study.
Even though both the interview study and pilot trial were carried out successfully, because the children
recruited were not as unwell as expected, the trial, as currently designed, is not feasible.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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Fluid bolus therapy is integral to the management of children presenting to NHS hospitals with septic
shock. Current guidelines recommend boluses of 20 ml/kg. However, this recommendation is based on
weak evidence from small observational studies. In Africa, a recent large multicentre randomised controlled
trial (RCT), Fluid Expansion as Supportive Therapy (FEAST) (Maitland K, Kiguli S, Opoka RO, Engoru C,
Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus in African children with severe infection.
N Engl J Med 2011;364:2483–95), compared fluid bolus resuscitation of 20 ml/kg with maintenance fluid
in > 3000 children with severe infection. The FEAST trial showed a 35% increase in mortality associated
with fluid bolus. Although conducted in a low-income setting with limited resources, the FEAST trial
raised uncertainty and highlighted the lack of evidence in higher-income settings. No trials to date have
investigated fluid bolus volumes given to children in a high-income setting.
To address this problem, we developed the Fluids in Shock (FiSh) trial. This was a RCT that aimed to
evaluate whether or not a restrictive strategy (fluid bolus volume of 10 ml/kg), compared with the current
recommended strategy (fluid bolus volume of 20 ml/kg), is associated with improved outcomes for children
presenting to UK emergency departments (EDs) with presumed septic shock. We conducted a combined
feasibility and external pilot RCT to determine if a large-scale trial would be feasible.
Objectives
Feasibility study
1. To provide evidence of the willingness of clinicians to participate and the sign-up of sites.
2. To review and explore, with input from parents/legal representatives, acceptability, potential barriers,
information/documentation, decision-making and research without prior consent (RWPC).
3. To review and explore, with input from parents/legal representatives, the potential, patient-centred
primary and important secondary outcome measures.
External pilot trial
1. To test the willingness of clinicians to screen, recruit and randomise eligible patients.
2. To estimate recruitment rate.
3. To test, following randomisation, the delivery of and adherence to the intervention and demonstrate
separation between the groups.
4. To test the acceptability of the deferred consenting procedures and documentation.
5. To test follow-up for identified, potential, patient-centred primary and other important secondary
outcome measures and for adverse event (AE) reporting.
6. To inform the final selection of a patient-centred primary outcome measure.
7. To estimate the characteristics of the selected patient-centred primary outcome measure to inform
sample size estimation.
8. To inform the content and time needed for final data collection.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
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Methods
Study design
This was a qualitative semistructured interview study, seeking the views of parents/legal representatives
with experience, in the previous 3 years, of a child with severe infection requiring hospital admission.
Design and development of the protocol
The protocol, sample size, recruitment strategy, draft trial documentation and interview topic guide were
informed by our previous research.
Recruitment
It was anticipated that 15–25 parents/legal representatives would be recruited. Parents or legal
representatives with a child presenting to an ED or admitted to a paediatric intensive care unit (PICU)
with severe infection within the previous 3 years were eligible to take part, unless they were unable to
speak and read English. Several recruitment strategies were employed: postal contact and posters
advertising the study in PICUs in four participating hospitals, and social media.
Interviews
Informed consent was taken. Interviews aimed for data saturation, that is, the point at which no new major
themes are discovered in analysis. No further interviews were conducted once data saturation was reached.
Data analysis
Analysis was interpretative and iterative and informed by the constant comparative approach. NVivo 10
(QSR International, Warrington, UK) was used to code data.
Results
Of the 58 parents who registered interest, 29 were screened. Three were deemed ineligible and five did
not confirm an interview date. Data saturation was reached when 21 parents had been interviewed.
Seventeen parents were recruited via social media, four by post and none via advertising in PICUs.
The sample included 18 mothers (five bereaved) and three fathers (two bereaved).
The trial in general
Overall, parents supported RWPC and the FiSh trial. Some parents were concerned that a change from
current practice might jeopardise their child’s chances of survival. In response, recommendations were made
for tailored verbal explanations to be made by site staff and for adjustments to the participant information
sheet (PIS).
When to ask for consent
Parents suggested that consent should occur after stabilisation of their child’s condition. The majority of
bereaved parents supported contact via post.
Outcomes of importance to parents
Parents prioritised the following outcomes: (1) long-term morbidity, (2) looking and behaving more
normally, (3) organ/physiological functioning, (4) time spent on treatments and machines and (5) survival.
Bereaved parents found it difficult to consider outcome measures other than survival.
Conclusions
Overall, the feasibility study findings suggested that parents whose child had experienced severe infection
supported the FiSh trial. Some specific concerns and misunderstandings were revealed. These findings were
used to develop the pilot trial documentation, the site staff training package and guidance on consent.
Parents’ views on outcomes were incorporated into potential outcome measures collected in the pilot trial.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Methods: pilot randomised controlled trial
Study design
Pragmatic, open, multicentre individual RCT.
Sites
Sites were set up in a ‘hub-and-spoke’ model in three regions: (1) Bristol, (2) London (North Thames) and
(3) Southampton. The ‘hubs’ were four regional hospitals with integral PICUs (two hospitals covered the
same region), three of which also had an integrated ED. The ‘spokes’ were nine hospitals that had an ED
but not a PICU.
Recruitment
Inclusion criterial
l
l
l
l
l
l
l
l
l
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Park,Aged ≥ 37 weeks (corrected gestational age) and < 16 years.
Clinical suspicion of infection.
Clinical signs of shock [defined as age-adjusted hypotension or prolonged capillary refill time (CRT) of
≥ 3 seconds] after receipt of 20 ml/kg of fluid bolus.
Recruitment and randomisation to take place while child is in an acute assessment area (e.g. paediatric
assessment unit or ED).Exclusion criteriaPrior receipt of > 20 ml/kg of fluid bolus.
Conditions in which fluid bolus resuscitation should be curtailed.
Full active resuscitation not within current goals of care.Randomisation, allocation, intervention and consent
Eligible children were randomised using sealed envelopes and allocated 1 : 1 to either 10-ml/kg or 20-ml/kg
fluid bolus resuscitation over a 4-hour period. The period was divided up into 15-minute cycles and one
bolus was delivered per cycle. At the end of each cycle, if signs of shock were present, then another bolus
of the allocated volume was given within a cycle. Cycles were repeated until either the end of the 4-hour
period or any of the hold criteria occurred (resolution of shock or signs of fluid overload). If hold criteria
were present, the delivery of further fluid boluses was withheld. If, within the 4-hour resuscitation period,
hold criteria were no longer present, then cycles were recommenced with the allocated fluid bolus volume.
After 4 hours, further treatment was at clinical discretion.
The maximum volume of fluid within the pilot protocol was 120 ml/kg (excluding the 20-ml/kg fluid bolus
pre randomisation). If > 120 ml/kg of fluid was required, then further treatment was at clinical discretion.
A member of the site research team approached parents/legal representatives as soon as appropriate after
randomisation to take consent.
The combined objectives were to test whether or not all of the processes worked together, and to inform
the design and ensure the successful conduct of the FiSh trial (should this be the recommendation).
Objectives 1, 2 and 4 were measured by the:proportion of eligible children recruited
number of children recruited per site per month
proportion of parents/legal representatives refusing consent.een’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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xxivObjective 3 was measured by the:l
l
l
l
l
l
l
NIHRproportion of fluid boluses delivered at the correct volume and time during the intervention period
total volume of fluid received during the intervention period in each treatment group.Objectives 5–8 were measured by the:proportion of complete data for each outcome measure
characteristics of potential outcome measures
observed AEs
time taken for data collection and entry
proportion of required data that could be linked to routine sources.Data collection
A secure, dedicated electronic case report form (eCRF) was set up for trial data, which were to be entered
by site staff. Inclusion criteria, baseline characteristics, intervention, physiology and location of care data to
the point of hospital discharge were collected by the sites. Death at 30 days was determined by linking the
eCRF data with data from the NHS Spine web portal. For children admitted to a PICU, daily intervention
data (mechanical ventilation, PICU length of stay, PICU mortality) were obtained via linkage with the
Paediatric Intensive Care Audit Network (PICANet), the national clinical audit for paediatric intensive care.
Sample size
Based on available data, it was anticipated that the 12 EDs would recruit approximately one child per
month, that is, around 108 children over 9 months.
Statistical analysis
Statistical analyses were based on the intention-to-treat principle. All tests used were two-sided with
significance levels set at a p-value of < 0.05 and with no adjustment for multiplicity. The final analyses
were conducted using Stata/SETM version 14.0 (StataCorp LP, College Station, TX, USA).
Methods: integrated perspectives study
Study design
The integrated qualitative perspectives study comprised questionnaires and interviews with parents/legal
representatives, and focus groups and interviews with site staff. The aim was to explore the experiences
and views of parents/legal representatives and staff in relation to the pilot trial.
Participants
The parents or legal representatives of children who were randomised into the pilot trial were eligible to
take part, unless they were unable to speak and read English. Site staff who were involved in the pilot trial
were also eligible to take part. There were no exclusion criteria for staff. Informed consent was taken.
Interviews and focus groups
Parents/legal representatives
An interview topic guide was used to explore the views and experiences of parents about the FiSh trial in a
similar manner to the feasibility study (see above).
Site staff
A topic guide was also used for the focus groups and interviews with site staff to explore their views and
experiences of the FiSh trial.Journals Library www.journalslibrary.nihr.ac.uk
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Analysis was performed in accordance with the methodology used in the feasibility study (see above).
Results: pilot randomised controlled trial
The pilot trial was conducted in 13 hospitals from July 2016 to April 2017. Seventy-five children were
randomised, 40 to the 10-ml/kg fluid bolus group and 35 to the 20-ml/kg fluid bolus group. Two children
were withdrawn. The overall recruitment rate was 0.9 children per site per month [95% confidence
interval (CI) 0.7 to 1.2 children per site per month]. Baseline characteristics were similar, with some
imbalance in age and weight.
Most children (59% in the 10-ml/kg fluid bolus group and 74% in the 20-ml/kg fluid bolus group)
required a single trial bolus before shock resolved. Fluid boluses were delivered in accordance with
protocol in 79% of children in the 10-ml/kg fluid bolus group and in 55% in the 20-ml/kg fluid bolus
group. The mean total volume of study fluid received was 23% lower in the 10-ml/kg fluid bolus group,
at 188 ml [standard deviation (SD) 325 ml], compared with the 20-ml/kg fluid bolus group [243 ml
(SD 275 ml); mean difference −54 ml, 95% CI −196 ml to 88 ml; p = 0.44]. However, when the children’s
weights were taken into account, the separation in study fluid volume was significant [14.5 ml/kg
(SD 11.1 ml/kg) versus 25.7 ml/kg (SD 12.0 ml/kg); p < 0.001].
There were no deaths and no serious AEs. Overall, 29% of children were admitted to a PICU. Length of
hospital stay, transfers to PICU, length of stay in PICU, and days alive and not in PICU at 30 days post
randomisation did not differ significantly between the groups.
Results: integrated perspectives study
Participants: parents/legal representatives
A total of 52 out of 75 (69%) parents of the children enrolled in the pilot trial consented. Questionnaires
were received from 45 out of 52 (87%) parents from 44 families.
Participants: site staff
Three focus groups were conducted with 20 site staff from the three ‘hub’ pilot trial sites. In addition,
seven telephone interviews were conducted with 7 out of 20 (35%) staff.
Parental perspectives
Some parents [7/20 (35%) interviewed and 13/45 (29%) who completed a questionnaire] were surprised
to discover that their child had been enrolled into the pilot trial without prior consent. However, all
supported RWPC in the FiSh pilot trial. Many parents said that they consented for altruistic reasons.
Parents felt that they were approached for consent at the appropriate time, when the emergency situation
had passed. Parents described the FiSh trial PIS as comprehensive and generally clear. Ranked in order
of importance, parents prioritised the following outcome measures: (1) organ/physiological functioning,
(2) looking and behaving normally, (3) fewer machines, (4) less time spent on various treatments, such as
mechanical ventilation, (5) long-term morbidity, (6) survival and (7) less time in hospital.
Site staff perspectives
Site staff stated that the training had prepared them for the pilot trial. Of the site staff in focus groups, 65%
(13/20) indicated that the screening process could be improved. Many staff found it difficult to complete the
case report form while resuscitating a child. Suggestions for improvement included the following: 24/7 research
nurse cover in the ED; making sure all staff are trained, including new staff on rotation; and ensuring that study
posters are placed in the optimal location. The randomisation methodology was viewed as straightforward.
Thirty per cent (6/20) of the site staff in focus groups experienced problems with adherence to the protocol.
Protocol deviations related to a lack of equipoise when clinicians favoured 10-ml/kg, rather than 20-ml/kg,
fluid boluses, and with difficulties in administering boluses within the 15-minute cycles.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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xxviConclusions
The population had lower severity of illness than expected and many sites struggled to recruit more than
a handful of children. The majority of the recruitment was led by three sites. Most children required only
one trial fluid bolus, fewer than one-third of children were transferred to PICU and all survived. There were
more adherence issues in the 20-ml/kg fluid bolus group, mainly because of difficulties delivering the fluid
boluses within the 15-minute cycles. Fewer than half of the children had confirmed infection and, of these,
only 13 had confirmed bacterial infections in sterile sites. Overall, such results would have been impossible
to imagine in the 1990s and 2000s, when the incidence of severe community-acquired sepsis was much
higher. Possible reasons for this finding include both the comprehensive childhood vaccination programme
now offered in the UK and implementation of ‘sepsis bundles’, which may have improved recognition and
early management in those who present to an ED.
The findings from the integrated perspectives study indicated that the FiSh trial was, in general, acceptable
to parents and site staff.
Data from both quantitative and qualitative analyses demonstrated that clinicians tended to favour the
smaller bolus size, suggesting that equipoise may no longer exist. Further work is thus required to confirm
that equipoise still exists before any trial on different volumes of fluid bolus is undertaken in the UK.Recommendations for research
1. The full FiSh trial, with the current design, is not feasible.
2. Further observational and epidemiological work is required to determine if there is still a population of
children in the UK of whom this study question could usefully be asked.
3. Further work is required to elucidate current treatment and to determine whether or not equipoise still
exists in relation to the research question among clinicians in the UK.Study registration
This trial is registered as ISRCTN15244462.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Infectious diseases remain a major cause of mortality and morbidity, accounting for > 25% of deaths in
children < 5 years of age in Europe.1 In the UK, approximately 1000 children present to paediatric intensive
care units (PICUs) with severe sepsis each year, of whom ≈8% die.2 Mortality increases, sometimes up to
17%, when children presenting to emergency departments (EDs) with severe sepsis are included.3 In
addition, serious morbidity in PICU survivors is high.4
Rapid fluid bolus resuscitation is integral to the UK management of children presenting to EDs with septic
shock. In 2009, based on the best available evidence, the American College of Critical Care Medicine –
Pediatric Advanced Life Support (ACCM-PALS)’s clinical guideline5 recommended fluid bolus resuscitation
with a bolus size of 20 ml/kg, up to a total of 200 ml/kg over the first hour, for the management of
children and neonates with septic shock. However, this recommendation is predominantly based on
weak evidence from retrospective observational studies involving small numbers of children.6–8
In Africa, a recent, rigorous, multicentre, randomised controlled trial (RCT), the Fluid Expansion as Supportive
Therapy (FEAST) trial,9 compared fluid bolus resuscitation of 20ml/kg with maintenance fluid in > 3000 children
with severe infection. The study reported a 35% increase in mortality associated with fluid bolus resuscitation.9
Although conducted in a low-income setting, the FEAST9 trial raised considerable uncertainty and highlighted
the lack of evidence for fluid bolus resuscitation for children in middle- and high-income settings.10,11
A recent systematic review of fluid bolus resuscitation in children with septic shock reported that fluid
boluses were associated with increased mortality compared with maintenance fluid.12 However, the only
RCT comparing bolus with maintenance fluid identified in this review was the FEAST9 trial. The systematic
review identified one additional RCT comparing different fluid volumes.13 This trial compared an aggressive
fluid resuscitation strategy (20–40 ml/kg over 15 minutes) with usual fluid bolus resuscitation (20 ml/kg
over 20 minutes up to a maximum of 60 ml/kg over 60 minutes) in 147 children, aged from 1 month to
12 years, presenting with septic shock to a single ED in India.13 The total volume of fluid administered was
higher in the aggressive fluid resuscitation group than in the usual fluid resuscitation group, but there
was no difference in mortality or in the other clinical outcomes measured, except for an increase in
hepatomegaly at 20 minutes in the aggressive fluid resuscitation group.
To date, no trials have compared a restrictive fluid bolus resuscitation strategy with recommended fluid
bolus resuscitation in children with septic shock in the developed world. One single-centre pilot RCT has
been completed in Canada.14 This trial aimed to achieve a ‘fluid-sparing’ resuscitation strategy through
earlier initiation of vasoactive medication (following initial fluid bolus resuscitation of ≥ 40 ml/kg within
the 2 hours prior to randomisation).
When considering repeating the FEAST9 trial in the UK, the existence and adoption of clinical guidelines
(such as the ACCM-PALS guideline)5 and training courses (such as Advanced Paediatric Life Support15)
make it very unlikely that clinicians in UK EDs would accept a randomisation allocation to maintenance
fluid only. However, with accumulating adult and paediatric data suggesting that excessive fluid
administration is associated with worse patient outcomes, and even an increased risk of death,16 the
optimal volume of fluid for children presenting with septic shock remains an important unanswered
question.
The Fluids in Shock (FiSh) trial proposed to evaluate, in a pragmatic RCT, whether or not a restrictive
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2(fluid bolus resuscitation of 20 ml/kg), is associated with improved outcomes for children presenting to UK
EDs with presumed septic shock.
First, it was imperative to establish whether or not a large multicentre RCT of a restrictive fluid bolus
resuscitation strategy would be feasible and acceptable in the UK. Clinical trials, such as the proposed
FiSh trial, are expensive, and the chances of successful completion are improved if the feasibility and
pilot testing of certain key parameters can be clearly demonstrated.Aim
To explore and test, in a combined feasibility study and pilot trial (conducted as a smaller version of the full
trial), important key parameters needed to inform the design and ensure the successful conduct of the FiSh
trial and to report a clear recommendation for continuation or not to the full trial.Objectives
Feasibility study
1. To review and explore, with input from parents/legal representatives, acceptability, potential barriers,
information/documentation, decision-making and deferred consenting [or research without prior
consent (RWPC)].
2. To review and explore, with input from parents/legal representatives, the potential patient-centred
primary, and other important secondary, outcome measures.
Pilot trial with integrated perspectives study
1. To test the willingness of clinicians to screen, recruit and randomise eligible participants.
2. To estimate the recruitment rate.
3. To test, following randomisation, the delivery of and adherence to the intervention and demonstrate
separation between the groups.
4. To test acceptability of the deferred consenting procedures and documentation.
5. To test follow-up for the identified, potential patient-centred primary and other important secondary
outcome measures and adverse event (AE) reporting.
6. To inform the final selection of a patient-centred primary outcome measure.
7. To estimate the characteristics of the selected patient-centred primary outcome measure to inform
sample size estimation.
8. To inform the content of, and time needed for, final data collection.
Progression criteria
The objectives would be reported against the following progression criteria:
1. Formal sign-up of sites (the required number of hub-and-spoke models) to achieve the overall sample
size based on the observed recruitment rate, as determined by the pilot trial objectives concerning
identification, recruitment rate, acceptability of deferred consenting procedures, selection of the
patient-centred primary outcome measure and sample size estimation.
2. The recruitment rate achieved in the pilot trial (taking into account loss of participants as a result of
declining deferred consent) being consistent with achieving the overall sample size required – as
determined by the objectives concerning selection of the patient-centred primary outcome measure
and sample size estimation – in an acceptable time frame from the sites giving formal sign-up in the
first feasibility objective.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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recommended fluid bolus resuscitation group, as determined by the external pilot study objective
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Study design
The FiSh feasibility study was a qualitative semistructured interview study.
Research governance
The FiSh feasibility study was sponsored by Imperial College Healthcare NHS Trust and co-ordinated
by the University of Liverpool and Intensive Care National Audit and Research Centre (ICNARC) Clinical
Trials Unit (CTU). An ethics application was made to the North West – Liverpool Central Research
Ethics Committee (REC) on 16 October 2015 and a favourable opinion was received on 15 December
2015 (REC reference number: 15/NW/0913). The protocol is available at www.journalslibrary.nihr.ac.uk/
programmes/hta/1304105/#/ (accessed 23 May 2016). Local NHS permissions were obtained for the
NHS trusts that participated as Participant Identification Centres (PICs) for recruitment routes 1 and 2
(see Recruitment).
Study management
The FiSh feasibility study was led by a qualitative researcher co-investigator (KW) with support from the
Study Management Group (SMG), which included the chief investigator (DI) and other co-investigators
(AC, DAH, NJ, MDL, PRM, SN, MJP and KMR). An experienced research associate (CBOH) was employed
to conduct, transcribe and analyse the interviews.
Network support
To maintain the profile of the study, updates were provided at national meetings, such as the Paediatric
Emergency Research in the UK and Ireland (PERUKI) annual meeting and the biannual Paediatric Intensive
Care Society Study Group (PICS-SG) meetings.
Patient and public involvement
Two parents (NJ and AC) of children with experience of admission to hospital with severe infection
were co-investigators and members of the SMG. They provided valuable input into the design and
conduct of the study, including reviewing documents for parent interviews [e.g. draft pilot trial participant
information sheets (PISs) and a list of potential outcomes, including outcome descriptions] and informing
study recruitment approaches (i.e. identification of social media groups and charities). They were also
involved in the review of study progress and findings.
Design and development of the protocol
The design and development of the protocol, including sample estimation, recruitment strategy and
interview topic guide, were informed by previous trials conducted in paediatric emergency and critical
care in the NHS and earlier research.17–20 Previous relevant research was used to develop an interview
topic guide (see Appendix 1) and draft PIS for the pilot trial (see Appendix 2).18,19,21 The topic guide
contained open-ended questions and prompts to help explore parents’/legal representatives’ views on the
acceptability of the FiSh trial, including the draft pilot trial PIS and approach to consent. A separate set of
questions was developed for bereaved parents/legal representatives.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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6Literature review
The literature review for potential outcome measures was conducted prior to the FiSh feasibility study start
date (December 2015). The review included:l
l
l
l
l
NIHRprevious systematic reviews of the literature
a search through literature referenced in guidelines provided by the International Liaison Committee
on Resuscitation
a search on the Core Outcome Measures in Effectiveness Trials (COMET) Initiative database
a search on the Evidence in Paediatric Intensive Care Collaboration database
a search on ClinicalTrials.gov for recent paediatric emergency and critical care studies, including the
SQUEEZE14 (Septic Shock Reversal is Quicker in Pediatric Patients Randomized to an Early Goal Directed
Fluid-sparing Strategy vs. Usual Care) pilot trial.A number of studies, trials and systematic reviews were identified. From these, a list of potential outcome
measures (see Appendix 3) was compiled to inform discussions with parents/legal representatives during
the interview.
Amendments to the study protocol
Following receipt of a favourable opinion of the study protocol from the REC on 15 December 2015,
there were no amendments.
Recruitment
Hospitals
Invitations for expressions of interest in participating as a PIC for recruitment routes 1 and 2 were sent
to lead clinicians in paediatric emergency and paediatric critical care medicine at a number of UK
NHS hospitals.
Eligibility
Parents/legal representatives with a child presenting to an ED or being admitted to a PICU with a severe
infection within the previous 3 years were eligible to take part in the study, unless they were unable to
speak and read English. In this instance, severe infection was defined as any condition leading to inpatient
treatment for sepsis or septic shock, such as meningococcal septicaemia.
Recruitment and sampling procedure
Based on previous studies,19 it was anticipated that 15–25 parents/legal representatives would need to be
recruited to reach data saturation. The study procedures for recruitment are summarised in Figure 1.
Recruitment route 1: postal contact
Clinicians used hospital medical records to identify the 15 most recent parents/legal representatives
(including up to five bereaved) of children who met the inclusion criteria. Those identified were sent
a postal invitation, including a covering letter and FiSh feasibility study PIS describing how to register
interest in taking part.
Recruitment route 2: advertising in paediatric intensive care units
Posters and copies of the FiSh feasibility study PIS were placed in family/relative waiting rooms near
the PICU.Journals Library www.journalslibrary.nihr.ac.uk
Provided with study information
Parents register interest in participation by e-mail/telephone
Informed consent obtained
Conduct interview
Copy of consent form sent and study exit
Identification of eligible families
Recruitment via ED/PICU
(route 1  or  2)
Recruitment via online support
groups/social media (route 3)
FIGURE 1 Summary of study procedures for recruitment of participants.
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An advertisement was posted on Twitter (Twitter Inc., San Francisco, CA, USA; www.twitter.com) and
Facebook (Facebook Inc., Menlo Park, CA, USA; www.facebook.com), which invited parents/legal
representatives to register interest in participating in the study. Relevant charities and parent support
groups were asked to place the advertisement on their website and social media.
Interviews
Screening
Parents’/legal representatives’ requests to participate were responded to in sequential order. Once eligibility
was confirmed, an interview date and time were scheduled. The draft pilot trial PIS (see Appendix 2) and
list of potential outcomes (see Appendix 3) were e-mailed to parents/legal representatives to read before
the interview. Interviews aimed for data saturation, that is, the point at which no new major themes are
discovered in analysis.22,23 Screening stopped when data saturation was reached.22,23
Informed consent
Audio-recorded verbal consent was sought over the telephone before the interview. This involved reading
each aspect of the consent form to parents/legal representatives, including consent for audio-recording
and to receive a copy of the findings when the study ended. Each box was ticked on the consent form
when verbal consent was provided. Informed consent discussions were audio-recorded for auditing
purposes.
Conduct of the interview
The telephone interview began with a discussion about the aims of the study, an opportunity for questions
and checking that the parent/legal representative had had sufficient time to read the draft pilot trial PIS
and list of potential outcomes.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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8The interview then commenced using the interview topic guide to explore:l
l
l
l
l
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NIHRthe acceptability of the proposed trial
any potential barriers for participation in the trial and how these could be addressed
parents’/legal representatives’ views on the length and content of the draft pilot trial PIS, leaflets
and posters
parents’/legal representatives’ decision-making in the emergency setting
the acceptability of RWPC (deferred consent)
the trial design, including the selection of outcome measures.Example questions are shown in Appendix 1. Respondent validation was used to add unanticipated topics
to the topic guide as interviewing and analysis progressed.24 After the interview, participants were sent a
copy of the consent form and a thank-you letter, including a £30 Amazon (Amazon.com, Inc., Bellevue,
WA, USA) voucher to thank them for their time.
Transcription
Digital audio-recordings were transcribed verbatim by a professional transcription company (Voicescript
Ltd, Bristol, UK) in accordance with the Data Protection Act 1998.25 Transcripts were anonymised and
checked for accuracy. All identifiable information, such as names (e.g. of patients, family members or
the hospital that their child was admitted to), was removed.
Data analysis
A psychologist (CBOH) led the analysis with assistance from a sociologist (KW). Analysis was broadly
interpretive and iterative (Table 1).31,32 Informed by the constant comparative approach, the aim was
to provide accurate representation of parental views on trial design and acceptability.29,33–35 NVivo 10
(QSR International, Warrington, UK) software was used to assist in the organisation and coding of data.LE 1 Approach to qualitative data analysis
ase Description
iliarisation with data and
nerating initial themes
CBOH read and reread a sample of transcripts, noting down initial ideas around
main themes and potential codes
veloping the coding framework Using NVivo 10 software, CBOH created codes for initial main themes (e.g.
thoughts on the FiSh trial, thoughts on the draft pilot trial PIS, thoughts on
RWPC, decision-making in the emergency setting and misunderstandings and
misconceptions) and began developing a coding framework using line-by-line
coding, comparing between transcripts as part of a constant comparative
approach26–28
ial coding meeting CBOH and KW met to discuss early themes and develop the coding framework
ond coding (coded by a second
rson)
KW second coded a sample of transcripts (two bereaved parent interviews, one
non-bereaved parent interview – 15% of transcripts) and made notes on any
new themes identified and how the framework could be refined
ond coding meeting CBOH and KW met to discuss, reflect and refine the specifics of each theme in
the coding framework29
mpletion of coding of transcripts CBOH completed coding of all transcripts in preparation for write-up
ite-up and final revision of coding CBOH and KW developed the manuscript using themes to relate back to the
study aims, ensuring key findings and recommendations were relevant to the
FiSh trial design and site staff training (i.e. catalytic validity).28,30 Final discussion
and development of selected themes occurred during the write-up phase
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Participating NHS trust hospitals
Expressions of interest were received from seven NHS hospitals. Local research and development approval
was obtained for four NHS hospitals in January 2016 for recruitment via routes 1 and 2.
Participants
A total of 58 parents registered interest, of whom 29 were screened (Figure 2); three were deemed
ineligible and five did not confirm a date for interview. Data saturation was reached when 21 parents
from 20 families were interviewed.22,23,35 No individuals identified themselves as legal representatives
and, therefore, this term is not used in the remainder of this chapter.
Characteristics
The sample included 18 mothers (five bereaved) and three fathers (two bereaved). Bereaved parents were
interviewed a mean of 12.3 months [standard deviation (SD) 10.1 months] since admission (range 3–31 months)
and non-bereaved parents a mean of 17.6 months (SD 9.9 months) since admission (range 1–41 months).
The mean length of hospital stay for their children was 7.1 days (SD 9.6 days; range: 1–25 days) for
bereaved parents and 33.9 days (SD 47.4 days; range 4–140 days) for non-bereaved parents. Eight parents
had previously participated in a clinical trial. One mother had experience of RWPC. Interviews took between
30 and 55 minutes.
Parental perspectives
Research without prior consent is acceptable but some initial concerns
A general definition of RWPC was first read to parents (Box 1). Many said that they may be initially surprised
to discover that their child had been entered into a trial without their prior consent (see Appendix 4 for
quotations by theme). However, concerns subsided once reasons for using RWPC in emergency situations
were considered. Parents went on to respond favourably to the concept of RWPC, describing it as a logical
solution to enable research in challenging circumstances.1. Postal recruitment 2. Advertising in PICU/ED 3. Social media
Recruitment to FiSh via three routes
Took part in an interview: n = 21 parents from 20 families
Invited: n = 68 parents/68 families
• No response: n = 64/68, 94.1%
• Screened: n = 4/68, 5.9%
• Eligible: n = 4/4, 100%
• Consented: n = 4/4, 100%
Response: n = 1 parent/1 family
• Screened: n = 1/1, 100%
• Eligible: n = 0/1, 0%
• Consented: n = 0/1, 0%
Response: n = 53 parents/52 families
• Screened: n = 24/53, 45.3%
• Eligible: n = 22/24, 91.7%
• No response: n = 5/22, 22.7%
• Consented: n = 17/22, 77.3%
• Mothers: n = 18/21, 85.7%
• Fathers: n = 3/21, 14.3%
• Bereaved: n = 7/21, 33.3%
FIGURE 2 The FiSh feasibility study recruitment process.
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
BOX 1 Description of RWPC read to participants during interview
Due to the need to treat a patient in an emergency without delay, or because parents may not always be
present when a child needs treatment, it is not always appropriate or possible to obtain consent before a child
is entered into a trial. To enable research to be conducted in the emergency setting, many countries (including
the UK) allow consent to be sought as soon as possible afterwards. This is for permission to use the data
already collected and to continue in the trial. This is research without prior consent (sometimes called deferred
consent). Research without prior consent is a relatively new approach to seeking consent in the UK.
FEASIBILITY STUDY
10Support for the FiSh trial but some concerns and misconceptions
Overall, parents supported the FiSh trial. Many viewed trial participation as a way to help other families
and children in the future. Some parents thought that the consent discussion could provide a ‘distraction’
[Participant (P) 9, mother, non-bereaved] but foster ‘a sense of control in a situation where you feel
completely out of control’ (P6, mother, non-bereaved).
However, support for the FiSh trial appeared to be dependent on the intervention being successful and
‘how well [their child] was’ (P4, mother, non-bereaved). Parents, including those who were bereaved,
said that they would wonder if their child’s participation in the trial was ‘the reason [their child] didn’t
survive’ (P19, mother, bereaved), in that eventuality.
Some parents had specific concerns and misconceptions that influenced their views on the acceptability
of the FiSh trial. Many were concerned that a change from current practice might jeopardise their child’s
chances of survival. This was linked to the misconception that the currently recommended fluid bolus
volumes are evidence based. Parents were concerned that restrictive fluid bolus therapy would be
insufficient, with the current liberal approach to fluid bolus resuscitation viewed as being more likely
to save a child’s life.
In response, parents were directed to the relevant sections of the draft pilot trial PIS and provided tailored
explanations, such as the weak evidence base for current recommended practice, how fluid resuscitation
is part of a larger treatment package, and monitoring procedures. Such explanations appeared to address
parents’ initial concerns and misconceptions about the proposed FiSh trial.
Unclear or missing study information
All parents considered the draft pilot trial PIS to be clear and concise. However, parents raised questions
about some aspects of the trial (Box 2), indicating that key information was missing. Importantly, this
information was prioritised by parents, affecting their understanding and views about the acceptability
of the trial. Many said that they would not ask questions or raise concerns with a member of site staff
approaching them for consent.BOX 2 Examples of questions raised by parents
l Would the amount of fluid given be corrected if my child was not stabilising?
l Does the amount of fluid have a direct impact on outcome?
l What is a fluid bolus?
l What is the timing of fluid bolus administrations?
l Would I be able to find out which group my child was randomised to?
l Does the fluid treatment apply regardless of the child’s age?
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Parents suggested that the discussion about consent should occur after the initial stress had subsided and
their child’s condition had stabilised, preferably within 24–48 hours. Parents expressed the need for the
research team to gauge appropriate timing of this discussion in consultation with the clinical team.
The researcher asked bereaved parents to consider a scenario in which their child had been entered into
the trial before death and a practitioner approached them after death to discuss the trial. They suggested
that site staff should be prepared to address concerns about whether or not trial participation was ‘a
reason as to why [death] happened’ (P21, mother, bereaved). They emphasised a need for sensitivity and
time, particularly if a child had died very quickly and without warning. Parents described their anger in the
initial stages of bereavement, which they believed would negatively affect their decision-making abilities
and their response to a discussion about consent. Nevertheless, all bereaved parents agreed that it would
be acceptable to discuss the trial at a later time, after they had left hospital. Bereaved parents valued
medical research and, in general, said that they would have consented to the use of their child’s data as a
way to help other children in the future.
Bereaved parents’ views were then sought on the most appropriate way of contacting parents to discuss the
trial following the death of a child (Box 3). Several parents thought that an appropriately timed face-to-face
discussion with a nurse or consultant would be preferable to a telephone call or letter. The majority, however,
supported contact via post at 4 weeks and then at 8 weeks after death as long as the proposed ‘opt-out’
approach provided was emphasised in bold and the letter personalised, ideally by a known member of the
clinical team. However, parents described grief as a ‘very personal matter’ (P17, mother, bereaved), making it
difficult to develop general recommendations on how best to approach parents in this situation.
Outcomes of importance to parents
Appendix 3 includes the list of outcomes and accompanying descriptive text sent to parents before the
telephone interviews. In this section of the interview, a definition of an outcome was first read to parents,
including an explanation about why it was important to explore parents’ perspectives about important
outcomes (see Appendix 1). Parents were asked to think about their experience of their child being
admitted for severe infection and then prompted to share their views on what effects of treatment they
hoped for (i.e. what indicators were most important to suggest that their child was getting better).
Many parents described looking for important indicators of improvement as ‘a gradient of seriousness’
(P6, mother, non-bereaved), initially looking for ‘the worst [outcome] and then . . . you sort of progressively
aim towards the sort of next hurdle to get over’ (P10, mother, non-bereaved).BOX 3 Options for approaching bereaved parents to discuss the FiSh trial after a child has died
Research associate presented several options to consider:
l Face-to-face discussion with a nurse or doctor.
l Telephone call from a nurse or doctor.
l Personalised letter 4 weeks after randomisation, followed by a second letter 8 weeks after randomisation
(i.e. if no response is received after sending the initial letter). Letters would explain how to opt out of the
study and that there would be no need to respond if they wanted their child’s data to be used in the trial.
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12Appendix 3 shows the full list of outcomes identified in the analysis of parent descriptions. On average,
parents described six outcomes. In order of importance (i.e. defined as how many parents mentioned a
particular outcome when asked directly which indicators were most important to them), parents prioritised
the following outcomes:l
l
l
l
l
l
NIHRlong-term effects, for example long-term health and development, disabilities
‘getting better’, for example looking and behaving more like their normal selves
organ/physiological functioning, for example blood pressure, temperature and heart rate
time spent on treatments and machines
survival
time spent in hospital.The majority of parents described the provided list of outcome measures as ‘fair’ (P16, father, bereaved)
and ‘thorough’ (P20, mother, non-bereaved). No additional outcomes (i.e. unrelated to categories provided
on the list) were identified by parents. Bereaved parents found it difficult to consider outcome measures
other than survival:Now that’s difficult, because coming from where I am coming from I would just say that they survive.
For me would be the number one criteria.
P19, mother, bereavedKey findings to inform the pilot trial
This qualitative study provides insight into the acceptability of the FiSh trial to parents by exploring the
views of parents with relevant experience. Consistent with the CONNECT (CONseNt methods in paediatric
Emergency and urgent Care Trials) study findings and associated guidance on RWPC,18,19,26,27 some parents
initially expressed concerns about the concept of RWPC. However, initial concerns subsided when reasons
why informed consent could not be sought were offered. As also shown in previous research,17,28 parents
thought that they might be unable to provide a rational, informed decision about research in an acute
emergency situation and supported alternative approaches to prospective informed consent as a way to
enable research in time-critical situations to improve treatments for critically ill children.17,19,28,30,36,37
The findings highlight specific concerns and misunderstandings that initially influenced parental views on
the acceptability of the FiSh trial.38 Concerns included the proposed change from current clinical practice
and its potential effect on a child’s recovery. Although the draft pilot trial PIS included a description of
the weak evidence for current practice, many held a misconception that this was the proven optimal
treatment. Moreover, several parents were unclear about the nature of fluid bolus therapy and only one
understood that 20 ml/kg of fluid would be given to all children before being entered into the trial.
Nevertheless, all parents reported that they would have provided consent for the use of their child’s data in
the FiSh trial, valuing the opportunity to advance medical research and viewing their child’s participation as
a means to help similar families in the future.19 This is consistent with previous findings that emphasise the
need for simple, non-medicalised information to improve parental understanding of trial information and
inform their research decisions.19,21,39 Tailored explanations appeared to address parents’ priorities, concerns
and misconceptions. These findings were used to develop the FiSh pilot trial site staff training, which
emphasises the need for recruiters to provide opportunities for questions as parents are unlikely to voice
potential concerns.38,40
Consistent with previous studies, which explored approaches to consent in time-critical situations,17,19,20,30,41
the timing of the consent was found to be likely to affect parental responses to the trial. Although many
parents said that consultation with the clinical team would help research staff to gauge when to approach
families for consent,27 their views on when and how this initial contact should happen differed depending on
whether or not their child had survived. Parents of children who had survived a severe infection expressedJournals Library www.journalslibrary.nihr.ac.uk
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child’s condition had stabilised.26 In contrast, bereaved parents emphasised that parents in this situation
should not be approached immediately after their child’s death, as this may heighten feelings of grief
and anger. It was this perceived burden to vulnerable families that led to a waiver of consent (i.e. no trial
discussion) when a child died in the FEAST trial.17,30,42 However, our findings do not support the model used
in the FEAST trial,43 as the bereaved parents we interviewed expressed a wish to discuss the use of their
child’s information in the FiSh trial, as long as the timing of this discussion was appropriate.18,27
The FiSh feasibility study findings thus provide new insight into what should happen if a child dies after
being entered into a trial.26 Although some bereaved parents preferred a face-to-face research discussion,
the majority were happy to be contacted by post, with an opportunity to meet with a researcher at a
later date. Bereaved parents responded favourably to the opt-out approach proposed. Importantly,
parents recommended that the letter should be sent from a practitioner known to the family, with whom
they had developed a close and trusting rapport.26 As septic shock is associated with an 8–17% mortality
rate in the ED and PICU,2,3 these findings are particularly important and will help to design a trial that is
appropriate for the needs of vulnerable families. The views of bereaved parents also highlight the need
for practitioners to prepare to respond to parents who are concerned that trial participation may have
resulted in harm.
Finally, parents provided their views about the outcomes that are most important to them in children with
severe infection. These qualitative findings were incorporated into the FiSh pilot trial design to ensure the
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perspectives studyStudy design
The FiSh pilot trial was a pragmatic, open, multicentre, parallel-group, pilot RCT with an integrated
perspectives study element involving parents/legal representative of trial participants and site staff involved
in the RCT. The integrated perspectives study comprised questionnaires and interviews with parents/legal
representatives, as well as focus groups and interviews with the site staff towards the end of the pilot trial
recruitment period.Research governance
The pilot trial was sponsored by Imperial College Healthcare NHS Trust and co-ordinated by the ICNARC
CTU. An application was submitted to the Health Research Authority (HRA) on 19 April 2016 and received
full approval on 22 June 2016 (Integrated Research Application System reference number: 195544;
REC reference number: 16/LO/0854). The trial protocol is available at www.journalslibrary.nihr.ac.uk/
programmes/hta/1304105/#/.
The pilot trial was registered with the ISRCTN (International Standard Randomised Controlled Trial Number)
registry. Registration was confirmed on 11 August 2016 (ISRCTN15244462). The pilot trial was adopted
onto the National Institute for Health Research (NIHR) Clinical Research Network (CRN) portfolio on
9 June 2016 and issued the NIHR CRN portfolio number 31037.
Local confirmation of capacity and capability was obtained from each participating NHS trust. A clinical
trial site agreement, based on the model agreement for non-commercial research in the health service,
was signed by each participating NHS trust and the sponsor (Imperial College Healthcare NHS Trust).
Following guidelines from NIHR,44 a Trial Steering Committee (TSC), with a majority of independent members,
was convened to oversee the pilot trial on behalf of the funder (NIHR) and the sponsor (Imperial College
Healthcare NHS Trust). The TSC met three times during the pilot trial and comprised an independent
chairperson, an independent lay member (representing parent perspectives), independent clinicians
(specialising in paediatric emergency and critical care medicine), the chief investigator (DI) and the lead
qualitative researcher (KW).
In addition, an independent Data Monitoring and Ethics Committee (DMEC) was convened to monitor
pilot trial data and ensure the safety of pilot trial participants. The DMEC met twice during the pilot trial
and comprised two expert clinicians specialising in paediatric emergency and critical care medicine
(one of whom acted as chairperson) and an experienced statistician.Study management
The study manager was responsible for the day-to-day management of the pilot trial, with support from
the senior trial manager, data manager, study statistician and research assistant. The researcher was
responsible for the day-to-day management of the integrated perspectives study elements with support
from the qualitative researcher co-investigator. The SMG, chaired by the senior trial manager, was
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16(DI) and co-investigators (AC, DAH, NJ, PRM, SN, MJP, KMR and KW). The SMG met regularly throughout
the pilot trial to ensure adherence to the pilot trial protocol and to monitor its conduct and progress.Network support
To maintain the profile of the pilot trial, updates were provided at national meetings, such as the PERUKI
annual meeting and biannual PICS-SG meetings.Patient and public involvement
Two parents (NJ and AC) of children with experience of admission to hospital with severe infection were
co-investigators and members of the SMG. They provided valuable input into the design and conduct of
the study. They were also involved in the review of study progress and findings.Design and development of the protocol
Using the FEAST trial9 as a starting point, the FiSh pilot trial protocol was originally conceived as a comparison
of fluid bolus resuscitation with no fluid bolus resuscitation (i.e. solely maintenance fluid). However, following
consultation with clinicians in UK paediatrics, paediatric ED and PICU, it became clear that this approach
would not be acceptable, and that the lowest agreed intervention bolus size was 10 ml/kg after an initial
bolus of 20ml/kg. The 10-ml/kg fluid bolus size was then proposed and deemed acceptable, following
discussion, at a meeting of would-be collaborators of the FiSh pilot trial in 2012, with the comparator being
the currently recommended bolus size of 20ml/kg. This strategy was then further ratified by the PERUKI research
collaborative. Thus, the proposed intervention bolus size of 10ml/kg represented the current position of
equipoise among UK clinicians.
The use of vasopressors was considered during protocol development. However, the clinical consultation
indicated that the protocolised use of vasopressors would not be pragmatic in an ED-based study, in which
central venous access and advanced monitoring would be variably available, and that the study question
should be limited to fluid bolus size.
Following submission of the grant application and approval of funding, the SMG updated their review
of the recent literature,45 which resulted in some additional minor changes to the protocol: tachycardia was
removed as one of the clinical signs of shock for the pilot trial, as it could be a symptom of many different
conditions outside the scope of the pilot trial and could thus lead to inappropriate randomisations. The
SMG came to a consensus view that the most pragmatic clinical criteria for shock in the context of
suspected infection in childhood were systolic blood pressure below the fifth percentile for age or a CRT of
≥ 3 seconds. Fluid boluses would be delivered within a 15-minute cycle rather than the 10 minutes initially
proposed as this was thought to be too quick, and hence difficult to achieve, particularly in older children
and adolescent patients. Additional safety features were added to prevent the administration of excessive
amounts of fluid. Fluid bolus resuscitation would be withheld if participants showed signs of fluid overload,
defined as rales (crackles) on auscultation with a stethoscope, pulmonary oedema (lung) fluid in the
endotracheal tube or new or increasing hepatomegaly (liver enlargement), as per the 2009 ACCM-PALS
guidance,5 which was current when the protocol was written. The maximum volume of fluid that could be
given with the pilot trial protocol would be 120 ml/kg (excluding the original 20 ml/kg given as part of the
inclusion criteria) rather than the initially proposed volume of 160 ml/kg.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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develop pilot trial information materials and sections of the protocol related to recruitment and consent
seeking, as well as site staff training. These findings were also used to develop parent/legal representative
interview and site staff focus group topic and interview guides for the integrated perspectives study elements.Amendments to the pilot trial protocol
Following receipt of approval of the pilot trial protocol from the HRA on 22 June 2016, three
non-substantial amendments were submitted and categorised; there were no substantial amendments.
1. Minor amendment 1 (10 August 2016): the addition of a new research site and change of principal
investigator (PI) at one site.
2. Minor amendment 2 (16 November 2016): edits were made to the protocol to clarify the maximum
volume of fluid that can be delivered per bolus, as this was not clear in the previous iteration.
Following review by the TSC, updates were also made to the PISs for parents/legal representatives to
clarify the unknown risks and benefits of 10-ml/kg versus 20-ml/kg fluid boluses. In addition, minor
amendments were made to the information sheet for 8- to 10-year-olds to make the description of the
two interventions clearer and to update some of the images to make them more relatable to the pilot
trial (i.e. a picture of a child in bed with a bag of fluid vs. a child sneezing). The TSC also suggested the
addition of two new participant materials, namely a contact details card, with the telephone numbers
of parents/legal representatives who agreed to take part in a telephone interview and a reminder when
that would occur, to help potentially boost contact and arrangement of interviews, and an additional
envelope label, to be added onto the envelope when contacting bereaved parents/legal representatives
about the pilot trial, informing parents/legal representatives that the contents were related to their
child, providing them the opportunity to open the envelope at their own discretion.
3. Minor amendment 3 (10 February 2017): a 1-month extension to the recruitment period.NHS support costs
Studies in emergency and critical care are challenging and expensive to conduct. Unlike other areas of
health care, such as oncology, recruitment cannot take place solely within usual office hours. Resources
are needed to enable screening and recruitment 24 hours per day, 7 days per week. To this end, resources
equivalent to 0.12 whole-time equivalent band 6 research nurses were successfully agreed with the North
Thames Local Clinical Research Network (LCRN) before the submission of the research grant. Resources
were based on an estimated 12 eligible admissions per hospital per year, of whom approximately
nine would be recruited and randomised 1 : 1 between 10-ml/kg and 20-ml/kg fluid boluses. Using these
recommendations, participating sites, assisted by the SMG, negotiated the resources required locally
for the pilot trial with their respective research and development departments and LCRNs.Patient and public involvement
Engagement with patients was vital to the successful conduct of the pilot trial. Three parents of children
who had experienced septic shock and had been admitted to a PICU provided oversight of the pilot trial:
two were co-investigators (AC and NJ) and members of the SMG, and one was an independent member
of the TSC. They provided input into the conduct of the pilot trial, including reviewing the literature to be
given to participants and their families (e.g. PISs and parent/legal representative interview topic guide).© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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18Pilot trial
Sites
Sites were set up under a ‘hub-and-spoke’ model within three geographical regions: Bristol, London (North
Thames) and Southampton. The ‘hubs’ were four regional hospitals with integral PICUs (two hospitals
covered the same region), three of which also had an integrated ED and paediatric assessment unit [(PAU)
or equivalent]. The ‘spokes’ were nine hospitals within the selected regions, which had an ED but did not
have an integral PICU. The criteria for inclusion as a study site were:l
l
l
l
l
l
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NIHRsites meet all responsibilities as stated in the pilot trial clinical trial site agreement
sites identify and sign up a local PI
sites identify a responsible FiSh trial research nurse (to be funded, or part-funded, centrally)
sites agree to incorporate the FiSh trial into routine ED and PAU (or equivalent) activity, in particular,
by highlighting the importance of screening at ED and PAU (or equivalent) presentation
sites agree to adhere to randomisation allocation and to ensure adherence to the protocol
sites agree, when possible, to recruit all eligible patients to the FiSh trial and to maintain a
screening log.The ‘hub’ sites were chosen during the grant application stage. For the nine ‘spoke’ sites, invitations for
expressions of interest were sent to lead clinicians in emergency and critical care medicine at NHS hospitals
within the three regions. Sites that expressed interest were asked to complete a site feasibility questionnaire.
After reviewing the questionnaires, teleconferences were held with all potential hospitals to assess the
engagement and support of the clinical team, the integration of the pilot trial into clinical practice
(e.g. screening, randomising, delivering the intervention) and any potential challenges/barriers to running
the pilot trial at their site. The final sites included in the study are listed in Table 2.LE 2 Final sites included in study
e Name of PI
stol Royal Hospital for Children (B) Dr Mark D Lyttle
elsea and Westminster Hospital (NT) Dr Hester Yorke
eat Ormond Street Hospital for Children (NT) Professor Mark J Peters
sgrove Park Hospital (B) Dr Esther Wilson
rthwick Park Hospital (NT)a Dr Sathish Bangalore
een Alexandra Hospital (S) Dr Alan Charters
yal Devon and Exeter Hospital (B) Dr Simon Parke
yal United Hospital (B) Dr Elizabeth Gilby
isbury District Hospital (S)a Dr Nick Brown
uthampton General Hospital (S) Dr Jane Bayreuther
Mary’s Hospital (NT) Dr David Inwald
tford General Hospital (NT) Dr Solomon Kamal-Uddin
ittington Hospital (NT) Dr Kerry Robinson
Bristol network; NT, North Thames network; S, Southampton network.
Replacement site.
Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 51Site initiation
Site teams from all participating sites attended a site initiation meeting before the commencement of
patient screening. Site initiation meetings were held at each participating site between 13 June 2016 and
23 November 2016. The purpose of these meetings was to present the background and rationale for the FiSh
trial, present the FiSh feasibility study findings and discuss delivery of the protocol, including the screening and
recruiting of patients, as well as the delivery of the intervention, data collection and validation, and safety
monitoring. The operational challenges of conducting the pilot trial at sites were discussed in detail, including
strategies for ensuring effective communication within the ED, PAU (or equivalent), retrieval transport services
and PICU. The PI from each participating site attended the relevant meeting. A standardised slide set from the
site initiation meetings was circulated to facilitate internal training within a participating site.
Investigator site file
An investigator site file was provided to all participating sites. This contained all essential documents
for the conduct of the pilot trial and included the approved pilot trial protocol; all relevant approvals
(e.g. local confirmation of capacity and capability); a signed copy of the clinical trial site agreement; the
delegation of trial duties log; copies of the approved PISs, parent/legal representative consent forms and
participant assent form (one for 8- to 10-year-olds and a second for those aged ≥ 11 years); and all
standard operating procedures, for example for screening patients, randomising participants, delivering
the intervention, obtaining informed consent or assent and collecting and entering data onto the secure,
dedicated, electronic case report from (eCRF). The site PI was responsible for maintaining the investigator
site file. Responsible staff at sites were authorised to carry out pilot trial duties (e.g. consenting, oversight
of the delivery of the intervention) by the site PI on the delegation of trial duties log. This included a
confirmation that the individual had been adequately trained to carry out the specific duty.
Communication
The study manager, with support from the data manager and research assistant, maintained close contact
with the PI and research team at participating sites by e-mail and telephone throughout the pilot trial.
Teleconferences were held every month with research teams at participating sites. The purpose of these
was to provide updates on pilot trial progress and to provide a forum for site teams to ask questions,
discuss local barriers and challenges to the conduct of the pilot trial and delivery of the intervention,
and to share successes and best practice. Notes, including ‘hints and tips’, from the teleconferences were
distributed to all participating sites. Teleconferences were also held with individual site teams as required
to address site-specific issues in the conduct of the pilot trial.
Site monitoring visits
At least one routine monitoring visit was conducted at all participating sites during the pilot trial. During
the site visit, the investigator site file was checked for completeness (i.e. that all essential documents were
present); the parent/legal representative consent forms and participant assent forms (if applicable) were
checked to ensure that the relevant correctly completed form was present for each participant recruited
into the pilot trial (or, if the parents/legal representatives were followed up for consent by post, evidence
of the postal consent covering letters for non-responders); and a random sample of participant case report
forms (CRFs) were checked against the source data for accuracy and completeness. After the visit, the PI
and site team were provided with a report summarising the documents that had been reviewed and any
actions required by the site team. The site PI was responsible for addressing the actions and reporting back
to the ICNARC CTU. Additional visits were conducted on a risk-based approach using recruitment rates,
data quality and adherence to the protocol as central monitoring triggers.
Maintenance and motivation
During the pilot trial, an e-mail was sent each week to site teams with an update on participant recruitment
and a newsletter was sent every 2 months. These provided an opportunity to clarify any issues related to the
conduct of the pilot trial and to share ideas for maximising recruitment, as well as maintaining motivation
and involvement through regular updates on progress. To maintain the profile of the pilot trial at participating
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20the ED and resuscitation bays, PAU (or equivalent) and PICU, for example, in fluid-bag storage areas.
Furthermore, information posters were displayed in family/relative waiting rooms, pocket cards summarising
the eligibility and shock criteria were distributed, branded pens were distributed to staff, labels for patient
notes (e.g. ‘This is a patient is on a clinical trial’) were provided and certificates were given from PIs to clinical
staff in recognition of their contribution to the trial. Additional materials, such as a quiz and biweekly localised
newsletter, were provided to boost the profile of the pilot trial going into the last few weeks of recruitment.
Support
A 24 hours per day, 7 days per week, telephone support service was available to site teams, via the CTU,
for advice on the screening and recruitment of patients and the delivery of the intervention. This ensured
access to clinicians to answer any queries on the eligibility of patients and delivery of the intervention.
Recruitment
The trial procedures for recruitment and follow-up of participants are summarised in Figure 3.
Eligibility criteria
Patients were eligible for inclusion in the pilot trial if they met all of the following criteria:l
l
l
l
l
l
l
FIGU
NIHRaged ≥ 37 weeks (corrected gestational age) and < 16 years
clinical suspicion of infection
clinical signs of shock (defined as age-adjusted hypotension or prolonged CRT of ≥ 3 seconds) after
receipt of 20 ml/kg of fluid bolus
recruitment and randomisation to take place while patient is in an acute assessment area.Exclusion criteria
Patients were excluded from the pilot trial if they met any of the following criteria:prior receipt of > 20 ml/kg of fluid bolus
conditions in which fluid bolus resuscitation should be curtailed
full active resuscitation not within current goals of care.Screening
Eligibility met while in ED or PAU or equivalent
Randomisation
Via sealed envelopes
Follow-up to 30 days
• Predefined outcome measures
• Mortality at 30 days
Bolus fluid resuscitation
with 10-ml/kg fluid boluses
Bolus fluid resuscitation
with 20-ml/kg fluid boluses
Informed consent
RE 3 Summary of trial procedures for recruitment and follow-up of participants.
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Following attendance at a site initiation meeting, screening and recruitment was commenced at
participating sites once the clinical trial site agreement had been signed and necessary approvals were in
place. To promote awareness of the pilot trial and to facilitate recruitment, posters and leaflets providing
information about the FiSh trial were displayed in the ED, PAU (or equivalent) and family/relative waiting
rooms. Potentially eligible patients were identified, confirmed as eligible by the local research and clinical
teams and then randomised before informed consent was obtained, because patients requiring fluid
bolus resuscitation as treatment for septic shock would most often need this treatment to be started in a
life-threatening emergency, in which any delay in commencing treatment could have been detrimental.
Randomisation and allocation procedure
Following confirmation of eligibility, participants were randomised using sealed randomisation envelopes
located at each hospital. Participants were randomly allocated, 1 : 1, to either the 10-ml/kg fluid bolus
group or the 20-ml/kg fluid bolus group, from an a priori computer-generated list of randomised permuted
blocks (with variable block lengths) stratified by recruiting site. Staff at participating sites were advised to
call either their local FiSh trial on-call clinicians or the 24 hours per day, 7 days per week, telephone
support service if they needed to address any emergency recruitment/randomisation issues.
Screening log
To enable full and transparent reporting for the pilot trial, brief details of all patients who met eligibility
criteria, those who met all inclusion criteria plus one or more of the exclusion criteria and those who
did not meet the ‘clinical signs of shock after receipt of 20 ml/kg of fluid bolus’ inclusion criterion were
recorded in the screening log. The reasons for eligible patients not being recruited were recorded and
included the patient being excluded by the treating clinician and logistical reasons. No patient identifiers
were recorded in the screening log.
Consent
Staff members who had received training on the background, rationale and purpose of the FiSh trial
and on the principles of the good clinical practice guidelines were authorised by the PI to take informed
consent from parents/legal representatives. This method used for the FiSh pilot trial is known as ‘deferred’ or
‘retrospective’ consent, referred to here as RWPC. However, the terms ‘deferred’ and ‘retrospective’ are
misnomers, as a child will have already received an intervention as part of the pilot trial before any information
is given or consent is sought. Rather, the process should be understood, first, as the provision of information
about what has already happened, and, second, as an invitation to consent for future procedures (when
appropriate) and permission for the use of any data already collected.
Once notified of the recruitment of a participant to the pilot trial, a member of the site research team
approached the parents/legal representatives as soon as practically and appropriately possible after
randomisation to discuss consent for the pilot trial.
Information about the pilot trial was provided to the parents/legal representatives and included the
purpose of the pilot trial, the reasons why informed consent could not be sought from parents/legal
representatives before their child was entered into the pilot trial, what participation in the pilot trial meant
(i.e. permission for the use of data already collected and for their child to continue to take part in the pilot
trial), participant confidentiality, future availability of the results of the pilot trial and funding of the pilot
trial. Information on completing an optional questionnaire and/or taking part in a telephone interview was
also provided. This information was provided in the pilot trial PIS, along with the name and contact details
of the local PI and research nurse(s), which was given to the parents/legal representatives to read before
making their decision for their child’s data to be used, or not, and for their child to continue to take part,
or not, in the pilot trial. Once the staff member taking informed consent was satisfied that the parents/
legal representatives had read and understood the PIS and all their questions about the pilot trial had been
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22Death prior to consent being sought
The views of bereaved parents who participated in the FiSh feasibility study (see Chapter 2) and guidance
on RWPC in emergency and critical care trials were used to inform the approach to consent when a
child had died before consent had been sought from parents/legal representatives.27 In this situation,
a researcher would obtain information from colleagues and bereavement counsellors to establish the most
appropriate research team member to notify the parents/legal representatives of the pilot trial. Consent
could have been sought from parents/legal representatives following the death of their child and before
their departure from the hospital; however, it was at the discretion of the site staff to determine if this was
appropriate for each individual family. If consent was not sought before the parents’/legal representatives’
departure from the hospital, then the parents/legal representatives were sent a covering letter (personalised
by the most appropriate clinical team member) and a copy of the PIS (a version for bereaved parents/legal
representatives) and consent form (postal version for bereaved parents/legal representatives) by post 4 weeks
after randomisation. The letter explained how to opt in or out of the pilot trial, directed them to the PIS for
detailed information on the pilot trial and provided telephone contact details if parents/legal representatives
wished to discuss the pilot trial with a member of the site research team. If there was no response 4 weeks
after sending the initial letter, a follow-up letter, along with the PIS and consent form, was sent. The second
letter provided the same information as the first letter; in addition, this letter also confirmed that, if no
consent form was received within 4 weeks of receipt of the letter, then the participant’s data would be
included in the pilot trial unless the family notified the site research team otherwise.
Discharge prior to consent being sought
In the situation in which a participant was discharged from hospital before consent had been sought,
the most appropriate member of the site research team attempted at least one telephone call to
the parents/legal representatives within 5 working days of hospital discharge to inform them of the
participant’s involvement in the pilot trial and to provide details of the pilot trial. Following on from the
call, as well as if there was no response to the call, the parents/legal representatives were sent a covering
letter (personalised by the most appropriate clinical team member) and a copy of the PIS and consent form
(postal version) by post. The letter explained how to opt in or out of the pilot trial, directed parents/legal
representatives to the PIS for detailed information on the pilot trial and provided telephone contact details
if parents/legal representatives wished to discuss the pilot trial with a member of the site research team.
If there was no response 4 weeks after sending the initial letter, a follow-up letter, along with the PIS and
consent form, was sent. The second letter provided the same information as the first letter; in addition,
this letter also confirmed that, if no consent form was received within 4 weeks of receipt of the letter,
then the participant’s data would be included in the pilot trial unless the family notified the site research
team otherwise.
Assent
Owing to the severity of illness and its effect on the mental state of the target population, it was not
considered possible to involve pilot trial participants in the consenting process. Instead, there was a
possibility for participants to assent to the trial, before hospital discharge, if the participant was ≥ 8 years
old (e.g. old enough to be able to make an informed decision) and their condition allowed (e.g. they
regained capacity). Pilot trial participants would have been provided with an age-appropriate PIS and
asked to sign an assent form, if appropriate. Parents/legal representatives would have been involved in
this discussion. In all other respects, the assenting procedures followed the consenting procedures as
described above. If the participant was likely to regain capacity following hospital discharge, then an
age-appropriate PIS was provided to parents/legal representatives to discuss with the participant,
following recovery.
Treatment groups
Participants were randomly allocated to fluid bolus resuscitation using boluses of two different sizes
over a 4-hour period (Figure 4). The period was divided up into 15-minute cycles, with one bolus of either
10 ml/kg or 20 ml/kg to be delivered within each cycle, at a rate left to the discretion of the treating
clinician. There was no attempt to blind clinicians to the allocated treatment group as this was not felt toNIHR Journals Library www.journalslibrary.nihr.ac.uk
Randomise by envelope in participating
acute assessment units (e.g. ED, PAU)
At end of 15-minute cycle: assess for hold criteria:
•  Resolution of age-adjusted clinical signs of shock
       •  Hypotension OR CRT ≥ 3 seconds
•  Signs of fluid overload
If hold criteria not met, administer another fluid bolus
to a maximum of 120 ml/kg (excludes original 20 ml/kg)
Restrictive bolus
fluid resuscitation
10-ml/kg fluid bolus completed
within 15 minutes
Current recommended
bolus fluid resuscitation
20-ml/kg fluid bolus completed
within 15 minutes
Continue to monitor as per usual practice
If hold criteria are no longer present during the 4 hours post
randomisation
Revert to usual care at 4 hours post randomisation
Hold criteria met
Hold
criteria
not met
Hold criteria
no longer
present
Hold
criteria
not met
Hold criteria
no longer
present
FIGURE 4 Fluid bolus resuscitation algorithm.
DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 51be pragmatic, given the ED setting and the need for clinical staff to prescribe, draw up and administer the
fluid boluses. The maximum volume of fluid that could be given per bolus was either 500ml (for those allocated
to 10-ml/kg fluid boluses) or 1000 ml (for those allocated to 20-ml/kg fluid boluses). Other interventions,
including referral to PICU, were not protocolised and were left to the discretion of the treating clinician. As a
pragmatic pilot trial, FiSh also did not dictate the use of specific fluid products. At the end of each cycle, should
the age-adjusted clinical signs of shock [defined as age-adjusted hypotension (Table 3) or prolonged CRT of
≥ 3 seconds] persist, then another bolus of the same size (i.e. according to the randomly allocated group) was
given – again, at a rate left to the discretion of the treating clinician but within a 15-minute cycle.TABLE 3 Age-adjusted hypotension shock criteria
Age group SBP (mmHg)
0 days–1 week < 60
1 week–1 year < 70
1–2 years < 75
2–5 years < 80
5–12 years < 85
12–16 years < 90
SBP, systolic blood pressure.
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24The cycles repeated until either the end of the 4-hour resuscitation period or any of the hold criteria
occurred. If a participant’s age-adjusted clinical signs of shock resolved or if a participant showed signs of
fluid overload (defined as pulmonary oedema – either rales on auscultation or pulmonary oedema fluid in the
endotracheal tube – or new or increasing hepatomegaly), the delivery of further fluid boluses was withheld.
If, within the 4-hour resuscitation period, fluid boluses were indicated again, that is, age-adjusted clinical
signs of shock were present without signs of fluid overload, then the cycles were recommenced with the
allocated boluses until the end of the 4-hour resuscitation period. After the 4-hour resuscitation period, any
further treatment was at the discretion of the treating clinician.
The maximum volume of fluid that could be given within the pilot trial protocol, regardless of allocation,
was 120 ml/kg (excluding the 20-ml/kg fluid bolus pre randomisation). If > 120 ml/kg of fluid was required,
then further treatment was at the discretion of the treating clinician.
Outcome measures
The combined objectives were to test whether or not all of the processes could work together, and to inform
the design, and ensure the successful conduct, of the FiSh trial (should this be the recommendation).
Objectives 1, 2 and 4 were measured by the:l
l
l
l
l
l
l
l
l
l
NIHRproportion of eligible patients recruited
number of participants recruited per site per month
proportion of parents/legal representatives refusing consent.Objective 3 was measured by:the proportion of fluid boluses delivered at the correct volume and time during the intervention period
comparing the total volume of fluid received in each arm during the intervention period.Objectives 5–8 were measured by the:proportion of complete data for each outcome measure
characteristics of potential outcome measures
observed AEs
time taken for data collection and entry
proportion of required data that could be linked to routine sources.Safety monitoring
Participants were monitored for AEs occurring between randomisation and 30 days following randomisation.
Specified AEs were as follows: pulmonary oedema, cerebral oedema, extravasation injury, amputation and
skin graft. An unspecified AE was defined as an unfavourable symptom or disease temporally associated with
the use of the pilot trial treatments (regardless of whether or not it was related to the pilot trial treatment)
that was not deemed to be a direct result of the participant’s medical condition and/or standard emergency
or critical care treatment. All AEs were recorded in the eCRF and reported, as part of routine reporting
throughout the pilot trial, to the DMEC. AEs that were assessed to be serious (i.e. causing prolonged
hospitalisation or resulting in persistent or significant disability/incapacity), life-threatening or fatal – collectively
termed serious adverse events (SAEs) – were reported to the ICNARC CTU and reviewed by a clinical member
of the SMG. SAEs that were unspecified and considered to be possibly, probably or definitely related to the
pilot trial treatment were reported to the REC within 15 calendar days of the event being reported.
Data collection
A secure, dedicated eCRF, hosted by ICNARC, was set up to enable pilot trial data to be entered by staff at
participating sites. The eCRF was accessible only to authorised users and access was approved centrally byJournals Library www.journalslibrary.nihr.ac.uk
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duties log). Each individual was provided with a unique username and password and had access to data
only for participants recruited at their site. The data set for the FiSh trial included the minimum data
required to confirm patient eligibility, describe the patient population, monitor and describe the delivery
of the intervention, assess outcomes and enable linkage to the Paediatric Intensive Care Audit Network
[(PICANet) the UK national clinical audit for paediatric intensive care] and the NHS Spine web portal.
PICANet data were available only for patients admitted to a PICU and included mechanical ventilation
days, length of PICU stay and PICU mortality.
Baseline data
Data were collected to enable the patient to be randomised and included confirmation that the patient
met all of the inclusion criteria and none of the exclusion criteria. The following data were also collected
at baseline to enable follow-up and describe the patient population:l
l
l
l
l
l
l
l
l
l
l
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Park,full name and home postcode of the patient
date of birth
sex
raw physiology data to enable calculation of the Paediatric Index of Mortality version 2r (PIM2r) score,
the standard severity of illness scoring system in use across UK PICUs, according to the 2016
recalibration46–48
severe comorbidities defined according to PIM2r that were present and documented in past medical
history.Intervention data
Data were collected before, during and after each bolus delivery throughout the 4-hour intervention
period to monitor adherence to the treatment allocation (10-ml/kg or 20-ml/kg, fluid boluses) and to
describe delivery of the 10-ml/kg fluid boluses compared with 20-ml/kg fluid boluses (usual resuscitation).
The data collected included fluid bolus delivery, including volume and type of fluid and bolus end time,
and assessments, including systolic blood pressure, CRT and shock-confirmed time.
Treatment summary data
Following the intervention period, the following data were collected:other interventions delivered during the intervention period, including mechanical ventilation and
vasoactive drugs
total fluid bolus and total fluids (including fluid bolus) received from randomisation to the end of both
4 and 24 hours
site of infection and causative organism (if available) and type of intravenous antibiotics first
administered.For patients who were admitted to a PICU, daily intervention data were obtained through PICANet.
Outcome data
At the time of discharge from the acute hospital, the following data were collected:the locations of care during the patient’s stay in the acute hospital, for example ED, PAU (or equivalent),
PICU or ward
date of discharge from, or death in, the acute hospital
discharge location, for example home, nursing home or other hospital.All patients were followed up at 30 days post randomisation for all-cause mortality via the NHS Spine
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26Data management
Data management was an ongoing process. Data entered by sites onto the eCRF were monitored
and checked throughout the recruitment period to ensure that they were as complete and accurate as
possible. Two levels of data validation were incorporated into the eCRF. The first was to prevent obviously
erroneous data from being entered, for example entering a date of birth that occurred after the date of
randomisation. The second level involved checks for data completeness and any unusual data entered, for
example a physiological variable, such as systolic blood pressure, that was outside the predefined range.
The data manager could generate data request checks, listing all outstanding data queries, at any time via
the eCRF. The site PI was responsible for ensuring that all data queries were resolved. Ongoing data entry
and validation at sites was closely monitored by the data manager and any concerns were raised with the
site PI.
Adherence to the pilot trial protocol was closely monitored, including adherence to all elements of the
fluid bolus resuscitation protocol. Any queries relating to adherence were also generated as data request
checks via the eCRF. For each query, the PI and/or site research team were asked to explain the reason for
any non-adherence to the protocol. If deemed necessary, a teleconference was arranged with the site to
ensure effective plans were put in place to improve future adherence.
Sample size
The pilot trial was set up as a small RCT without a defined primary outcome and, hence, without a usual
power calculation to determine sample size. Instead, the sample size had been determined to be adequate
to estimate critical parameters to be tested to a necessary degree of precision. With respect to sample
size, a frequently quoted ‘rule of thumb’ for the sample size of pilot trials is to recruit 30 participants.49
However, more recent research has demonstrated that such a sample size will result in an imprecise
estimate of the SD of a potential outcome measure, which will frequently lead to definitive studies that
are either underpowered (if the imprecision of the estimated SD is not taken into account in the sample size
calculation) or inefficient (if it is).50 Sim and Lewis50 suggest that a sample size of around 60 participants
would usually be sufficient to estimate the SD for a continuous outcome measure; however, the authors
note that estimating the precision of a binary outcome will require a larger sample size, typically requiring
between 98 and 260 participants. Based on available data from PICANet and the PICS-SG severe sepsis
audit,3 it was anticipated that each of the EDs of regional hospitals with PICUs in the pilot trial and each of
the nine feeder hospital EDs – a total of 12 sites – would recruit approximately one child per month, giving a
total of around 108 children.
Interim analysis
Unblinded, comparative data on recruitment, withdrawal, adherence (to the allocated treatment) and AEs
were regularly reviewed by an independent DMEC. No formal interim analyses were performed owing to
the nature of the pilot trial.
Analysis principles
All analyses were based on the intention-to-treat principle. Participants were analysed in accordance with
the treatment group they were randomised to, irrespective of whether or not the allocated treatment was
received (i.e. regardless of whether they did or did not adhere to the fluid bolus resuscitation protocol).
All tests were two-sided with significance levels set at a p-value of < 0.05 and with no adjustment
for multiplicity.
Statistical analysis
Statistical analyses were conducted in accordance with a prespecified statistical analysis plan written before
the final analysis. The final analyses were conducted using Stata®/SE version 14.0 (StataCorp LP, College
Station, TX, USA).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Recruitment to the pilot trial, treatment allocation and completeness of follow-up were illustrated using a
Consolidated Standards of Reporting Trials (CONSORT) flow diagram. All participating sites maintained
screening logs of patients who were eligible (fulfilled all of the inclusion criteria and none of the exclusion
criteria) but were not randomised, who fulfilled all of the inclusion criteria but met one or more of the
exclusion criteria, and who did not fulfil ‘clinical signs of shock after receipt of 20 ml/kg of fluid bolus’
inclusion criterion. Reasons for non-recruitment were categorised and summarised (see Figure 7). Numbers
and percentages of screened and randomised infants and children were presented. The following were
reported for each treatment group:l
l
l
l
l
l
l
l
l
l
l
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the number of patients who received a 20-ml/kg fluid bolus
the number of patients with resolved shock after the initial 20-ml/kg fluid bolus
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the exclusion criteria.eRecruitment rate
Recruitment to the pilot trial was presented as a rate over the recruitment period and per month, overall
and per site. The variation in recruitment rates across sites was presented as a funnel plot (recruitment rate
against months open to recruitment).
Refused consent
The number and percentage of participants in each treatment group that had RWPC either refused initially
or subsequently withdrawn was reported.
Baseline characteristics
Baseline demographic and clinical data were summarised by treatment group. Statistical tests for
differences between the groups were not reported, as these may be misleading. Discrete variables were
summarised as numbers and percentages, which were calculated according to the number of participants
for whom data were available; when values were missing, the denominator was reported. Continuous
variables were summarised by standard measures of central tendency and dispersion, either mean and SD
and/or median and interquartile range (IQR) as specified below:age, mean (SD) and median (IQR)
sex, n (%)
weight, mean (SD) and median (IQR)
inclusion criteria –clinical signs of shock, n (%)
¢ systolic blood pressure value at which criterion for clinical signs of shock was met, mean (SD)
¢ CRT value at which criterion for clinical signs of shock was met, mean (SD)Printer
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28Adherence
Non-adherence to the allocated treatment was reported for each treatment group as the number and
percentage of participants:l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
NIHRwho did not receive first bolus
for whom for subsequent boluses –¢
¢
Jourbolus was given but shock criteria were not met
shock criteria were met but no bolus was given.nDelivery of care
Delivery of care was summarised by treatment group but not subjected to statistical testing. As with
baseline characteristics, discrete variables were summarised as numbers and percentages. Percentages
were calculated according to the number of participants for whom data were available; when values were
missing, the denominator was reported. Continuous variables were summarised by both mean (SD) and
median (IQR) to maximise information on the distribution of these key parameters of the intervention.
Variables reported were:number of boluses delivered
total volume of fluid bolus resuscitation at 1 hour and during the intervention period
receipt of fluid bolus resuscitation of 10 ml/kg (± 10%)
receipt of fluid bolus resuscitation of 20 ml/kg (± 10%)
delivery of boluses within 15 minutes (overall and by age group)
fluid boluses delivered at correct volume and within 15 minutes during the intervention period.Overall adherence was reported as the number and percentage of participants in each treatment group with
fluid boluses delivered at the correct volume and timing during the intervention period. The distribution of
the total volume of fluid received during the intervention period in each treatment group was presented
as a histogram. Separation between the treatment groups was assessed by the difference in the mean total
volume of fluid, tested with a t-test and reported difference in means with 95% confidence interval (CI).
Outcomes
The following potential outcome measures were reported for each treatment group:hospital mortality
mortality within 30 days post randomisation
length of hospital stay
transferred to a PICU
length of stay in a PICU among those admitted
days alive and not in a PICU up to 30 days (deaths within 30 days score of 0; infants and children not
admitted to PICU score of 30)
receipt of mechanical ventilation
duration of mechanical ventilation among those ventilated
days alive and free of mechanical ventilation up to 30 days (deaths within 30 days score of 0; infants
and children not receiving mechanical ventilation score of 30).Although this was a pilot RCT and not powered to detect differences in outcomes, the potential outcome
measures were tested between the groups to gain further understanding of the potential magnitude of
any treatment effect from the width of the CIs. Differences in binary outcomes were tested with Fisher’s
exact test and presented as the number and percentage in each treatment group, absolute risk difference
and relative risk with 95% CIs. Differences in lengths of stay and duration of organ support were tested
with the Wilcoxon rank-sum test and presented as median (IQR) in each treatment group. Differences inals Library www.journalslibrary.nihr.ac.uk
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presented as difference in means with 95% CI.
For all potential outcome measures, the number of participants with complete data in each treatment
group was reported. For measures requiring data linkage with routine data sources, the proportion of
successfully linked records was reported.
Safety monitoring
The number and percentage of participants experiencing each AE and SAE (occurring between
randomisation and 30 days) were reported for each treatment group.Integrated perspectives study
Participants
Based on previous research and the pilot trial sample size,18 it was estimated that 100–150 parents/legal
representatives (including both mothers and fathers of randomised children) would be recruited to the
questionnaire element and 15–25 parents/legal representatives would be recruited to the interview
element. In addition, three focus groups at the hub sites and up to 10 telephone interviews with staff
who could not attend the focus groups were planned.
Eligibility
Parents/legal representatives
Parents/legal representatives who did and did not consent to their child’s participation in the pilot trial
were eligible to take part in the questionnaire and interview elements, unless they were unable to speak
and read English.
Site staff
Site staff who were involved in screening, recruiting, randomising and consenting parents/legal
representatives during the pilot trial were eligible to take part in the focus groups or interviews.
There were no exclusion criteria.
Recruitment and consent procedure
Parents/legal representatives
As part of the pilot trial consent discussion, parents/legal representatives were provided with information
about the integrated perspectives study elements in the pilot trial PIS. Researchers explained the different
aspects of the pilot trial and asked parents/legal representatives if they would like to complete the FiSh
trial consent questionnaire (see Appendix 5) and/or provide contact details on the consent form if they wished
to take part in a telephone interview. Following the consent discussion, parents/legal representatives (both,
if present) were asked to complete the questionnaire and place it in a stamped addressed envelope to be
returned, preferably before they left hospital. Parents/legal representatives contacted about the pilot trial by
post (see Death prior to consent being sought and Discharge prior to consent being sought) were provided
with information on the telephone interview only. A researcher contacted parents/legal representatives to
arrange an interview within 1 month of consent. Consent for audio-recording of interviews was checked
verbally before the interview began.
Site staff
An invitation to participate in a focus group at one of the three hub sites was e-mailed to site PIs and/or
lead research nurses. They were also asked to send the invitation to all staff involved in the FiSh pilot trial
at their site. The e-mail included a PIS for staff, which provided information about the purpose of the
integrated perspectives study elements; what the focus group/interview would involve; how the integrated© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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METHODS FOR PILOT TRIAL WITH INTEGRATED PERSPECTIVES STUDY
30perspectives study elements were funded; and the consequences of participating or not. Telephone
interviews were provided as an alternative option for staff who could not attend a focus group. An e-mail
invitation was also sent to the PI and/or lead research nurse at each spoke site inviting them to take part
in a telephone interview. Written consent was sought from staff before the focus group began, and verbal
consent was sought before the telephone interview began. Consent for audio-recording of interviews was
checked before the focus group or interview began.
Interviews and focus groups
Telephone interviews with parents/legal representatives
The telephone interview began with a discussion about the parent’s/legal representative’s child’s admission
to hospital and current well-being, the aims of the interview, an outline of the topics to be covered in the
interview and an opportunity for questions. The interview then commenced using the interview topic guide
to explore views and experiences about the child’s admission to hospital, including their diagnosis; the
pilot trial consent process, including how the pilot trial was communicated by staff and information
materials; consent and decision-making, including how pilot trial processes could be improved; child
assent; and outcome measures. Example questions are shown in Appendix 6. Respondent validation was
used to add unanticipated topics to the topic guide as interviewing and analysis progressed.24 After the
interview was complete, parents/legal representatives were sent a copy of the consent form, a thank-you
letter and £30 shopping voucher to thank them for their time.
Focus groups and interviews with site staff
Focus groups and interviews began by asking staff to introduce themselves and their role within the
FiSh pilot trial. The focus group/interview aims and topics to be covered were discussed, followed by an
opportunity for questions. In the focus groups, a voting system, using TurningPoint software version 5
(Turning Technologies, Youngstown, OH, USA), was used alongside verbally administered questions. This
involved some of the questions (see Appendix 7) being presented to the group via a laptop presentation
and each participant using a wireless handset to select their answer from those shown on the screen.
A test question was used at the beginning of the focus group to help demonstrate how the voting system
would work alongside verbal questions. This method was to used enable the collection of data from all
participants, as well as to generate statistical data from all sites alongside qualitative data from group
discussions. The same topic guide was used for focus groups and interviews, although questions
(e.g. voting system questions) were adapted for telephone interviews.
Focus groups and interviews explored staff views on, and experiences of, site training; FiSh pilot trial
screening and randomisation processes; protocol deviations; recruitment and consent, including parent/
legal representative responses to RWPC; and FiSh pilot trial forms, including CRFs and consent forms.
Example questions are shown in Appendix 7. Respondent validation was used to add unanticipated topics
to the topic guide as interviewing and analysis progressed.24 After the focus groups and interviews were
complete, all participants were sent a copy of the consent form (if applicable) and thanked for their time.
Transcription
Digital audio-recordings were transcribed verbatim by a professional transcription company (Voicescript
Ltd) in accordance with the Data Protection Act 1998.25 Transcripts were anonymised and checked for
accuracy. All identifiable information, such as names (e.g. of patients, family members or the hospital that
their child was admitted to), was removed.
Data analysis
The analysis of qualitative data were broadly interpretive and iterative (see Table 19).31,32 Informed by the
constant comparative approach, the aim was to provide accurate representation of parental views on trial
design and acceptability.29,33–35 NVivo 10 software was used to assist in the organisation and coding of data.
Data from voting handsets were cleaned and entered into IBM SPSS Statistics version 20.0 (IBM Corporation,
Armonk, NY, USA). Descriptive statistics are presented with percentages.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The four ‘hub’ sites were chosen during the grant application stage. For the nine ‘spoke’ sites, expressions of
interest were received from 21 NHS hospitals across the three UK regions, with 18 completing a site feasibility
questionnaire. After the initial selection of the nine ‘spoke’ sites, two sites withdrew and were replaced:l
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Park,one hospital had a restructuring of their research team that led to a reduction in resources in ED
(date of withdrawal – 3 June 2016)
one hospital had a lack of resources and support for the study in their paediatric team (including
capacity for additional workload) (date of withdrawal – 18 August 2016).A total of 12 hospitals in England obtained local confirmation of capacity and capability and opened to
recruitment between 13 July and 23 November 2016. Seven sites were opened within the first 2 months
of the pilot trial opening on 13 July 2016 (Figure 5). The London region included a second hub site (PICU
only), which did not recruit patients as it has no ED, but was open to receive patients randomised at the
spokes from 9 August 2016.
The median time from receiving the local document pack, including the HRA initial assessment letter, to the
pilot trial opening at sites (i.e. start of screening) was 95 days (IQR 81–124 days) and to the first participant
recruited was 150 days (IQR 124–178 days) (Figure 6). Reasons for delays in opening were as follows:hospital research and development teams transitioning to the new HRA approval
delays in contracting with the sponsor
time needed to train staff across up to four departments (ED, paediatrics, PICU and retrieval) – this
affected not only arranging the initial site initiation visit but the training to be done by the local teams
arranging replacement sites for the withdrawn sites
a new area of research for some sites – for some of the sites, this was their first foray into paediatric
research in the emergency care setting, thus additional time and training was needed.R
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RESULTS OF THE PILOT TRIAL
32Overall, sites participated in the FiSh pilot trial for a median of 7 months (IQR 6–8 months). All sites
remained open until the end of recruitment on 31 March 2017 (see Figure 5). One site recruited an
additional participant on 3 April 2017 after the study had closed to recruitment, as not all staff in the
site were aware that the study had closed.
Characteristics of participating sites
The characteristics of the 12 EDs recruiting patients to the FiSh pilot trial, compared with all EDs participating
in the PERUKI research collaborative, are shown in Table 4. The characteristics were broadly similar. There was
a lower percentage of paediatric hospitals participating in the FiSh pilot trial than in PERUKI, and a slightly
lower proportion with PICU on site, but these characteristics are likely to be over-represented among PERUKI
participants relative to the national picture.Participants: patients
In total, 297 patients were screened between 13 July 2016 and 3 April 2017 (Table 5 and Figure 7). Of
these, 88 (29.6%) patients received a fluid bolus of < 20 ml/kg and did not meet the defined clinical signs
of shock. The remaining 209 (70.4%) patients received a fluid bolus of ≥ 20 ml/kg; of these, 101 (48.3%)
patients were assessed as requiring further fluid boluses within the ED or PAU (or equivalent). Of these
101 patients, there were 18 (17.8%) patients who met one or more exclusion criteria. Of these, 12 had
received an initial bolus of > 20 ml/kg and met no other exclusion criteria and so were potentially eligible
patients who were missed. In total, 83 of the patients screened were eligible for the pilot trial. Eight
(9.6%) of these were not recruited. As a consequence of clinical staff having insufficient knowledge of
the pilot trial, most of the small number of eligible patients were not recruited. Overall, 75 out of theNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 4 Characteristics of participating EDs compared with all EDs in PERUKI
Characteristics
EDs
Participating in FiSh pilot trial All in PERUKI
Number of EDs (n) 12 52
Tertiary referral hospital, n (%) 5 (41.7) 28 (53.8)
Type of paediatric ED, n (%)
Combined adult and paediatric ED 6 (50.0) 17 (32.7)
Separate paediatric ED in mixed hospital 5 (41.7) 24 (46.2)
Paediatric hospital ED 1 (8.3) 11 (39.3)
Annual paediatric ED census (thousands), median (IQR) [n] 22.5 (17–30) [12] 27 (20–37) [49]
PICU on site, n (%) 3 (25.0) 20 (38.5)
TABLE 5 Screening and recruitment
Variables Participants
Screened (n) 297
Received fluid bolus
≥ 20ml/kg, n (%) 209 (70.4)
< 20ml/kg, n (%) 88 (29.6)
N 297
Still in shock after bolus
Yes, n (%) 101 (48.3)
No, n (%) 108 (51.7)
N 209
Met exclusion criteria
No, n (%) 83 (82.2)
Yes, n (%) 18 (17.8)
N 101
Randomised
Yes, n (% of those eligible) 75 (90.4)
Missed, n (% of those eligible) 6 (7.2)
Other, n (% of those eligible) 2 (2.4)
N 83
DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 5183 eligible patients (90.4%) were recruited to the trial. The percentage of eligible patients recruited reduces
to 78.9% if the 12 patients who received an initial bolus of > 20 ml/kg are included in the denominator.
The 75 participants were recruited between 17 August 2016 and 3 April 2017 (Figure 8), with 40 randomised
to the 10-ml/kg fluid boluses and 35 randomised to 20-ml/kg fluid boluses (Table 6). Nine participants were
subsequently identified as having been randomised in error: seven had not met the inclusion criteria (six met
local definitions for shock using lactate or heart rate but did not meet the FiSh trial shock criteria; one was
randomised on the ward) and two had met an exclusion criterion. All nine participants randomised in error
had been allocated to the 10-ml/kg fluid bolus group.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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Children and infants
(n = 297)
Did not meet inclusion criteria
(n = 196)
Met exclusion criteria
(n = 18)
• Missed, n = 6
• Had study logistical issues, n = 2
Children and infants
(n = 75)
Were eligible but not randomised
(n = 8)
Were assigned to restricted bolus
(n = 40)
Were assigned to usual treatment
(n = 35)
Were eligible for analyses
(n = 39)
Were eligible for analyses
(n = 34)
• Was not approached for consent, n = 1
• Received initial bolus < 20 ml/kg, n = 88
• No longer in shock after initial bolus,
   n = 108
• Had initial fluid bolus of > 20 ml/kg, n = 12
• Had conditions in which bolus fluid
   resuscitation should be curtailed, n = 3
• Had initial fluid bolus of > 20ml/kg and
   conditions in which bolus fluid
   resuscitation should be curtailed, n = 2
• Did not have full active resuscitation
   within current goals of care, n = 1
• Was not approached for consent, n = 1
FIGURE 7 The CONSORT flow diagram.
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TABLE 6 Participants randomised in error, consented and withdrawn, by treatment group
Variables
Treatment group
10ml/kg 20ml/kg
Randomised, n 40 35
Subsequently identified as randomised in error, n (%)
Did not meet inclusion criteria 7 (17.5) 0 (0.0)
Met exclusion criteria 2 (5.0) 0 (0.0)
Consent obtained, n (%)
Yes – in hospital 26 (65.0) 30 (85.7)
Yes – post discharge 8 (20.0) 1 (2.9)
No response (included) 5 (12.5) 3 (8.6)
Not approached (withdrawn) 1 (2.5) 1 (2.9)
Included in ITT analysis, n 39 34
ITT, intention to treat.
DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 51There was variation across the 12 sites in the rate of recruitment (Figure 9). The overall recruitment rate
was 0.9 participants per site per month (95% CI 0.7 to 1.2 participants per site per month), compared
with a pre-trial estimate of one participant per site per month. The median recruitment rate across
individual sites was 0.6 participants per month (IQR 0.3–1.0 participants per month), and the highest
recruitment rate was 3.2 participants per month.
Participants were recruited into the pilot trial throughout all days of the week, but the lowest recruitment
was on Friday (Figure 10). Participants were generally recruited after 17.00 up until midnight (Figure 11).0
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RESULTS OF THE PILOT TRIAL
36The majority of parents/legal representatives provided informed consent while their child was still in
hospital (n = 56, 74.7%; see Table 6). For the remaining children, parents/legal representatives were
approached via post, that is, after their child had been discharged and before consent could be sought;
a response was received for nine (52.9%) patients. No response was received for eight (47.1%) patients;
the follow-up letters, approved by the REC, indicated that, if no response was received, then the patient’s
data would be used. Two (2.7%) patients (one from each treatment group) were withdrawn from the pilot
trial as the parents/legal representatives could not be approached for informed consent, resulting in data
from 73 patients for analysis. With regard to participant assent, although attempts were made to include
children and young people in the discussion about the pilot trial, child assent was not taken by any of the
participating sites, because children were either too young or too sick before discharge for a discussion
about research. Follow-up was completed on 3 May 2017.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The treatment groups were, on the whole, well matched at baseline (Table 7), with slight differences in
age and, consequently, weight. The median age of patients was 11 months for the 10-ml/kg fluid bolus
group and 2 months for the 20-ml/kg fluid bolus group (Figure 12). The participants randomised to the
10-ml/kg fluid bolus group had a mean weight at baseline of 13.3 kg, compared with 9.1 kg for the
20-ml/kg fluid bolus group, which is in line with the slightly older age distribution in this group.
More than half the participants were male (61.5% in the 10-ml/kg fluid bolus group; 52.9% in the
20-ml/kg fluid bolus group). Most participants met the shock criteria because their CRT was ≥ 3 seconds
(76.9% in the 10-ml/kg fluid bolus group; 88.2% in the 20-ml/kg fluid bolus group). The PIM2r score was
balanced across treatment groups.TABLE 7 Baseline characteristics of participants, by treatment group
Characteristics
Treatment group
10ml/kg (n= 39) 20ml/kg (n= 34)
Age (months)
Mean (SD) 30 (47) 21 (41)
Median (IQR) 11 (1–35) 2 (1–17)
Gender, n (%)
Male 24 (61.5) 18 (52.9)
Female 15 (38.5) 16 (47.1)
Weight (kg)
Mean (SD) 13.3 (15.6) 9.1 (9.4)
Median (IQR) 9 (5–13) 5 (4–10)
Shock criteria met, n (%)
CRTa only 30 (76.9) 30 (88.2)
Age-adjusted hypotension only 2 (5.1) 2 (5.9)
Both CRTa and age-adjusted hypotension 1 (2.6) 2 (5.9)
Neither 6 (15.4) 0 (0.0)
PIM2r (2016) score (%)
Mean (SD) 2.4 (1.5) 2.4 (1.8)
Median (IQR) 2.1 (1.6–2.7) 2.0 (1.6–2.5)
Infection confirmed, n (%)
No 19 (48.7) 17 (50.0)
Yes 20 (51.3) 17 (50.0)
a CRT of ≥ 3 seconds.
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FIGURE 12 Distribution of age, by treatment group. (a) 10-ml/kg fluid bolus group; and (b) 20-ml/kg fluid
bolus group.
RESULTS OF THE PILOT TRIAL
38There were 37 participants (51.3% in the 10-ml/kg fluid bolus group; 50% in the 20-ml/kg fluid bolus
group) recorded as having a confirmed infection. For 32 of these, the organism causing the infection
was identified (Table 8). Of these, only 13 were bacterial infections in sterile sites. These included five
Escherichia coli infections, two Enterococcus faecalis infections, three Streptococcus (two group A and one
group B) infections, one Staphylococcus aureus infection, one Neisseria meningitidis infection and one
Gram-positive coccal (unspecified) infection. There were 18 viral infections, 15 of which were respiratory
pathogens (eight respiratory syncytial virus, five rhinovirus, one influenza A and one metapneumovirus),
two of which were identified as enterovirus on blood polymerase chain reaction (PCR) analysis and one of
which was identified as rotavirus in stools. One patient had falciparum malaria.TABLE 8 Type of infection, by treatment group
Type of infection
Treatment group, n (%)
10ml/kg (n= 20) 20ml/kg (n= 17)
Bacterial 5 (25.0) 8 (47.1)
Viral 10 (50.0) 8 (47.1)
Other 1 (5.0) 0 (0.0)
Confirmed but not identified 4 (20.0) 1 (5.9)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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All participants randomised to the 20-ml/kg fluid bolus group received their first bolus (Table 9). Three
participants randomised to the 10-ml/kg fluid bolus group did not receive their first bolus, although were
correctly identified as being in shock, because it was deemed that they no longer required fluid post
randomisation. Of the subsequent boluses, one participant in the 20-ml/kg fluid bolus group was
administered a bolus despite the shock criteria (age-adjusted hypotension and CRT) not being met. Five
participants in total (three from the 10-ml/kg fluid bolus group and two from the 20-ml/kg fluid bolus group)
met the shock criteria; however, they were not identified or given a bolus. No participant experienced more
than one deviation.Treatment delivery by group
The majority of participants in both groups received only one bolus (Table 10). During the total 4-hour
intervention period, only four patients received four or more boluses.
The mean total volume of fluid given during the first hour of the intervention period was 6% lower in the
10-ml/kg fluid bolus group than in the 20-ml/kg fluid bolus group (173 vs. 184 ml). The mean total volume
of fluid given during the entire 4-hour intervention period was 23% lower in the 10-ml/kg fluid bolus
group than in the 20-ml/kg fluid bolus group (188 vs. 243 ml; Figure 13), but the difference was not
statistically significant (mean difference −55 ml, 95% CI −196 to 88 ml, p = 0.448; Table 11).TABLE 9 Protocol deviations, by treatment group
Variables
Treatment group, n (%)
10ml/kg 20ml/kg
Number of participants 39 34
Did not receive first bolus 3 (7.7) 0 (0.0)
Of subsequent boluses
Bolus given, shock criteria not met
Deviations 0 (0.0) 1 (2.9)
Shock criteria met, no bolus given
Deviations 3 (7.7) 2 (5.9)
TABLE 10 Treatment delivery, by treatment group
Variables
Treatment group
10ml/kg 20ml/kg
Number of patients 39 34
Number of boluses delivered, n (%) of patients
0 3 (7.7) 0 (0.0)
1 23 (59.0) 25 (73.5)
2 8 (20.5) 6 (17.6)
3 3 (7.7) 1 (2.9)
≥ 4 2 (5.1) 2 (5.9)
continued
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TABLE 10 Treatment delivery, by treatment group (continued )
Variables
Treatment group
10ml/kg 20ml/kg
Total volume of fluid received during the first hour (ml)
Mean (SD) 173 (254) 184 (190)
Median (IQR) 100 (50–180) 121 (76–200)
n 39 34
Total volume of fluid received during the first hour (ml/kg)
Mean (SD) 13.5 (8.0) 20.7 (8.3)
Median (IQR) 10 (10–20) 20 (20–20)
n 39 34
Total volume of fluid received during the intervention period (ml)
Mean (SD) 188 (325) 243 (275)
Median (IQR) 100 (50–210) 124 (76–263)
n 39 34
Total volume of fluid received during the intervention period (ml/kg)
Mean (SD) 14.5 (11.1) 25.7 (12.0)
Median (IQR) 10 (10–20) 20 (20–29)
n 39 34
Total number of boluses delivered 58 48
Volume of bolus, n (%) of boluses
< 10ml/kga 2 (3.4) 3 (6.3)
10 ml/kga 56 (96.6) 5 (10.4)
20 ml/kga 0 (0.0) 40 (83.3)
n 58 48
Delivery of bolus within 15 minutes, n (%) of boluses
No 9 (19.1) 14 (31.8)
Yes 38 (80.9) 30 (68.2)
n 47 44
Delivery of bolus within 15 minutes by age group, n (%) of boluses
< 1 year
No 3 (11.1) 7 (24.1)
Yes 24 (88.9) 22 (75.9)
n 27 29
1–< 2 years
No 2 (22.2) 1 (33.3)
Yes 7 (77.8) 2 (66.7)
n 9 3
RESULTS OF THE PILOT TRIAL
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TABLE 10 Treatment delivery, by treatment group (continued )
Variables
Treatment group
10ml/kg 20ml/kg
2–< 5 years
No 1 (14.3) 2 (50.0)
Yes 6 (85.7) 2 (50.0)
n 7 4
≥ 5 years
No 3 (75.0) 4 (50.0)
Yes 1 (25.0) 4 (50.0)
n 4 8
Fluid boluses delivered at correct volume and within 15 minutes, n (%) of boluses
No 10 (21.3) 20 (45.5)
Yes 37 (78.7) 24 (54.5)
n 47 44
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FIGURE 13 Distribution of total volume of fluid received during intervention period (ml). (a) The 10-ml/kg fluid
bolus group; and (b) the 20-ml/kg fluid bolus group.
DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 51
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
TABLE 11 Separation in mean total volume of fluid between the treatment groups
Variables
Treatment group, mean volume (SD)
Mean difference (95% CI) p-value10ml/kg (n= 39) 20ml/kg (n= 34)
Total volume of fluid (ml) 188 (325) 243 (275) –54 (–196 to 88) 0.448
Total volume of fluid (ml/kg) 14.5 (11.1) 25.7 (12.0) –11.2 (–16.6 to –5.8) < 0.001
RESULTS OF THE PILOT TRIAL
42Owing to the baseline imbalance in weights, separation between the groups was also assessed in ml/kg
(not prespecified in the statistical analysis plan). The mean total volume of fluid, in ml/kg, given during
the first hour was 35% lower in the 10-ml/kg fluid bolus group than in the 20-ml/kg fluid bolus group
(13.5 ml/kg vs. 20.7 ml/kg), and during the entire 4-hour intervention period was 47% lower (14.5 vs.
27.5 ml/kg; Figure 14). At the end of the 4-hour intervention period, this corresponded to a statistically
significant mean difference of –11.2 ml/kg (95% CI –16.6 to –5.8 ml/kg; p < 0.001; see Table 11).
None of the boluses delivered in the 10-ml/kg fluid bolus group was > 10ml/kg; however, two (3.4%) were
< 10ml/kg (see Table 10). In the 20-ml/kg fluid bolus group, no boluses of > 20ml/kg were delivered;
however, five boluses (10.4%) of 10 ml/kg and three (6.3%) of < 10ml/kg were delivered.
Out of 106 boluses delivered, there were a total of 91 boluses (85.8%) with complete data to determine the
timing of bolus delivery (47 in the 10-ml/kg fluid bolus group and 44 in the 20-ml/kg fluid bolus group).
Thirty-eight out of 47 boluses (80.9%) delivered to the 10-ml/kg fluid bolus group were administered within0
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FIGURE 14 Distribution of total volume of fluid received during intervention period (ml/kg). (a) The 10-ml/kg fluid
bolus group and (b) the 20-ml/kg fluid bolus group.
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DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 5115 minutes, whereas 30 out of 44 (68.2%) delivered to the 20-ml/kg fluid bolus group were administered
within 15 minutes. There were no clear indications of difference when looking at different age groups, owing
to the smaller numbers of older children.
Thirty-seven boluses (78.7%) were delivered at the correct volume and within 15 minutes in the 10-ml/kg
fluid bolus group, whereas 24 boluses (54.5%) were delivered at the correct volume and within 15 minutes
in the 20-ml/kg fluid bolus group.Potential outcome measures
All participants (n = 16) admitted to a PICU in one of the FiSh trial sites were successfully linked to PICANet
data. Five participants were admitted to a non-FiSh-trial PICU and were not able to be linked as research
approvals were not in place. Mechanical ventilation was defined as invasive ventilation via endotracheal
tube, invasive ventilation via tracheostomy tube, advanced ventilatory support (jet ventilation) or advanced
ventilatory support (oscillatory ventilation). All patients were successfully followed up for mortality
following hospital discharge using the NHS Spine web portal.
No participants died either in hospital or by 30 days post randomisation in either treatment group (Table 12).
As anticipated for a small pilot trial, there were no significant differences between the groups in any of the
other outcomes. To assist with powering any future trial, 95% CIs for the outcomes in each treatment group
are presented in Table 13.TABLE 12 Potential outcome measures, by treatment group
Potential outcome measures
Treatment group
Effect estimate
(95% CI) p-value10ml/kg (n= 39) 20ml/kg (n= 34)
Hospital mortality, n/N (%) 0/39 (0.0) 0/34 (0.0) Not estimable
Length of hospital stay (days),
median (IQR) [n]
4 (3–7) [39] 5 (4–8) [34] 0.225a
Transferred to PICU, n/N (%) 10/39 (25.6) 11/34 (32.4) –6.7 (–27.6 to 14.1)b 0.354
0.79 (0.38 to 1.63)c
Length of stay in PICU (hours),
median (IQR) [n]
45 (18–143) [10] 119 (52–228) [11] 0.091a
Days alive and free of PICU up to
30 days,d mean (SD) [n]
28.9 (2.4) [39] 27.9 (3.6) [34] 1.0 (–0.4 to 2.4)e 0.160
Receipt of mechanical ventilation,
n/N (%)
4/36 (11.1) 8/32 (25.0) –13.9 (–32.1 to 4.3)b 0.119
0.44 (0.15 to 1.34)c
Duration of mechanical ventilationf
(days), median (IQR) [n]
6 (4–8) [4] 5.5 (4–8.5) [8] 0.797
Days alive and free of mechanical
ventilation up to 30 days,d mean (SD) [n]
29.3 (2.1) [36] 28.5 (2.7) [32] 0.8 (–0.4 to 2.0)e 0.192
Mortality at 30 days,d n/N (%) 0/39 (0.0) 0/34 (0.0) Not estimable
IQR, interquartile range; PICU, paediatric intensive care unit; SD, standard deviation.
a Wilcoxon rank-sum test.
b Absolute risk difference (%).
c Relative risk.
d Post randomisation.
e Mean difference.
f Among those patients ventilated.
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TABLE 13 Within-group estimates of potential outcome measures with 95% CIs
Potential outcome measures
Treatment group, estimate (95% CI)
10ml/kg (n= 39) 20ml/kg (n= 34)
Hospital mortality (%) 0 (0.0 to 9.0) 0 (0.0 to 10.2)
Length of hospital stay (days), median 4 (3 to 5) 5 (4 to 7)
Transferred to PICU (%) 25.6 (14.6 to 41.1) 32.4 (19.1 to 49.2)
Length of stay in PICU (hours), median 45 (8 to 143) 119 (51 to 230)
Days alive and free of PICU up to 30 days,a mean 28.9 (28.2 to 29.7) 27.9 (26.7 to 29.2)
Receipt of mechanical ventilation (%) 11.1 (4.4 to 25.3) 25.0 (13.3 to 42.1)
Duration of mechanical ventilationb (days), median 6 (2 to 10) 5.5 (2 to 9)
Days alive and free of mechanical ventilation up to 30 days,a mean 29.3 (28.6 to 30.0) 28.5 (27.5 to 29.6)
Mortality at 30 daysa (%) 0 (0.0 to 9.0) 0 (0.0 to 10.2)
a Post randomisation.
b Among those patients ventilated.
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44Safety monitoring
There were no reported SAEs; four AEs in total were reported (Table 14). Three were reported in the
10-ml/kg fluid bolus group. One of these was pulmonary oedema (an expected AE), which was deemed
unlikely to be related to the trial intervention, and the other two AEs were not related to the intervention
(Table 15). There was one AE in the 20-ml/kg fluid bolus group, which was not related to the trial
intervention.TABLE 14 Reported AEs, by treatment group
AEs
Treatment group, n (%)
10ml/kg (n= 39) 20ml/kg (n= 34)
AEs 3 (5.1) 1 (2.9)
SAEs 0 (0.0) 0 (0.0)
TABLE 15 Details of AEs
Treatment group Event Expectedness Severity Relatedness
10ml/kg Pulmonary oedema Expected Moderate Unlikely
10 ml/kg Recurrent urinary tract infection Unexpected Moderate None
10ml/kg Head injury Unexpected Mild None
20ml/kg Rash after taking oral antibiotics at home Unexpected Mild None
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Baseline characteristics and treatment delivery for participants admitted to a PICU compared with
participants not admitted to a PICU are presented in Table 16. Participants admitted to a PICU had a
higher average severity of illness as assessed by the PIM2r (2016) score (mean 3.6% vs. 1.9%), were
more likely to have an infection (71% vs. 42%) and received a greater average volume of fluid during
the intervention period (mean 24.4 ml/kg vs. 17.8 ml/kg).
Potential outcome measures for participants admitted to a PICU (pooled across the treatment groups)
are presented in Table 17.TABLE 16 Baseline characteristics and treatment delivery for participants admitted to a PICU and those not
admitted to a PICU
Characteristics
Admission to PICU
Admitted (n= 21) Not admitted (n= 52)
Age (months)
Mean (SD) 41 (59) 19 (35)
Median (IQR) 10 (0–65) 4 (1–19)
Gender, n (%)
Male 11 (52.4) 31 (59.6)
Female 10 (47.6) 21 (40.4)
Weight (kg)
Mean (SD) 14.4 (19.4) 10.1 (9.6)
Median (IQR) 7 (3–18) 7 (5–12)
Shock criteria met, n (%)
CRTa only 16 (76.2) 44 (84.6)
Age-adjusted hypotension only 3 (14.3) 1 (1.9)
Both CRTa and age-adjusted hypotension 2 (9.5) 1 (1.9)
Neither 0 (0.0) 6 (11.5)
PIM2r (2016) score (%)
Mean (SD) 3.6 (2.6) 1.9 (0.6)
Median (IQR) 2.6 (2.3–3.8) 1.8 (1.5–2.1)
Infection confirmed, n (%)
No 6 (28.6) 30 (57.7)
Yes 15 (71.4) 22 (42.3)
Number of boluses delivered, n (%) of patients
0 2 (9.5) 1 (1.9)
1 10 (47.6) 38 (73.1)
2 3 (14.3) 11 (21.2)
3 3 (14.3) 1 (1.9)
≥ 4 3 (14.3) 1 (1.9)
continued
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
TABLE 16 Baseline characteristics and treatment delivery for participants admitted to a PICU and those not
admitted to a PICU (continued )
Characteristics
Admission to PICU
Admitted (n= 21) Not admitted (n= 52)
Total volume of fluid received during the intervention period (ml)
Mean (SD) 267 (305) 192 (301)
Median (IQR) 120 (60–360) 104 (73–185)
Total volume of fluid received during the intervention period (ml/kg)
Mean (SD) 24.4 (17.9) 17.8 (9.6)
Median (IQR) 20 (20–30) 20 (10–20)
a CRT of ≥ 3 seconds.
TABLE 17 Potential outcome measures for patients admitted to a PICU
Potential outcome measures
Number of
patients Value 95% CIa
Length of hospital stay (days), median (IQR) 21 8 (4–12) 4 to 12
Length of stay in PICU (hours), median (IQR) 21 95 (35–145) 35 to 145
Days alive and free of PICU up to 30 days,b mean (SD) 21 24.7 (3.5) 23.1 to 26.3
Receipt of mechanical ventilation, n (%) 16 12 (75.0) 50.5 to 89.8
Duration of mechanical ventilationc (days), median (IQR) 12 6 (4–8.5) 4 to 9
Days alive and free of mechanical ventilation up to 30 days,b mean (SD) 16 25.6 (3.5) 23.7 to 27.4
a For median, mean or percentage, as indicated.
b Post randomisation.
c Among those patients ventilated.
RESULTS OF THE PILOT TRIAL
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perspectives studyParticipants: parents/legal representatives
A total of 52 out of 75 (69%) parents of patients enrolled in the pilot trial consented for inclusion
in the perspectives study element of the study (i.e. agreed to complete a questionnaire and/or to be
interviewed). No participants identified themselves as legal representatives. Of the 52 parents who agreed
to be approached for interview, 34 (65%) were purposively selected and invited by telephone or e-mail.
Of these, 11 (32%) did not respond, one was deemed ineligible owing to an inability to understand
English and two declined to be interviewed on telephone contact. Data saturation was reached following
interviews with 20 parents.22,23 Of the 18 parents not contacted for interview, 10 (19%) were from one
high-recruiting site already represented in the interview sample, and so were not contacted to prevent
sample bias. A total of eight (15%) parents were not contacted as a result of data saturation22,23 being
reached. A questionnaire was received from 45 out of 52 (87%) parents from 44 families. Figure 15
presents the recruitment process.Family questionnaire recruitment
Consented: n = 52/75 families, 75%a
Declined: n = 8/75 families, 11%
Family interview recruitment
Consented: n = 52/75 families,a 75%
Declined: n = 13/75 families, 17%
No response to postal consent: n = 7/13 families, 54%
Withdrawn (unable to obtain consent): n = 2/75 families, 3%
Not applicable (recruitment closed): n = 1/75 families, 3%
•  Mothers: n = 34/45, 78%
•  Fathers: n = 11/45, 24%
•  Mothers: n = 19/20, 95%
•  Fathers: n = 1/20, 5%
•  To prevent sample bias: n = 10/52 families, 19%
•  Saturation point reached: n = 8/52 families, 15%
•  No response to contact: n = 11/34 families, 32%
•  Deemed not eligible upon contact: n = 1/34 families, 3%
•  Declined when contacted: n = 2/34 families, 6%
Completed a questionnaire: n = 45 parents
from 44 families, 87%
Took part in interview: n = 20 parents from 52 families, 38%
Contacted for interview: n = 34/52 families, 65%
Not contacted for interview: n = 18/52 families, 35%
Not applicable (postal consent, not asked):
n = 13/75 families, 17%
Withdrawn as unable to obtain consent:
n = 2/75 families, 3%
FIGURE 15 Parent/legal representative recruitment process and sample characteristics in the integrated perspectives
study element of the pilot trial. a, Does not include if more than one parent was asked to participate – data unknown.
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48Characteristics
Of the 20 parents (19 mothers and one father) interviewed by telephone and 45 parents (34 mothers and
11 fathers) who completed a questionnaire, all had consented to the use of their child’s information in
the pilot trial and none was bereaved. Parents interviewed were recruited from 10 out of the 12 (83%)
recruiting sites and questionnaires were received from 9 out of the 12 (75%) recruiting sites. Parents were
interviewed a median of 26.5 days after admission (range 14–96 days) and the median length of hospital
stay for their child was 3 days (range 1–23 days). One parent had previous experience of their child
participating in medical research; none had experience of RWPC. Telephone interviews with parents took
between 30 and 60 minutes. All 45 parents completed the questionnaire on site, before their child was
discharged from hospital.Participants: site staff
Three focus groups were conducted with 20 site staff from the three recruiting ‘hub’ pilot trial sites
(Figure 16). In addition, seven telephone interviews were conducted with 7 out of 20 (35%) invited staff,
one of whom was from a ‘hub’ site and six of whom were from a ‘spoke’ site.
Characteristics
Of the 27 participating site staff, 22 (81%) were involved in the clinical care of children [17/20 (85%) of
focus group participants and 5/7 (71%) of telephone interview participants]. The staff sample included
14 (52%) nurses and 13 (48%) registrar- or consultant-grade doctors with a modal range of 1–2 years of
experience in recruiting to paediatric clinical trials. Telephone interviews took between 30 and 60 minutes
and focus groups lasted approximately 90 minutes.Pilot trial site staff eligible for recruitment
6 – 8 staff at four sites eligible for three hub site
focus groups
Up to 10 (depending on data saturation) telephone
interviews with hub-and-spoke staff who could
not attend a focus group
Consented and took part in
a focus group
(n = 20)
Consented and took part in
a telephone interview
(n = 7)
E-mail invitation purposively sent to n = 24
Four principal investigators at four sites to participate in and
arrange three hub site focus groups
•  10 doctors
•  10 nurses
•  three doctors
•  four nurses
FIGURE 16 Site staff focus group and telephone interview recruitment process and sample characteristics in the
integrated perspectives study element of the pilot trial.
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Research without prior consent is acceptable
Before any discussion of the pilot trial during interviews, parents were prompted to describe their understanding
of RWPC to explore explanations provided to them during the consent discussion, as well as their views on this
method of consent. Although no parents had any previous knowledge of RWPC, the majority (n= 15/20, 75%)
were able to appropriately describe this approach, explaining and supporting its use in emergency situations:TAB
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Park, SThey just said that in these situations they just obviously stabilise the child as a priority and then
discuss it afterwards because then there’s obviously no pressure to be involved and that’s sort of how
it was explained. Um, so I hadn’t heard of it, no, but it doesn’t surprise me. In an emergency situation,
you do what you’ve got to do, don’t you, and then deal with stuff afterwards.
P25, mother, telephone interviewFollowing the general discussion of RWPC, the focus shifted towards parents’ views on the use of this
method in the pilot trial. Consistent with previous studies18,19,27 and the feasibility study findings described
in Chapter 2, several parents (n = 7/20, 35%) were initially shocked or surprised to discover that their child
had been enrolled into the pilot trial without prior consent. As shown in Table 18, 13 out of 45 (28%)
parents who completed a questionnaire agreed with statement 2: ‘I was initially surprised to find out that
my child had already been entered into FiSh’. However, following tailored explanation from site staff about
why informed consent was not sought,30 all parents stated that they supported RWPC in this pilot trial:I was initially surprised that obviously this had happened, because obviously the consent happened
afterwards, but I wasn’t sort of concerned or anything, and then they explained everything really
clearly, and the information leaflet was very good as well.
P12, mother, telephone interviewLE 18 Parents’ survey responses regarding the pilot trial consent process (N = 45)
tement
Responses, n (%)
Agree
Neither agree nor
disagree Disagree
he practitioner checked that it was a convenient time
iscuss research before discussing FiSh
41 (91.1) 2 (4.4) 2 (4.4)
was initially surprised to find out that my child had
ady been entered into FiSh
13 (28.9) 19 (42.2) 13 (28.9)
he information I received about FiSh was clear and
ightforward to understand
42 (93.3) 3 (6.7) 0 (0)
understood why consent for my child’s participation in
was sought after the treatment had been given
44 (97.8) 1 (2.2) 0 (0)
had enough opportunity to ask questions about FiSh 43 (95.6) 2 (4.4) 0 (0)
was satisfied with the deferred consent process for FiSh 39 (86.7) 6 (13.3) 0 (0)
t was difficult to take in the information I was given
ut FiSh
1 (2.2) 6 (13.3) 38 (84.4)
t was difficult to make a decision about FiSh 1 (2.2) 3 (6.7) 41 (91.1)
made this decision 42 (93.3) 1 (2.2) 2 (4.4)
Someone took this decision away from me 2 (4.4) 1 (2.2) 42 (93.3)
I was not in control of this decision 4 (8.9) 1 (2.2) 40 (88.9)
The decision about the research was inappropriately
uenced by others
2 (4.4) 3 (6.7) 40 (88.9)
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50Indeed, the majority (n = 39/45, 86.7%) of parents who completed the questionnaire agreed with
statement 6: ‘I was satisfied with the deferred consent process in FiSh’; no parents disagreed with
this statement. Parents (n = 44/45, 97.8%) also agreed with statement 4, indicating that they had
‘understood why consent for my child’s participation in FiSh was sought after the treatment had been
given’. Moreover, both questionnaire and interview responses indicated that, despite their children being
entered into the FiSh pilot trial without prior consent, the majority of parents felt that their consent
decision about the use of their child’s data was voluntary18,51,52 [42/45 (93.3%) agreed with statement 9:
‘I made this decision’; 42/45 (93.3%) disagreed with statement 10: ‘Someone took this decision away
from me’; 40/45 (88.9%) disagreed with statement 11: ‘I was not in control of this decision’ and 40/45,
88.9% disagreed with statement 12: ‘The decision about research was inappropriately influenced by others’].
Importantly, however, support for RWPC in emergency care trials was felt by some to depend on the
context of the specific study:NIHRI think probably my concern was probably a strange concern, insomuch on this study, ‘cause I completely
agree with it. It’s more, I think, a concern to give the impression that I think that consent after the fact is
a good thing, because I don’t necessarily think it is. I think there are situations where I would strongly
disagree with it. That’s really my only concern, that I would be in some way condoning that process as a
process in itself, rather than it being a process specifically about, you know, this sort of subject.
P06, mother, telephone interviewMore specifically, several parents stated that practitioners explained that rapid fluid bolus resuscitation is the
standard treatment for children presenting to UK EDs, despite a lack of evidence for current recommended
practice (i.e. 20 ml/kg).3–5 This explanation, combined with a detailed description of fluid bolus therapy,
helped to reassure parents that there were good reasons for RWPC in the FiSh pilot trial and that their child’s
safety would not be compromised, as both treatment arms involved carefully titrated administrations of fluid:I think because he was still getting the same, he was still getting the fluids and essentially still had
the same amount but it was just over different sort of periods of time, I personally didn’t feel like
it mattered ‘cause he was still getting the same thing.
P12, mother, telephone interviewObviously the fluid is what he needed so just giving him a small amount wouldn’t have made a
difference because they were keeping an eye on him, so it could have been added to.
P26, mother, telephone interviewSimilarly, several parents indicated that they would have been concerned about site staff not seeking their
prior consent if the trial had involved the administration of a new drug or any other ‘unknown’ clinical
procedure, including surgery:Um, if it’s a trial, I would want to know if it was medicine or drugs or if it was unknown surgery.
So, unknown territory. The fluids, they’re going to get fluids anyway so for me, [RWPC] was not
even vaguely a concern.
P40, mother, telephone interviewFinally, the majority (15/20, 75%) of parents interviewed said that their child’s survival probably affected
their response to the pilot trial and willingness to provide consent. This was consistent with parental survey
responses that explored parents’ reasons for consenting to the trial (see Table 19 and subsequent text):I think that again it’d be down to outcome. If you have a positive outcome, I think the reaction would
be completely different than if you had a negative outcome. I think then it could cause a lot of, kind
of questioning on the parents’ part, had, you know, he been given a different drug or whatever,Journals Library www.journalslibrary.nihr.ac.uk
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Park, Swould the outcome be different. And actually it could, it could cause an awful lot of ongoing pain,
wondering, you know, whether or not that was a factor that tipped the balance, you know.
P06, mother, telephone interviewNevertheless, the remainder of parents interviewed stated that they would have supported the pilot trial
and its method for consent even in less positive circumstances, suggesting that they would not have linked
the trial to poor recovery. These views appear to have been influenced not only by the nature of the trial,
but also by parental trust in doctors to prioritise their child’s life over research, as well as the sensitive
manner of site research staff:No, I’m pretty sure that if, if they started to do the FiSh and then something went completely wrong,
I’m sure rather than stick to the trial, they’d put the patient first and think, right we need to do this,
forget looking at the clock, this needs to be done.
P37, mother, telephone interviewThe following conversation is from a telephone interview:Researcher: Hypothetically speaking, how would you have felt if they approached you about this study
and your son had not recovered as well as he did?
P33, mother: Well the approach was really gentle and it wasn’t at all, um, you know, we weren’t
being strong-armed into anything. So I don’t think, err, I know it’s a, would be a stressful and awful
time anyway but I think it was done so delicately that I don’t think we would have been upset to
be asked.
Researcher: Do you think you would have had any concerns that the trial was linked to poor recovery?
P33, mother: No, I don’t think so. I mean, like I’ve said previously, if it was to do with different drug
trials, then yeah 100%, but not for a you know, rehydration solution or whatever the trial is.However, as the following quotation illustrates, some parents might question whether or not trial
participation was to blame for a child’s poor recovery. This finding suggests that in such circumstances site
staff should be prepared to address parents’ questions and concerns about their child’s poor recovery in
the context of trial participation:I understand how serious it was and I can’t thank them enough but I think everyone sometimes wants
someone to blame and I think if it didn’t go the way that, that it was supposed to, I wouldn’t
necessarily be blaming them but I would want an answer to that question.
P36, father, telephone interviewResponses to the pilot trial
Following the discussion of RWPC, the interview conversation shifted to the pilot trial. Parents were
prompted for their views on several aspects of the trial, including their understanding of the aims,
acceptability of the interventions involved and the reasons for consent (Table 19).
All parents interviewed had provided consent for the pilot trial. The parents cited their child’s trial
participation as a way to help advance children’s emergency treatment to help other children in the future:I kind of thought about other children and thought ‘do you know what, like it’s probably a good idea
that they relook at this just to make sure that every child is getting the right treatment’.
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TABLE 19 Parents’ survey responses regarding reasons for consenting to the pilot trial, including the main reason
when stated (n = 25/45)
Reason for consent
Identified as [n (%)]
A reason (n= 45) The main reason (n= 25)
1. To help my child 23 (52.3) 1 (4.0)
2. To help other children in the future 44 (100) 19 (76.0)
3. I felt that medical studies like FiSh are important 33 (75.0) 3 (12.0)
4. I trusted the doctor or nurse who explained FiSh 27 (60.0) 0 (0)
5. The treatment had already been given to my child 26 (57.8) 0 (0)
6. My child recovered 22 (48.9) 2 (8.0)
7. I did not feel comfortable saying no to the nurse or doctor
who explained
0 (0) 0 (0)
8. Other 0 (0) 0 (0)
Note
Missing responses: statement 1: 1; statement 2: 1; statement 3: 1; statement 4: 1; statement 5: 1; statement 6: 1;
statement 7: 1; main reason: 20.
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52The questionnaire included a series of statements to establish the reasons why parents had consented for
their child’s information to be used in the pilot trial. Many parents ticked multiple reasons (mode, five reasons;
mean, four reasons). In line with the qualitative findings, all parents indicated that a reason they provided
consent for the use of their child’s information in the pilot trial was to help other children in the future (see
Table 19), with 19 out of 25 (76%) indicating that this was the main reason for consent. A high proportion
also indicated that they provided consent owing to a belief that medical research studies like the FiSh trial are
important, with 3 out of 25 (12%) indicating that this was their main reason. Interestingly, half of parents in
both interviews and questionnaires stated that they had participated because their child had recovered, which
supports our qualitative findings that show that parents were happy to consent as their child had recovered
by the time of consent.
Also of interest was that half of parents indicated that they consented to help their child, although this
was a main reason for consent for only one parent. Only half of the parents interviewed appeared to
understand the uncertainty around optimal fluid bolus resuscitation therapy and how the FiSh trial is
needed because ‘we don’t know what is best’ (P33, mother, telephone interview). Interviews also revealed
a potential lack of equipoise among some parents (7/20, 35%). This related to beliefs that one arm of
fluid bolus resuscitation for septic shock was safer than the other, that the volume administered to their
child was the correct amount given their recovery, or that both interventions were ‘the same essentially’
(P12, mother, telephone interview):NIHRI really didn’t mind that. Obviously, they’re saying the small amount would be better for the child, so
to me, you know, he was fine and he came round quick . . . so if someone had given him the larger
amount I would have probably panicked anyway.
P26, mother, telephone interviewThe operation was a success, you gave the right amount of fluid. Her, in our daughter’s case, we
believe that that was the right amount because she didn’t need any more until the operation and
I think that kind of kept her going.
P36, mother, telephone interviewJournals Library www.journalslibrary.nihr.ac.uk
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significant impact on some parents. Specifically, 3 out of 20 (15%) mothers who took part in an interview,
one of whom also completed a questionnaire, described their upset at finding out that their child had
been treated for septic shock during the consent discussion. As the following quotations illustrate, clinical
staff had not spoken to these parents using this term before research staff had approached them to
discuss the pilot trial:© Que
Health
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Park, SI had no idea my child had septic shock. When I was told about the study was the first time I found
out, which was quite distressing.
P06, mother, questionnaireWe didn’t actually know he was being treated for septic shock . . . until they gave me the letter and I
read it, I didn’t actually know that’s what he was being treated for.
P07, mother, telephone interviewI just heard sepsis and then I almost hit the floor.
P39, mother, telephone interviewOne mother stated that ‘it was almost awkward for the nurse ‘cause she didn’t realise that she was
breaking the news’ (P06, mother, telephone interview).
These parents recommended that, in future research, a member of the clinical team should have a
discussion with parents about what has happened and their child’s condition, before a discussion about
research occurs:What could have been improved was to make sure the parents know what actually happened in the
situation before speaking about a trial.
P26, mother, telephone interviewApproaching parents for consent
The majority of parents, including 41 out of 45 (91%) of those who completed the questionnaire, indicated
that site staff had checked that it was a convenient time to discuss the pilot trial. During interviews, parents
stated that they felt that they were approached appropriately within 24–48 hours of their child’s admission,
‘after sort of the initial, um, scary period’ (P01, mother, telephone interview), when the emergency situation
had passed. Parents appeared to appreciate the timing of the discussion and that the research nurse had
‘made sure that it was the right time’ (P03, mother, telephone interview) to discuss research.
Two parents who completed a questionnaire indicated that the researcher had not checked the timing of
the consent discussion, although this did not appear to affect their ability to understand the information
or their satisfaction with the consent process. Although 38 out of 45 (84.4%) disagreed with statement 7
(see Table 18), indicating that they did not find it difficult to take in the pilot trial information, one parent
agreed that it had been difficult to take in the information and six neither agreed nor disagreed with the
statement. Furthermore, consistent with other studies in this area,38,40 many parents said that they did not
ask questions or raise concerns with site staff. A few parents stressed that it was important for staff to
tailor the amount of trial information provided to help meet individual needs and preferences:You’ve got parents with very different levels of interest, education and cultures. I am somebody who
likes to be as informed as possible and I’ll ask questions if I don’t understand. But, I think it’s a
two-way process. Maybe the researcher has the option of going down the road of explaining to a
parent if they want to know but perhaps doesn’t go down that road if the parent chooses to have
sufficient information. Err, I think I would have appreciated a little more information in situ.
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54As per the findings in other critical care studies,19,27 parents stated that they would not wish to be
approached for consent during resuscitation, as their child’s life was the priority. As the following
quotation illustrates, parents questioned if they would want, or be able to take in, study information when
their child was being resuscitated. One-third of parents indicated that they would have felt pressured to
provide a decision about the pilot trial if approached by staff during resuscitation. They also suggested
that, under such circumstances, parents would be more likely either to refuse to take part or to provide a
decision that was uninformed as heightened emotions may affect parental capacity:NIHRMy focus had to be on my child. He needed me, right there and right then, it would have been,
you know, noise in the background, and I probably would have nodded and not even taken it in.
P06, mother, telephone interviewI mean it’s such a stressful situation, you just need to be, but you just need to be as calm and relaxed
as possible. By throwing that on to you I think people would just say no.
P13, mother, telephone interviewInterestingly, 5 out of 20 (25%) parents who were interviewed described how they were spoken to by site
staff about the pilot trial during resuscitation. Of these, most parents (4/5, 80%) were unperturbed by this
method of approach; however, this appeared to depend on the brevity of the conversation. One mother
suggested that being approached by site staff during resuscitation was inappropriate and ‘just not necessary
and just not a priority for the parent’ (P38, mother, telephone interview). She stated that she ‘would have
been happy for them [site staff] to be there’, provided the explanation provided was simplified and
kept brief:I don’t think it’s necessary in the resus [resuscitation] department unless the parent asks. I think there’s
so much going on so unless they ask or they overhear and they say, ‘oh, what’s that?’ Without
brushing them off, you know, just a brief explanation is sufficient, which is what I had, which
was perfect.
P40, mother, telephone interviewSo, I was in A&E [accident and emergency] and there was a lady standing by the door sort of
watching everything that was going on in the Resus [Resuscitation] Room. She introduced herself to
me as somebody doing research and she said FiSh trial like the FiSh research project. And obviously I,
you know, I remember because FiSh is obviously a fairly memorable acronym. And then she described
it, but to be honest I remember her talking about fluids and giving probably too much information for
me at that point in time.
P38, mother, telephone interviewFinally, during interviews parents were asked to reflect on who (doctor, nurse or researcher) approached
them to discuss the pilot trial and whether or not their role affected the trial acceptability and their
consent decision. The majority (70%) stated that they would not have a role preference so long as the
practitioner ‘believed in the trial and its purpose’ (P13, mother, telephone interview) and was able to
provide parents with ‘simple and clear’ (P40, mother, telephone interview) tailored explanations on
key trial information. Nevertheless, several parents stated that they would appreciate a consultant’s
involvement in the initial stages of consent. More specifically, they suggested that interacting with
someone directly involved in their child’s care could promote parental reassurance and foster confidence
in the pilot trial:Well we had, I think the doctor had mentioned it and I think coming from the doctor that’s looking
after your child, you feel a bit more confident in what they’re . . . because you’ve got confidence in
them, you’re gonna have confidence in what they’re coming to do.
P35, mother, telephone interviewJournals Library www.journalslibrary.nihr.ac.uk
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These factors appeared to positively affect pilot trial decision-making processes, reducing the likelihood of
confusion and helping parents decide to take part:© Que
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Park, SI don’t remember who it was but it was definitely a different person and that’s a bit confusing in
hospital ‘cause just as a consultant changes shift, then a nurse changes shift, so it seemed like the
research team changed shift and I think if it had have been the same person it would have been easier
to associate that individual with the research.
P38, mother, telephone interviewI would say yeah, their manner did play a part in us going ahead with it. I think if they’d have sort
of come in straight faced and very sort of to the point, then we may have been a bit like, ‘oh God,
what’s this?’. But because they sort of made it really easy to understand and, um, had a good rapport
and sort of made us feel a bit more light-hearted about our actual stay at the hospital, um, it, it sort of
made it easier to say yes.
P01, mother, telephone interviewParticipant written information and terminology
Parents thought that the PIS was comprehensive: ‘I think it was quite informative from what I can
remember . . . it pointed out probably everything that we needed to know at that point’ (P35, mother,
telephone interview), and generally clear: ‘It was really, really easy to read . . . very straightforward’ (P13,
mother, telephone interview), despite using certain medical terminology throughout: ‘I did think, you know
because I’m not a clinical person, that like the language that it was using, it was explained quite well.
I did actually understand what it was all about’ (P26, mother, telephone interview). These views were also
reflected in questionnaire responses, with 42 out of 45 (93.3%) parents agreeing with statement 3: ‘The
information I received about FiSh was clear and straightforward to understand’. No parents disagreed with
the statement (see Table 18). The majority of parents (43/45, 95.6%) also indicated that they had enough
opportunities to ask questions about the FiSh trial (statement 5, Table 18).
Although two parents reported that further explanation about their child’s treatment in the context of the
pilot trial would have been appreciated – ‘Um, explain it more. I don’t really know what happened to my
daughter in that sense, I don’t know what’s sort of gone on’ (P19, mother) – the large majority indicated
that detailed verbal explanation of the pilot trial had been given by site staff. This discussion, in addition
to the written PIS, was valued by parents and appeared to assist their understanding of the pilot trial:I think the conversation definitely helped. I don’t think I would have fully sort of understood it just from
the paperwork, but the doctor sort of went through it and made it, elaborated on some of the points.
P01, mother, telephone interviewSome parents suggested providing a shorter and more basic pamphlet which clearly summarises key
aspects of the trial prioritised by parents, including trial safety and aims:All I needed to know was that it wasn’t detrimental, it wasn’t harmful. You know, my son’s part of a
study but actually at the end of the day he’s going to be getting exactly the same as somebody else,
you know, not on the study. It’s just that you’re documenting it all and it’s going somewhere. Perhaps
that’s, you know, I don’t need any more information than my son is safe.
P40, mother, telephone interviewFinally, as discussed, a minority of parents described significant distress at finding out that their child
had been treated for septic shock during the consent process, which included delivery of the pilot trial PIS.
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56condition with the child’s parents, parents agreed with suggested changes to PIS sentence structure and
terminology specific to septic shock. For example, parents recommended emphasising ‘suspected’ infection
or ‘suspected’ sepsis throughout all written information materials alongside a clinical conversation that
briefs parents on how some words used (i.e. sepsis or septic shock) may be upsetting:l
l
l
l
l
l
l
NIHRThat leaflet is great but perhaps, like you say, the wording needs to change a little bit with regards
[sic] to the septic shock bit.
P34, mother, telephone interviewCertainly, even just the word, rather than, if I’d been told about it right from the beginning that it’s an
infection ‘cause you can tell that, you know, the immediate blood results and the high temperature
and whatever. But until the blood results come back they don’t necessarily know, it could just be viral,
couldn’t it? But I guess from a parental point of view, just knowing that your child is being treated
immediately for suspected infection, at the moment we don’t know what it is. But then if that comes
back as being more serious than an infection of whatever, this is actually the blood, then you know.
I think parents need a build-up of information so it’s not so shocking when it all gets slammed
into them.
P40, mother, telephone interviewOutcome measures
As part of an iterative process, findings from the FiSh feasibility study (see Chapter 2) were incorporated
into the topic guide as interviewing progressed, in order to further explore parents’ perspectives about
important outcome measures. Consistent with methods described in Chapter 2, parents were asked to
think about their experience of their child being admitted for severe infection and then prompted to
share their views on what effects they hoped the fluid bolus treatment had to help their child (i.e. what
indicators were most important to suggest that their child was getting better).
On average, parents discussed seven outcomes. Appendix 3 shows the full list of outcomes identified in
the analysis of parent descriptions when asked directly which indicators were most important to them.
The top prioritised outcomes, in order of the how commonly they were described as being most important,
were as follows:organ/physiological functioning, such as blood pressure, temperature and heart rate
looking and behaving more like self, including becoming ‘more alert’ (P25, mother)
machines as an indicator of improvement, including ‘the figures’ (P40, mother) and ‘the fewer
machines that were operating’ (P38, mother)
time spent on treatments
long-term effects
survival
time spent in hospital.Site staff perspectives
FiSh pilot trial site initiation training
Site staff focus groups and interviews began with questions aimed at exploring staff views and experiences
about the FiSh pilot trial site initiation training, including whether or not they felt that the training had
sufficiently prepared them for the pilot trial. Over half (17/27, 63%) had been trained at the site initiation
meeting, whereas 10 out of 27 (37%) had received training from a member of their own site team, often
the PI or research nurse. Three site staff had received both forms of training. Without exception, site staff
stated that the training had prepared them for recruitment and consent in the pilot trial. As the followingJournals Library www.journalslibrary.nihr.ac.uk
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to disseminate the pilot trial training to the rest of their team:© Que
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Park, SYeah, it was absolutely fine . . . it made me feel confident enough to go and do the training for the
extended team.
P02, focus group 1Site staff valued having access to the training slides after the site initiation meeting so that they could refer
back to them at a later date. Access to training materials had assisted the dissemination of training more
widely across relevant departments and teams:The mixture of having the information to refer back to, so the protocols that you’ve got along
with the consent inform – you’ve got to have the background knowledge, so you’ve got to sort of
attend the training to know what you’re doing to fully understand why you’re doing it, but also to
have the reminder bits of the bits that are important to explain to the families at the point at which
you’re getting consent.
P01, focus group 1I think having that resource was really good and everything you need to deliver training is in there.
P22, telephone interviewSome staff stated that the training had outlined clear pilot trial procedures, including simple recruitment
criteria, which they felt were important in ensuring the engagement of all site staff, particularly those who
work in the ED:Who you recruit, who you randomise into it is . . . they’ve made it so kind of simple . . . it was very
clear as to which cohort of patients they were looking for.
P21, telephone interviewYeah, it was simple, wasn’t it, and that’s why it encourages, in A&E [accident and emergency] for
instance, to get involved because it’s not complicated to pick the children out and to put them into
the study.
P02, focus group 2Others stated that, before the training, they had no previous experience of RWPC, which had made them
feel anxious about being involved in the pilot trial. However, the inclusion of specific training on this
approach to consent, which incorporated parents’ perspectives from the FiSh feasibility study, appeared to
help prepare them for consent discussions with families in the pilot trial:Um, I hadn’t really been involved in retrospective consent before, so it was very useful kind of hearing
them kind of talk about the kind of background of retrospective consent and why they were doing it,
and all that kind of stuff. Because it’s really helped when I’ve gone and consented people, explaining
why we’re doing it now and we didn’t do it yesterday type of thing. Um, so that probably was the
more useful bit out of it, if that makes sense.
P21, telephone interviewThe training package was very well put together and it had lots of relevance. Um, you know,
supporting evidence for the rationale and lots of interesting sort of qualitative stuff about the
methodology.
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58I think with this particular study, what was quite concerning for most was the consenting part,
obviously, because everybody was feeling how do we sort of speak to parents when they’re ready, so
like we’ve asked them when their child has already been entered into the study in a way. And I think,
having had the sort of the initiation day and sort of discussions, I think that gave me sort of a sound
understanding of it.
P26, telephone interviewScreening pilot trial patients
Site staff described the methods used to help raise awareness of the pilot trial to ensure that every patient
admitted to the ED or PAU (or equivalent) needing a fluid bolus was screened for the pilot trial. This
included placing FiSh trial posters, stickers and memos where fluid was stored to remind staff to screen,
as well as using computer systems to regularly search for potentially eligible recently admitted patients. In
most sites, all clinical staff were described as being involved in screening. In some sites, a bleep system was
successfully used, ‘so the A&E [accident and emergency] team know that in the event that there’s a child
coming in who’s requiring fluids and sort of fits into the sort of FiSh criteria’ (P26, telephone interview), to
inform research nurses that a consent discussion would be needed. Others stated that there were a few
designated research nurses responsible for monitoring patients for eligibility to the pilot trial, as well as
other studies being run at their site. One site used a rota system to ensure that someone was watching
and checking computer systems for potentially eligible patients during the day:We have a rota, and it’s Monday to Friday. There’s somebody watching from 8 till 6-ish, 8-ish, it
depends. Some days it’s later than others.
P13, focus group 2Site research staff stated that potentially eligible patients were sometimes missed at weekends, and that
they would use computer systems to identify them the following week and retrospectively complete
screening forms. During focus groups, staff members were asked to use the voting handsets to indicate
whether or not the screening process could be improved. A total of 13 out of 20 (65%) clinicians indicated
the process could be improved, whereas 7 out of 20 (35%) did not. Staff who took part in a telephone
interview also stated that the screening process worked well, with few suggestions for improvement.
Suggestions for improvements to the screening process to help ensure that patients are not missed in the
FiSh trial included ensuring 24/7 research cover in the ED, making sure that all staff were trained (including
new staff on rotation) and ensuring that study posters are placed in the optimal location:I mean I think it would be fantastic if the research cover could be a bit integrated into the areas that
we’re recruiting because I do think that it raises awareness.
P16, focus group 2So just in terms of improving it for the future, ‘cause we’ve said that there are multiple clinicians and
nurses involved and they change every 6 months. Training the clinicians.
P20, focus group 3We have got a big poster down there but maybe we need to think . . . of where it is. It’s on the
back wall.
P10, focus group 2Randomising pilot trial patients
The sealed-envelope method of randomisation was viewed as being simple and easy to use. During focus
groups, staff members were asked to use the voting handsets to indicate whether or not they felt that the
randomisation process could be improved. The majority (14/20, 70%) indicated that the randomisationJournals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 51process could not be improved. This view was shared by three out of seven (42.8%) staff who took part in
a telephone interview.© Que
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Park, SThe system is very much in place. I do like in ED the system where we use the sealed envelopes
because it’s quick and easy.
P23, telephone interviewProblems identified with the process included an envelope being opened in error when a child did not
meet the inclusion criteria or an envelope being opened too early. Staff stated that these issues occurred
at the start of the pilot trial when some site members who ‘didn’t really understand the process’ (P25,
telephone interview) were not completely familiar with the pilot trial protocol.
In one focus group, site staff stated that the treatment allocation had been misread. They suggested that,
for the FiSh trial, the allocation should be in larger, bold text on the case record form, so that there is no
doubt which treatment should be given:They [ED clinician] were very confident they had done the right thing, but from the paperwork, it obviously
was indicating they had not done the right thing, but they didn’t realise at all, because they felt, ‘we’ve
recruited them to FiSh, isn’t that great?’ And we’ve given the second bolus and then we reassessed them
and all of this, and it’s just such a great documentation but just unfortunately the wrong bolus.
P19, focus group 3One staff member described how their localised protocol for sepsis treatment differed from the pilot
protocol, which led to two patients being randomised in error:I think we’ve been slightly overenthusiastic, if that makes sense. So, our local protocol is currently very
heavily weighted towards lactates in sepsis, and if you’ve got high lactates, give fluid. Um, so we’ve
had two children that, as per FiSh randomisation criteria, haven’t fitted needing a second fluid bolus.
But as per our local sepsis protocol, have fitted being given a second bolus, i.e., their lactate hasn’t
improved. And people have I guess kind of rightly in the face of sepsis more than 20 kilo[gram]s let’s
randomise them into FiSh. But actually their cap [capillary] refill and their blood pressures have been
fine. So I think, that’s kind of local protocol fighting the FiSh protocol. It’s not the fault of FiSh, it’s just
it clashing with our local protocol.
P21, telephone interviewProtocol adherence
During the focus groups, staff members were asked to use the voting handsets to indicate whether or not
they had experienced any difficulties adhering to the pilot trial protocol. Of these, 6 out of 20 (30%) staff
indicated that they had experienced protocol adherence difficulties, whereas 5 out of 20 (25%) had not.
However, 9 out of 20 (45%) staff opted not to respond to the question using their handsets, although
insight was gained into protocol deviations at these sites through group discussion. Some staff (3/7, 43%)
who took part in telephone interviews described some difficulty with protocol adherence. In addition to
the randomisation issues described above, protocol deviations described by staff related to a lack of
equipoise and difficulties in administering fluid boluses within 15-minute cycles.
Lack of equipoise because of a belief that a restrictive fluid bolus resuscitation is safer
Descriptions of non-adherence to the 20-ml/kg fluid bolus allocated treatment indicated a lack of
equipoise among some staff. As the following quotation illustrates, some clinicians did not feel that it was
safe to give a patient the 20-ml/kg fluid bolus treatment allocation because of fears about fluid overload:I know that certainly one of the people who recruited said, ‘I recruited them and then thought, I really
hope that it’s not going to be 20 [ml] per kilo’.
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60The child was allocated to 10 or 20 [ml/kg], I think it was 10, but the doctor who was treating them
decided I don’t want them to have 10, I want them to have 5. Um, and it’s just, it’s just trying to get
that across where the 10 is safe, 20 is safe but you can’t deviate from what the protocol says.
P06, focus group 1There was the ICU [intensive care unit] consultant down there and the ED consultant, and there was a
problem with equipoise essentially, that they felt that, or they didn’t like the intervention so they just
went off, they just went off-piste, gave less.
P02, focus group 2As the following quotation illustrates, some staff had concerns about the safety of administering a 20-ml/kg
fluid bolus allocation to smaller children:I opened the envelope and it said 20 ml per kilo[gram] but at that time they’ve already decided 10 ml
per kilo . . . And I think the child was really quite distressed and was working really hard, the mum was
quite distressed so it was a very stressful situation . . . I think they would still have not given the 20 ml
because of her size and because of also at that precise moment she was working hard, you know,
I think they would have not . . . I don’t think it was clinically viable to give her 20 ml per kilo.
P26, telephone interviewSome staff suggested that smaller children (i.e. those < 3 kg) should be excluded from the FiSh trial:So the 2.1 kilo[gram]s, I suppose just raises issues with the very small ones, whether they should
exclude them in the next study.
P17, focus group 2But I think having 20 ml per kilo for babies which are like 2 kilos or 3 kilos, I think that itself is quite
difficult sometimes and we might probably have a lot more deviations. So that one size fits all, I think
personally doesn’t work.
P26, telephone interviewA few staff described the ‘clinical creep’ of a restricted fluid bolus resuscitation without scientific evidence,
highlighting the need to conduct the FiSh trial:It’s interesting the patient we failed to consent at the weekend, the registrar gave 20 ml per kilo and
then gave a further 10, rather than giving 20 and 20. I think that’s, you know, so what we’ve got
here is examples of clinical creep of lower volume fluid resuscitation in the absence of evidence. And,
I think, you know, it just highlighted for me that actually if we don’t do the study now, it’s going to,
you know, we’re never going to know. And so it was, and I think I can probably persuade a parent
about that, you know, that you just don’t know and we did the best.
P22, telephone interviewLack of familiarity with the trial protocol caused by low recruitment rates
There was some discussion in two focus groups about there being not enough children randomised for clinical
staff to become familiar with the protocol. This may be an additional factor contributing to protocol deviations:If you don’t get them coming through then people lose familiarity with the processes, however much
you know you train them.
P02, focus group 2Yeah. I mean that’s not trivial, ‘cause actually there’s something about the event rates being high
enough for enough staff being familiar with it. I think there were not quite as many as we hoped.
P02, focus group 2Journals Library www.journalslibrary.nihr.ac.uk
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Site staff were asked about the timing of the first fluid bolus administration after the randomisation envelope
was opened. Most stated that the bolus was administered promptly, often within 15 minutes ‘[be]cause
you’re wanting to get that bolus pretty quick’ (P06, focus group 1). Only one participant stated that they had
found it easy to adhere to the protocol because ‘the criteria and protocol are straightforward’ (P23, telephone
interview). Some spoke of how they had been initially concerned about being able to deliver fluid boluses
within the specified time frame and how they ‘changed their practice’ and had ‘gotten faster’ (P01, focus
group 1) at delivering the fluid bolus during the pilot trial. The majority of staff interviewed spoke of the
challenges that they had experienced in administering the allocated fluid bolus within 15-minute cycles. Staff
in one focus group stated that the 15-minute time frame did not intuitively fit with usual clinical practice:© Que
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Park, SGiving the bolus within 15 minutes of randomisation, I just don’t think that’s feasible. I don’t think I’ve
looked at the CRF for a single child who has actually been achieved within the 15-minute window.
P19, focus group 3Yeah, I mean that’s what I suppose I was referring to that process, trying to follow that protocol.
P20, focus group 3It’s challenging.
P18, focus group 3In real time doesn’t actually reflect practice.
P20, focus group 3I mean you were constantly reassessing right, but maybe not 15 minutely.
P19, focus group 3I think, yeah, so the rigid protocolisation of fluid therapy, although that was the way you were
supposed to, had to, do it for the trial process, doesn’t intuitively fit with clinical practice.
P20, focus group 3At two sites, staff described issues with the medical devices used to deliver a fluid bolus, such as a slow
pump or small cannula:Also we’ve got an issue at the minute in that our IVACs [IVAC® infusion pump (CareFusion, San Diego,
CA, USA)] will only . . . the fastest they go is 600 ml an hour, which isn’t fast enough for anybody’s fluid
bolus, whereas it used to go at 999 ml an hour. So that could give you, you know, your bolus every
15 minutes if you wanted. Whereas now the pumps are too slow, so I think people are resorting more
to pushing because the pump isn’t an option until they’re reconfigured. Honestly, this pump thing has
been a problem.
P08, focus group 1The calibre of the cannula allows it to be possible but you can’t necessarily push it that quickly in
through a cannula of that size in every child, depending on how it’s placed and things like that.
P18, focus group 3Case report form
Many staff stated that it was difficult to complete the CRF in ‘real time’ while they were focused on
resuscitating a child. Many felt that this had led to missing or incomplete CRF data, which were difficult for
research nurses to complete retrospectively:If they’re [ED staff] not recording things at the time that those boxes are wanting, then it makes it
difficult for us [research nurses] to know what to put in those boxes.
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62Many stated that research support in the ED was needed to help complete the CRF as, although the form
was ‘really straightforward’ (P24, telephone interview), it was difficult and ‘time-consuming’ (P23, telephone
interview) to complete while treating a critically ill child. As one ED clinician described, randomising and
treating participants over the weekend without research support was stressful:NIHRBoth of our patients were randomised at the weekends, so there was no research input whatsoever it
was all done off the back of the nurses that we had trained. Um, and so the only thing that they said
is that it’s just a very, very scary experience and that, you know, they’re still trying to concentrate on
the child. But they also want to get the trial right, so it’s a very stressful experience.
P25, telephone interviewSome staff suggested that additional training and experience of completing the CRF would help to
improve the quality of data entry, whereas others felt that changes should be made to the recording of
CRT to reflect a score rather than a number of seconds:You put your capillary refill time in like point whatever of a second. That isn’t how people measure it.
So that immediately put people off as a sort of first hurdle. And when you’ve sort of fallen at the first
hurdle, I think people lost trust with it.
P27, telephone interviewSuggestions were made to help improve the format of the CRF, including having specific sections to
complete in an emergency situation, as well as a clearer way of recording the time that a fluid bolus
was administered:It looks quite daunting, so maybe if there was a way of trimming it down so that only the bare
essentials that are needed from the emergency, and then the rest could be picked up retrospectively
from notes, from the research team. Which is kind of how we had to work the first one.
P25, telephone interviewOne comment would be just to allow for a time box at the top of each of those sections so that, you
know, I know it says 15 minutes but what time was that? Was it actually 15 minutes? And then that
would probably help you with the data collecting as well. Um, I don’t, I didn’t feel like a flow from
reassessing at the end of the 15 minutes to whether a trial bolus was given or not, I didn’t think that
was a natural progression.
P19, focus group 3Additional issues to consider for the FiSh trial protocol
Indices of shock: capillary refill time
Staff in one focus group questioned the use of CRT in seconds as an indication that a child was still in
shock and the quality of CRF data for this element of the pilot trial:I’m not quite sure how many people would have been using capillary refill [time] to help guide them
as to whether a child remained shocked or not, and I don’t know how much good data you’ve got
on the capillary refill time for all the children recruited.
P01, focus group 1No, noticed also our local early warning score observation charts, um when you record the cap refill
[time], if it’s recorded, it has a score rather than an actual number of seconds, so if it’s below 3 seconds
you score nought, if it’s above 3 seconds, so 3 to 4 seconds, you score one, or two or so forth. So it’s
not actually counting the number of seconds, so you don’t actually record um, a cap refill score, you
record an early warning score based off of them. Does that make sense?
P02, focus group 1Journals Library www.journalslibrary.nihr.ac.uk
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When staff members were asked to describe what they thought had been successful in the pilot trial,
many referred to communication between hospital teams and units:© Que
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Park, SI think the fact that we have had really good relationships with ED and with the Paed[iatric]s Team has
been really good.
P22, telephone interviewHowever, communication between hospitals and transfer teams was also one area which staff in one focus
group felt could be improved in the FiSh trial. As the following quotations illustrate, there is a need to keep
transfer teams informed when new sites open to recruitment:I think you have the staggered start with some of the sites. I think what’s confusing, the confusion I
think that from [transfer team name] end was knowing whether, say for example, [hospital] was live or
not live, ‘cause the poster just said these are the four hospitals, if you get a referral from any of these
four hospitals and they randomise the patient then you continue whatever is meant to be done . . .
But [hospital] wasn’t live for a long time, so teams that got referrals from [hospital] started asking
questions, saying, ‘oh have you randomised?’ And they didn’t know anything about it. It caused a bit
of confusion. I don’t know what the easy answer is.
P17, focus group 2Maybe we need to be better at communicating with you, which we probably should have done but
we didn’t.
P11, focus group 2Inclusion criteria
Two staff members suggested that a review of the inclusion criteria for the FiSh trial, if feasible, should
consider extending eligibility to include children who deteriorate on a ward rather than restricting eligibility
to children being randomised in the ED or PAU (or equivalent):So I guess in terms of feeding that back, thinking about that for a bigger study I guess what we should
think about . . . do we need to push out the window further to capture the patients that are the kind of
slow-burner patients that end up going to the ward and then collapsing maybe beyond the first 4 hours.
But then they haven’t been eligible to go into the study because they’re either beyond the first 4 hours,
they’re not in A&E [accident and emergency] anymore. So we need to think a little bit about that I think,
if there’s a bigger study.
P08, focus group 1Experiences of research without prior consent in the pilot trial
Staff involved in other NIHR-funded critical care research stated that they were ‘less daunted’ by the use
of RWPC in the pilot trial, as their previous experiences of such consent discussions with parents ‘had all
gone without a hitch’ (P21, telephone interview). Staff at one site stated that they did not have any initial
reservations about the use of RWPC in the pilot trial:It was going to be quite an interesting experience and we were all quite excited about it.
P25, telephone interviewHowever, the majority of staff involved did not have prior experience of RWPC and described their initial
anxieties about this consent method before the pilot trial began. As one PI described, the site team took
their time to consider the consent process before agreeing to participate in the pilot trial:We had to go through the process quite a lot, that was sort of the sticking point for the trial for quite
a long time until they understood why it’s working that way.
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64Many staff were concerned about how parents would react to being told that their child had been entered
into the pilot trial without their prior consent, particularly if their child was still ‘really sick’ at the time
of the conversation or ‘had died’ (P01, focus group 1). As described previously, the FiSh feasibility study
findings, which showed how parents support the use of RWPC in the FiSh trial, appeared to have alleviated
some initial staff anxieties:NIHRI think I, along with the majority of people, was quite anxious about the honesty with the parents to
begin with, was quite anxious about how they’d react, and I think the biggest thing that helped me
was hearing that there’d been views from parents that they actually were happy about it.
P20, focus group 3However, it was often the experience of conducting the pilot trial that helped to fully address any
remaining anxieties about the use of this approach to consent in the pilot trial. Staff stated that parents
had responded positively to the consent discussion and appeared to understand the reasons why informed
consent could not have been sought prospectively. Furthermore, staff confidence in conducting the pilot
trial appeared to increase over time:And obviously the first deferred consent . . . you know it’s the see one, do one, type thing and then
I think you realise, ‘oh, actually it is OK’.
P02, focus group 1Both of them [parents of two recruited patients] were really, really understanding and recognised why
we hadn’t asked them at the time.
P18, focus group 3But as time has gone on, people have bought into it more and more and more.
P02, focus group 1All staff supported the use of RWPC in the FiSh trial and thought that seeking prospective informed consent
in the ED or PAU (or equivalent) when a child was being resuscitated would not be acceptable to families.
Staff viewed the consent form as simple and easy to use. One focus group participant suggested that the
form should be one sided so that ‘nothing could be missed’ (P18, focus group 3). Finally, staff stated that
child assent had most often not been sought as children were ‘too young’ (P27, telephone interview), or
‘didn’t have the capacity’ (P19, focus group 3) to be involved in pilot trial consent discussions with parents.
Only one site member stated that ‘in retrospect, thinking about it, we should have thought to go back and
get assent from that child once she’d been woken up’ (P18, focus group 3).
Summary of parents’ perspectives in the pilot trial
The integrated perspectives study findings add to the feasibility work (see Chapter 2) to show that the trial
protocol was feasible and acceptable to parents. Consistent with the feasibility study findings and with
associated guidance on RWPC,18,19,26,27 some parents of children randomised to the FiSh trial were initially
surprised about the concept of RWPC. However, following tailored explanations from site staff about why
prospective consent was not sought, all parents stated that they supported the RWPC approach in the
pilot. Again, parents strongly valued the advancement of medical research and stated that they provided
consent as a way to help other families and children in the future.17,19,28,30,36,37
The use of the feasibility study findings to develop site staff initiation training on how to explain the pilot
trial, including RWPC, appeared to assist parents’ understanding in the pilot trial. Importantly, concerns and
misunderstandings about key aspects of the trial observed in parents who took part in the feasibility study
were not observed in the pilot trial sample. Parents of children who took part in the pilot trial recalled site
staff explanations about the nature of fluid bolus resuscitation and how this was standard care, not a new
or novel treatment for septic shock, and about the lack of evidence for current recommended practice
(i.e. 20 ml/kg). These verbal explanations, rather than written trial information, were prioritised by parentsJournals Library www.journalslibrary.nihr.ac.uk
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prior informed consent, and that their child’s safety would not be compromised, as both treatment arms
involved carefully titrated administrations of fluid. Nevertheless, researchers should bear in mind that parents
may struggle to voice their questions or concerns during research discussions.38,40 In line with previous
studies in this area, these findings should be incorporated into staff training to encourage site staff involved
in the FiSh trial to use open-ended questions and provide ample opportunities for questions,38,53 in order to
identify and respond to parental concerns.40,54
Importantly, trial acceptability and parents’ willingness to consent to their child’s information being included
in the pilot trial appeared to hinge, in part, on the nature of the trial and their child’s recovery.19,43 Not all
children who experience septic shock will make a full recovery; therefore, site staff should be prepared to
respond to parental questions or concerns related to the possibility that trial participation may have resulted
in harm.26,27 In line with our previous findings,19 parents viewed this study, involving variations in routinely
used fluid bolus resuscitation therapy, as safer than trials of a new drug or surgery, and therefore as an
acceptable study in which to use RWPC. Of added interest, several parents indicated that they consented in
order to help their child, and some revealed a preference for one fluid bolus volume over another. This may
indicate that parents did not understand that the optimal fluid bolus resuscitation volume for septic shock is
not known, and, therefore, any direct benefit could not be assured. We recommend highlighting this in staff
training programmes and including it as a key message to convey in consent for a full trial, if planned.
The professional background of the member of site staff approaching families for consent in the FiSh trial
did not appear to affect significantly trial acceptability and willingness to provide consent – provided that
adequate explanation was offered and familiarity was demonstrated with the child’s clinical case. Parental
accounts of the pilot trial consent process supports existing guidance for site staff to check appropriate
timing with the clinical team27 before approaching parents within 24–48 hours, when the acute situation
has resolved.17,19,30,38,41 Indeed, discussions during resuscitation were, for the most part, viewed as
inappropriate unless conversations were kept brief, or parents had explicit trial-related questions.
Importantly, some parents became distressed when first hearing that their child had been treated for septic
shock during the pilot trial discussion. We recommend that site staff check that a member of the clinical
team has spoken to parents about their child’s condition and treatment before discussing the FiSh trial.
To assist understanding and parent–practitioner communication, parents emphasised the need for clear
and concise written information materials alongside verbal tailored explanation.38,40 Similar to the findings
in other clinical trials,19,39 parents recommended amending language used in both written and verbal
explanations, and provided insight on what parents regard as appropriate language specifically in the
context of septic shock. This recommendation may be related to a recent increase in media coverage on
sepsis in children, with the term being associated with a high risk of mortality in children with severe
infection. As a result, terminology such as ‘suspected’ sepsis or ‘suspected’ septic shock may not have
been used sufficiently in the PIS and pilot trial verbal explanations. This small change to patient information
could reduce parents’ initial anxieties relating to the severity of their child’s illness.
Finally, parents provided their views about what outcomes are most important in children with severe infection.
In order of importance, parents reported that improvement in organ and physiological functioning, looking
and behaving more like their normal selves, improvement in clinical figures and less need for machines could
be used as indicators that fluid bolus resuscitation therapy was effective. Interestingly, these parents, who
were interviewed shortly after their children’s treatment for septic shock, prioritised shorter-term rather than
long-term outcomes, which were potentially most salient to them at the time of being interviewed. This is in
contrast to the prioritisation of longer-term outcomes, such as disabilities, by parents in the feasibility study
who were interviewed approximately 1 year after their children’s hospital admission. Child survival as an
outcome was rarely discussed by parents in the pilot trial sample, all of whom had children who had survived.
Such findings may suggest that parents’ prioritisation of outcomes may be influenced by their experience of
their child’s illness, the survival of their child and the point at which they are asked about outcomes of
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66into any future priority setting or core outcome set development work to ensure the selection and measurement
of outcomes that are patient centred.
Overall, these findings highlight the value of doing pre-trial research to inform approaches to recruitment
and consent in challenging trials.55 Incorporation of these findings into staff initiation training, approaches
to consent and information materials for the full FiSh trial, if recommended, will help parents to make
informed decisions about the use of their children’s information.
Summary of site staff perspectives in the pilot trial
Overall, findings demonstrated that site staff supported the pilot trial and were willing to screen, recruit
and randomise eligible patients to the FiSh trial. The study also provides new evidence in addition to the
existing literature18–20,27 that can be used by practitioners involved in the design, ethics approval and
conduct of children’s emergency care trials. Staff valued the FiSh pilot trial site initiation training, which
sufficiently prepared them for recruitment and approach to consent. Access to site initiation training
materials after the site initiation meeting helped PIs disseminate training across relevant departments
and teams, a model that can be replicated in the FiSh trial. Similar to previous studies,18,20 confidence in
conducting the pilot trial appeared to increase over the recruitment period, when staff became more
familiar with the screening, randomisation and consenting processes.
Some staff without prior experience of RWPC were initially anxious about being involved in the pilot trial.
Concerns were mainly related to how parents would react to being informed that their child had already
been included in the pilot trial without their prior consent, potentially affecting the parent–practitioner
relationship.20 The inclusion of FiSh feasibility study findings in site initiation training, which showed
parental support for the FiSh trial and its use of RWPC, helped to prepare staff for pilot trial consent
discussions with parents. However, in staff without previous experience of this method, it was often the
direct experience of conducting the pilot trial, and observing parents’ positive responses to the consent
discussion, that provided staff with full confidence about the acceptability of this approach to consent in
the FiSh trial. Consistent with previous findings,18,20 the views of practitioners with prior experience of
RWPC should be considered in the design and conduct of future paediatric critical care trials, which should
not focus solely on the beliefs of those without prior experience of this method of consent. Furthermore,
future research would benefit from audio-recording RWPC discussions20,56 to improve future training
by providing insights into how practitioners explain this to parents and to identify parental views and
concerns. Suggestions for improvements to the screening process for the FiSh trial included increasing
research support in the ED, ensuring that all relevant staff are fully trained when the medical staff rotation
occurs every 6 months, and ensuring that posters and study materials are placed in the optimal location.
The pilot trial recruitment process and inclusion criteria were described as being simple to follow in an
emergency situation. The majority of staff stated that the pilot trial randomisation process worked well,
and, although some protocol deviations had occurred, these often occurred in the first few patients
recruited at their site. Suggestions were made to improve the CRF for the FiSh trial. In addition to research
support in the ED to help complete the CRF, staff suggested that the form should be reformatted, so
that sections to be completed ‘in real time’ during resuscitation are clarified, or separated from sections
that could be completed retrospectively from medical notes. As shown in other studies, staff can find
recruitment difficult, with too many competing demands on their time,57 and this is particularly pertinent
in a paediatric emergency care situation. Additional training would be needed on randomisation and
CRF completion in a full FiSh trial, such as a simulation of the screening, randomisation and allocation
procedures in the FiSh trial site initiation training. A step-by-step guide, or video, might help to improve
the quality of CRF completion and, therefore, the quality of data obtained.
Staff found the administration of fluid bolus within the 15-minute time frame to be challenging. Although
some stated that they had changed their practice and had been able to administer fluid boluses more
quickly to adhere to the trial protocol, there were issues with medical devices (i.e. slow pumps and small
cannulas) used to deliver fluid boluses. Such medical devices would need to be reviewed in preparation for
the definitive FiSh trial.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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who had not adhered to the pilot trial protocol when a child had been randomised to a 20-ml/kg fluid bolus
allocation because of concerns about fluid overload. Some staff also described a ‘clinical creep’ of a tendency
to use restricted volume fluid bolus resuscitation without scientific evidence. Studies have consistently shown
that trial recruitment can be negatively influenced by staff perceptions and experiences, including the decision
not to recruit eligible participants because of a lack of equipoise with regard to particular treatments or
individuals.58–61 Although it appeared that only a small proportion of FiSh trial site staff were not in clinical
equipoise, it has been suggested by other studies that this number would probably increase in the light of
increasing use of one’s own preferred method of treatment and in the absence of forthcoming evidence.61
Moreover, previous findings suggest that the role and importance of equipoise may not always be fully
understood by all.60 Taken together, these findings highlight the crucial need to conduct the definitive FiSh
trial, incorporating explicit training on clinical equipoise, to identify the optimal fluid resuscitation volume for
children with septic shock, to achieve the best possible outcomes and to inform clinical guidelines and
practice in the NHS.
Overall, clear communication and ensuring that participants understand trial information and discussions
is a challenge for practitioners in many trials.62,63 This demonstrates the significant value and impact of our
findings for future trials by providing recommendations for the enhancement of staff training in preparation
for the conduct of ethically sound research in the paediatric critical care setting.Strengths and limitations
This study involved parents from 10 of the 12 hospital sites that took part in the FiSh pilot trial, and
staff from 9 of the 12 hospital sites that took part. Our sample size was relatively small. However, data
saturation was reached,22,23 and we involved parents with direct experience of their child being enrolled in
the FiSh pilot trial, as well as staff involved in recruitment and consent procedures. Data on whether or not
more than one parent agreed to take part in the questionnaire element of the study were unknown; thus,
a comparison of the consent rates for the interview element was not possible. We aimed to maximise
diversity within our qualitative sample by selecting for interview bereaved and non-bereaved mothers and
fathers who had consented and those who had declined to consent for the FiSh pilot trial, and doctors and
nurses, from both high-recruiting and low-recruiting sites. However, opportunities to purposively sample
fathers, bereaved parents and parents who declined to consent were limited as a result of high consent
rates, particularly among mothers, and no deaths in the trial. Therefore, our understanding of these groups
is limited and does not provide further insights beyond those described in the FiSh feasibility study (see
Chapter 2) on the acceptability to parents of RWPC when a child has died.
Interestingly, all questionnaires received were completed on-site and all parents interviewed reported that
they would be interested in taking part in future research. Therefore, our sample is likely to comprise
parents with an interest in research. Although a high proportion of participating parents were from the
highest recruiting site, interviews were purposively sampled across pilot sites to help ensure that there was
sample variance and to capture different recruitment experiences.
Our insight into the consent process was also limited by the subjective recollections of parents and
practitioners. Nevertheless, our qualitative data were strengthened by the integrated perspectives mixed-
methods approach, providing a multiperspective understanding of parents’ and site staff opinions and
experiences of RWPC, specifically in the context of the pilot trial.
As a final point, although attempts were made to include children in the discussion about the pilot trial,
child assent was not taken by any of the participating sites. Practitioners attributed this limitation to the
fact that children were often too young or too sick before discharge for a discussion about research. Thus,
there is a need to consider how children and young people with capacity might be informed and engaged
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Feasibility study
This was a qualitative interview study involving 21 parents (18 mothers and 3 fathers, and 7 of whom
were bereaved) with children admitted to a UK ED with presumed septic shock in the previous 3 years. The
study provided insight into the acceptability of the FiSh trial to parents. The majority of parents interviewed
were unfamiliar with RWPC, yet supported its use in the FiSh trial. Parents were concerned about the
change from currently recommended treatment, but were reassured by an explanation of the current
evidence base, the rationale for fluid bolus therapy and the monitoring procedures that would be in place.
Parents made recommendations about both the timing of consent and the patient information materials.
Bereaved parents suggested that site staff should not attempt to obtain consent immediately after a child’s
death, but supported a personalised postal ‘opt-out’ approach to RWPC for the FiSh trial. All parents
interviewed in this phase of the project would have provided consent for the use of their child’s data in
the FiSh trial, citing altruism as their main motive.
Parents also gave views on outcome measures that they considered to be most important in children with
severe infection. Parents commonly discussed the following outcomes: long-term effects, including health
and development; the child looking and behaving more normally; improvement in organ and physiological
function; less need for medications and machines; and survival.
Pilot trial
The pilot trial was conducted in 13 hospitals from July 2016 to April 2017. Inclusion criteria were children
presenting to ED with clinical suspicion of infection and shock after receiving 20 ml/kg of fluid. Children
were randomised to 10- or 20-ml/kg fluid boluses every 15 minutes for 4 hours if in shock. Exclusion criteria
were prior receipt of > 20 ml/kg of fluid, conditions requiring fluid restriction and full active resuscitation
not being within the goals of care. A number of potential end points were collected. Seventy-five children
were randomised: 40 into the 10-ml/kg fluid bolus group and 35 into the 20-ml/kg fluid bolus group.
Two children were withdrawn as their parents were unable to be approached to provide consent, but no
parents declined consent. Baseline characteristics were broadly similar, with some imbalance in age and
weight. The majority of children (59% in the 10-ml/kg fluid bolus group and 74% in the 20-ml/kg fluid
bolus group) required only a single trial bolus before shock resolved. The mean total volume of fluid received
(in ml/kg) was significantly lower in the 10-ml/kg fluid bolus group than in the 20-ml/kg fluid bolus group.
Fluid boluses were delivered in accordance with the protocol in 79% of children in the 10-ml/kg fluid bolus
group and 55% in the 20-ml/kg fluid bolus group. There were no deaths or SAEs. Overall, 29% were
admitted to PICU. Length of hospital stay, transfers to a PICU, length of stay in a PICU and days alive and
not in a PICU up to 30 days post presentation to an ED did not differ significantly between the groups.
Integrated perspectives study
This was a questionnaire, interview and focus group study involving all hospitals participating in the pilot
trial. Forty-five parents completed a questionnaire, 20 families and 7 site staff (3 doctors and 4 nurses)
were interviewed and 20 site staff (10 doctors and 10 nurses) participated in three focus groups. One-third
of parents were surprised to discover that their child had been entered into the pilot trial without prior
consent. Nevertheless, all parents supported the trial because they were reassured by explanations about
why prior informed consent could not be sought, the nature of fluid bolus resuscitation and lack of
evidence for current recommended practice. Parents suggested improvements to how the trial should be
introduced, including how ‘suspected’ sepsis should be emphasised. Parents prioritised shorter-term
physiological outcomes, such as reduced heart rate, over longer-term health outcomes, such as disabilities.
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70interviewed approximately 1 year after their child’s hospital admission. Child survival as an outcome was
rarely discussed by parents of children who took part in the pilot study, none of whom was bereaved.
Such findings may suggest that parents’ prioritisation of outcomes may be influenced by their child’s
illness experience, survival and the point at which they are asked about outcomes of importance in the
course of their child’s illness. These combined qualitative findings should be incorporated into any future
patient-centred outcome priority-setting exercise or core outcome set development work to ensure that
the selection and measurement of outcomes for sepsis research are patient centred. Site staff made some
suggestions to improve the protocol and the training package. There was a lack of equipoise among some
parents and some clinical staff who favoured a 10-ml/kg fluid bolus volume. However, overall, both clinical
and research staff supported the FiSh trial, with their confidence in delivering the protocol increasing
over time.Interpretation
The combined findings on whether or not the FiSh trial is both feasible and acceptable were that, in
general, parents whose children had been admitted to hospital with severe infection supported the
proposed FiSh trial, including the use of RWPC. The findings from the feasibility study were used to
develop the information sheets and consent forms, the pilot trial protocol, site initiation training and
outcome measures. Acceptability to families was confirmed by the findings from the pilot trial; although
two patients were withdrawn post randomisation, this was as a result of it being inappropriate to
approach the parents to obtain consent, and the remainder were consented into the study successfully.
The FiSh trial was seen to be acceptable by parents in the integrated perspectives study.
Logistical difficulties, including delays to local approvals, meant that the pilot trial started 6 weeks later
than expected, with the first site opening on 13 July 2016 rather than 1 June 2016 as originally planned.
Rather than all sites opening simultaneously, sites opened over a period of 4 months, with the final site
opening on 23 November 2016. The final two sites that were opened were replacements for two originally
planned sites that were subsequently found not to have adequate research infrastructure to support the
study. The delay in sites opening was mitigated as much as possible by extending the recruitment period
by 1 month; however, total study site months at the conclusion of the trial were 80 rather than 108.
This reduced the anticipated recruitment total from 108 to 80. In this challenging context, the trial was
successfully delivered, with screening logs showing 83 eligible patients across the study sites over the study
period. Out of 83 eligible patients, 75 (90.4%) were randomised. Nine of these randomised participants
were deemed to have been randomised in error (coincidentally, all were allocated to the 10-ml/kg fluid
bolus group). The main reason for this was one site applying its own criteria, based on lactate, to identify
children in shock rather than those specified in the protocol.
The intervention was delivered in accordance with protocol in the majority of participants. However, there
were a substantial minority of participants in whom protocol deviations occurred, with more deviations in
the 20-ml/kg fluid bolus group than in the 10-ml/kg fluid bolus group. One reason for non-adherence was
that some clinicians may lack equipoise, apparently preferring restrictive 10-ml/kg fluid boluses in some
scenarios, despite 20 ml/kg being the current recommended practice. There were also difficulties delivering
the 20-ml/kg fluid boluses within 15 minutes. Furthermore, the randomised population were also
significantly less unwell than expected when the study was designed, with only a minority of patients
receiving more than one fluid bolus or being admitted to a PICU.
These findings were further supported by the integrated perspectives study, which indicated that the FiSh
trial was acceptable to parents and site staff involved in the pilot trial, although some problems with
equipoise were revealed. If a definitive trial was to be delivered, the findings would have been used to
improve site initiation training and to refine the study protocol, aiming to increase the confidence of site
staff in screening, recruitment and consent, and to help parents to make informed decisions about the use
of their child’s information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Feasibility study
Overall, the findings supported the proposed FiSh pilot trial, including the use of RWPC. Although the
sample size was small, data saturation was achieved and, importantly, both bereaved and non-bereaved
parents were included. However, as the majority of parents were recruited via social media, our sample
may have comprised parents with a pre-existing interest in research and may not be representative of
the parents of children who might be recruited in a trial. Additional qualitative research was therefore
conducted within the FiSh pilot trial to confirm the findings in the feasibility study and to understand the
perspectives of site staff.
Pilot randomised controlled trial
The pilot trial was successfully delivered, with screening logs showing that > 90% of eligible patients were
recruited. Twelve patients were ineligible as a result of receiving > 20 ml/kg of fluid; the opportunity may
have been missed to randomise these patients earlier. It is also possible that these may have represented
a subset of sicker patients. Despite the logistical challenge posed by setting up 13 study sites for a short
pilot, recruitment was very close to the target of one child per site per month. The process of RWPC
worked smoothly, although it was not tested in the emotional aftermath of a child’s death, as, thankfully,
no patients died during the course of the study. The intervention was by and large delivered successfully,
with good separation being achieved in terms of volume of fluid delivered. Potential outcomes were
successfully collected as part of the trial data collection, with more data coming from the linkage with
PICANet. Some participants had missing data from the PICU stay because of referral to a PICU that was
not in the pilot trial. It would be vital to have local approvals for all PICUs for a larger trial.
However, there were significant logistical problems in setting up some of the smaller study sites, two of
which were discovered during this process to have inadequate research infrastructure to support the study.
This necessitated the recruitment of another two sites in the middle of the pilot trial. Although the overall
recruitment rate was just under the anticipated recruitment rate of one patient per site per month,
with a final rate of 0.9 patients per site per month, recruitment was driven mainly by three study sites
(Southampton, Chelsea and Westminster, and Bristol), which between them recruited 38 participants.
The remainder of the study sites struggled to recruit more than a handful of participants each.
In the event of a larger study looking at fluid bolus volumes being undertaken in the UK, it would be
important to consider those sites that might be best suited for such a study. These would probably be
large university hospitals with a children’s ED, an integrated PICU/high-dependency unit and good
pre-existing research infrastructure, rather than small district hospitals.
Most importantly, the population was not as unwell as expected. The mean PIM2r score (a PICU severity of
illness score giving a population risk of mortality) was 2.1%. There were 51 out of 73 (70%) participants
who required only one study fluid bolus and only 8 out of 73 (11%) participants required more than
two study boluses. Only 21 out of 73 patients (29%) were transferred to a PICU. All the participants
survived. Furthermore, despite many guidelines suggesting that elective intubation and ventilation should
be considered when ≥ 40 ml/kg of fluid has been administered in this clinical setting, because of the risk
of pulmonary oedema, out of the 46 children who received ≥ 40 ml/kg (±10%) of fluid, including the
20 ml/kg pre randomisation, 16 were transferred to a PICU. Thus, not only were the participants less
unwell than expected, but many of those who were apparently unwell enough to merit referral to a PICU,
or discussion with a PICU retrieval team, improved and remained under the care of general paediatricians.
As the intervention was not blinded, it is possible that potential outcome measures, such as admission to a
PICU, may be subject to bias either directly through knowledge of the allocated treatment (performance
bias) or through the decision to admit to a PICU being influenced by treatment factors including the
volume of fluid received. It was not considered practical to blind clinicians to the allocated treatment in
the ED setting.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71
DISCUSSION AND CONCLUSIONS
72Overall, the pilot trial was successfully delivered. However, there were more protocol deviations in the
20-ml/kg fluid bolus group than in the 10-ml/kg fluid bolus group and qualitative data implied that some
clinicians may lack equipoise. The randomised population was less unwell than expected and only a
minority of participants received more than one fluid bolus or ended up in a PICU. Thus, the trial as
currently conceived is not feasible.
Possible reasons for the patients being less unwell than expected in this study are explored below.
Integrated perspectives study
This study involved parents from 10 of the 12 hospital sites that randomised participants to the FiSh pilot
trial and staff from 9 of the 12 hospitals. Although the sample size was relatively small, data saturation
was reached. However, opportunities to sample fathers, bereaved parents and parents who declined to
consent were limited, as only one father consented to be interviewed, all children recruited into the pilot
trial survived and no parents declined consent. This limits our understanding of these groups and means
that firm recommendations cannot be made on how to conduct RWPC when a child has died. However,
our qualitative data were strengthened by the integrated perspectives mixed-methods approach, providing
an overall understanding by investigating the experiences and opinions of both parents and site staff.
Although attempts were made to include children and young people in the discussion about the pilot trial,
child assent was not taken by any of the participating sites, because children were either too young or too
sick before discharge for a discussion about research. Thus, children’s views on the FiSh trial remain unknown.Overall results in context
Parent and site staff perspectives: research without prior consent
Our findings add to the existing literature on RWPC in paediatric emergency and critical care settings: they
provide an important contribution and demonstrate the value of using qualitative methods in considering
the family-centred parameters needed to inform the design and conduct of challenging trials.53,64
Other studies looking at fluid bolus therapy
Current guidelines recommend aggressive fluid resuscitation in children with severe sepsis and septic
shock. The latest ACCM-PALS guidelines65 recommend rapid fluid bolus resuscitation (of 20 ml/kg, up to a
total of 60 ml/kg over the first 15 minutes) during the first hour of emergency assessment and treatment.
The literature supporting the ACCM-PALS recommendations consists of retrospective studies involving
small numbers of children.6–8 There are no data from prospective clinical trials. However, there is now
increasing evidence that fluid overload in critical illness is deleterious. In Africa, the recent FEAST9
multicentre RCT reported a 30% increase in mortality associated with fluid bolus resuscitation. A recent
systematic review66 identified only one RCT, other than FEAST, that investigated different size fluid
bolus therapy in children presenting to EDs in septic shock.13 This was a single-centre study in India,
randomising 147 children to 40 ml/kg of fluid over 15 minutes followed by dopamine, compared with
20 ml/kg of fluid over 20 minutes up to a maximum of 60 ml/kg over 1 hour followed by dopamine.
No difference was found in any outcome measure between the groups, although the 40-ml/kg fluid bolus
group had a higher incidence of hepatomegaly than the 20-ml/kg fluid bolus group, indicating
fluid overload.
Thus, at the time of writing, the optimum strategy for fluid bolus resuscitation in children with septic shock
remains unknown in the developed world. One paediatric fluid resuscitation RCT, other than the FiSh trial,
is currently in progress. The SQUEEZE14 trial is a Canadian RCT that is comparing fluid with early inotrope
therapy. Results are eagerly awaited. In PICU, many observational studies67–70 have recently shown that
fluid overload is associated with morbidity and mortality in a variety of clinical settings.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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clinician equipoise in the UK, with a preference for less generous fluid boluses than those recommended in
the current guidelines already entering routine clinical practice. Further work is thus required to confirm
equipoise still exists before a large-scale trial of fluid bolus volumes is undertaken in the UK.
The impact of vaccination
Only 32 out of 73 (44%) participants in this study had a confirmed bacterial infection in a sterile site
or a viral infection. Of these infections, 18 were viral, the majority of which were respiratory and likely,
therefore, to have minimal cardiovascular dysfunction. Thirteen participants had confirmed bacterial
infection in sterile sites, only one of which (a single case of meningococcal sepsis) was preventable by a
vaccine. Such results would until recently have been impossible to imagine – that, over a 9-month period
in the winter in 12 UK EDs, so few children would present with confirmed bacterial sepsis. A few years
ago, the incidence of meningococcal and pneumococcal sepsis, in particular, was much higher (about
600 cases of group B meningococcus were reported in 201371). Although more recent absolute figures are
not available, the incidence is now much lower, following the introduction of group B meningococcal
vaccination in September 2015. Since then, there has been a 50% incidence rate ratio reduction in group B
meningococcal cases in vaccine-eligible children.72 The incidence of group C meningococcal infection
was already very low following the introduction of the vaccine in 1999. In relation to pneumococcal
disease, in 2006, a seven-valent vaccine, pneumococcal conjugate vaccine (PCV7), was added to routine
childhood immunisation, and in 2010 a PCV containing polysaccharide from 13 common capsular
types (PCV13) replaced PCV7. Before the introduction of PCV7, the mean annual incidence of invasive
pneumococcal disease was 44.4 per 100,000 children < 2 years of age, with a mean case fatality rate of
3.5%. Following the introduction of PCV7 and now PCV13, the mean annual incidence of invasive
pneumococcal disease is currently at around 10–12 per 100,000 children. The impact of the comprehensive
childhood vaccination now offered in the UK on vaccine-preventable infections cannot, thus,
be understated.
Furthermore, there has been a recent trend in many hospitals to implement ‘sepsis bundles’ to help
staff recognise and manage early sepsis. In the UK, evidence-based guidelines for recognition and early
management of children with sepsis have been produced and disseminated by the National Institute for
Health and Care Excellence (NICE).73 Thus, it is also possible that some children presented early to the ED,
were recognised early, treated promptly and responded to treatment. This would reduce the severity of
illness in the population as a whole and also reduce the need for fluid bolus therapy. Unfortunately, data
that might determine whether or not this was the case were not collected as part of the FiSh feasibility
study; hence, this possibility must remain a speculation.
Overall, it is most likely that vaccination, and possibly improved recognition and management of early
sepsis, is the cause of both the unexpected low severity of illness of the population of children randomised
into the FiSh pilot trial and the difficulties many sites had in recruiting more than a handful of participants.Measurement against the progression criteria
Progression criterion 1l
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Park,Formal sign-up of sites (the required number of hub-and-spoke models) to achieve the overall sample
size based on the observed recruitment rate, as determined by the pilot trial objectives concerning
identification, recruitment rate, acceptability of deferred consenting procedures, selection of the
patient-centred primary outcome measure and sample size estimation.
Response: qualitative work showed that there was buy-in for the FiSh trial, but as a result of the full
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74Progression criterion 2l
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l
NIHRThe recruitment rate achieved in the pilot trial (taking into account the loss of participants as a
result of declining deferred consent) was consistent with achieving the overall sample size required
(as determined by the objectives concerning selection of the patient-centred primary outcome measure
and sample size estimation) in an acceptable time frame from the sites giving formal sign-up in the first
feasibility objective.
Response: the overall recruitment rate in the pilot trial was very close to anticipated, although there
was considerable variation across sites. However, the severity of illness of the participants recruited
was much lower than expected and, if the inclusion criteria were to be changed to restrict to a more
severely ill cohort, then the number of eligible children would inevitably be reduced and the feasibility
of completing recruitment in an acceptable time frame may be brought into question.Progression criterion 3At least 80% of fluid bolus resuscitation in the external pilot study was delivered at the correct volume
and timing, ± 10%, as determined by the external pilot study objective concerning adherence.
Response: adherence to both volume and timing was close to achieving the 80% threshold in the
10-ml/kg fluid bolus group but was substantially worse in the 20-ml/kg fluid bolus group, suggesting
that, despite current recommendations, rapid infusion of 20-ml/kg, fluid boluses does not represent
current usual practice in the UK.Progression criterion 4The absolute total volume of fluid administered during the first hour and during the first 4 hours
is lower (by ≥ 25%) in the more restrictive fluid bolus resuscitation group than in the current
recommended fluid bolus resuscitation group, as determined by the external pilot study objective
concerning separation.
Response: the absolute total volume of fluid administered during the first hour was only 7% lower in
the 10-ml/kg fluid bolus group than in the 20-ml/kg fluid bolus group, and by the end of the 4-hour
intervention period it was 23% lower. However, once imbalance in children’s weights between the
groups was taken into account, this criterion was achieved, with the volume of fluid (in ml/kg) being
35% lower in the first hour and 44% lower over the entire 4-hour period.Recommendations for research
Recommendation 1: the definitive FiSh trial, with its current design, should not
be conducted
The full FiSh trial, with the current design, is not feasible, for the reasons given above. However, the
optimal volume for fluid bolus resuscitation in the developed world remains unknown and infection is
still an important cause of death in young children, even in the post-vaccine era. Thus, it may be that a
different trial, with different inclusion criteria, or a different intervention, would be feasible and would
answer this question. Possibilities might include adjusting the inclusion criteria to randomise patients
to the trial only after receiving 40-ml/kg fluid bolus resuscitation, to select a more unwell population.
Disadvantages of this approach would be the lower number of eligible patients in each centre and the
difficulty in achieving separation. Alternatively, an intervention that compared usual management with a
fluid-sparing/early inotrope arm, such as that currently being tested in the SQUEEZE trial,14 might have
more chance of success.Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta22510 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 51Recommendation 2: further observational and epidemiological research should
be conducted
Further observational and epidemiological research is required, both in EDs and in PICUs, to determine
both current management and if there is still a population of children in the UK in whom a study looking
at fluid bolus volumes could usefully be conducted. This would require the prospective collection of data
on children presenting to EDs with suspected sepsis. In order to succeed, such a project would need a
collaborative approach involving paediatric EDs, Acute Paediatric Units and PICUs. In relation to PICUs,
it should be possible to perform an audit, linking to – and using – PICANet data collection systems, to
determine the number of children on PICUs with severe sepsis and septic shock, where they are being
admitted from (ED or ward) and their comorbidities.
Recommendation 3: further understanding of the moving clinical landscape is needed
Further qualitative work is required to determine whether or not clinical equipoise still exists among
front-line professionals dealing with acutely ill children in relation to the research question. Our data seem
to suggest that the equipoise, which previously existed, may already be lost in favour of clinicians using
smaller, more limited, fluid bolus volume resuscitation than that currently ‘officially’ recommended. This
may be a consequence of the FEAST9 trial or of smaller observational studies demonstrating a link between
fluid bolus administration or fluid overload and poor outcomes in critically ill children.© Queen’s Printer and Controller of HMSO 2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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ionalCould you give me an outline of what happened to your child for them to need
emergency treatment for severe infection?
Do you know if your child was given a fluid bolus?
Have you ever heard of a clinical trial before?
Have you ever been asked if your child could take part in a clinical trial?Participant information Looking at the information sheet, are there any parts of the study that you think parents
may find difficult to understand?
Would you have any questions about the FiSh trial?
Would you have any concerns about the FiSh trial?Consent decision-making Are there sections of the FiSh information sheet that you would prioritise when making
your decision about whether or not to consent?
How much time would you need to consider the information before making a decision
about the FiSh trial?Approach to consent (Following the description of RWPC, given in Chapter 2, Box 1)Have you ever heard of RWPC before?
What do you think about the use of RWPC in the proposed FiSh trial?
When do you think is the best time to approach a family to discuss the FiSh trial?Participation Would you have given your permission for the use of your child’s data in the FiSh trial?
(Prompt) Could you tell me a bit more about your reasons for this?Outcome measures Thinking about your experience of your child being admitted for a severe infection, what
would you hope the fluid bolus would do to help your child? (Prompt: what effect would
the treatment have to be useful?)
What would you be looking for as an indicator that your child was getting better?
What do you think about the outcome measures (recap the measures identified by
literature review)? Is there another outcome measure that you think is important to
families that we should be collecting information about in the FiSh trial?For bereaved parents only What do you think about approaching parents for consent for their child’s data after their
child has passed away?
What advice would you give doctors and nurses on how to go about approaching
bereaved parents for consent for the FiSh trial?
How do you think this should be done? (Prompt: explore face to face, telephone
call, letter)
When do you think is the best time for doctors and nurses to approach bereaved parents
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but some initial
concernsLogical solution At first I was like ‘What? You’d do that without even
finding out if it was OK?’ And then I kind of thought about
it and actually that does make sense
P15, mother, bereavedI had absolutely no problem with it [RWPC]
P2, mother, non-bereaved, prior experience of RWPCIt totally makes sense because as a parent that’s been
through it, if they had come and asked us lots of different
questions it probably would have brought up a lot more
questions, which would have resulted in the subsequent
delay in treating [child’s name] . . . and at that time there
wasn’t a lot of time to kind of faff about telling us things.
So yeah, it totally makes sense
P15, mother, bereavedAcceptability dependent on
nature of the trialIt depends what they’re actually doing . . . When it’s your
child, I think as long as it isn’t sort of sold as part of
an experiment
P6, mother, non-bereavedI mean I don’t have any issues with it. The only concern
would be that I would want to know if you’ve done
something without my consent has there been an impact
on him in a negative way . . . Would it have altered
anything? And if you can give me assurances around that,
I can’t see that there’s any risk either way
P10, mother, non-bereavedSupport for the FiSh
trial, but some
concerns and
misconceptionsOutcome dependent I wouldn’t have had a problem at all if someone had come
to me a few hours afterwards and said, ‘Can we use the
information?’ . . . I’d have been quite happy that she’d have
been involved in the trial because I know that obviously it’s
worked and she’s better
P4, mother, non-bereavedPersonally, if she had stabilised then yeah, that would be
fine . . . If I thought she was touch and go and she was
being used as a trial perhaps then I would feel ‘hang on a
minute . . .’ Because you want anything you can cling onto.
A reason or anything. So I would think what is the reason
that she didn’t survive, was it because she was given 10
and not 20?
P19, mother, bereavedMisconception: current
practice has been proven
to be effectiveI think you just want the tried and tested, don’t you? It’s
the difference between saying well we can put a plaster on
this, or not put a plaster on it. I would be like well, what do
you normally do? Well, we normally put a plaster on it.
Well, put a plaster on it then
P6, mother, non-bereavedObviously we know 20ml/kg works . . . That’s the thing,
isn’t it? It’s like, well why are you changing it if it already
works?
P21, mother, bereavedt al. under the terms of a commissioning contract issued by the Secretary of State for
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96ThemeIHR Journals Library www.journSubthemealslibrary.nihr.ac.ukExample quotationsMisconception: more fluid is
betterTo me it was just give her as much as you can, that’s what
was in my mind. They kept saying another bolus, another
bolus. In my mind, that was what was saving her life
P1, mother, non-bereavedUltimately at a rate of doing it 20 ml per kilo, obviously they
might stabilise faster
P21, mother, bereavedTailored explanation is
important to address concerns
and misconceptionsThat’s quite important, I think . . . reiterating that the fluid
treatment is part of a package of things and that it’s not
necessarily the be all and end all of the treatment
P17, mother, bereavedI think hearing those two points, the two key points around
there being limited or no evidence really that the way we’re
doing it is the right way . . . I think that would definitely
sway me to take part
P2, mother, non-bereavedI’d be quite happy that they’d keep an eye on things and
keep monitoring closely
P4, mother, non-bereavedUnclear or missing study
informationI mean it’s changed when you said he would have had the
standard treatment anyway and then they would go on to
the trial. I suppose if it’s emphasised that everyone gets the
same initial treatment, the emergency treatment . . . that
would be easier
P16, father, bereavedIf he was randomly selected to only have the 10ml which
is, you know, not with what the guidelines go with at the
moment, would he have been constantly monitored and
would that amount have been increased if they thought it
was necessary? Or would they have just rigidly stuck to
their guns? That sort of thing I think would have run
through my mind
P17, mother, bereavedDoes it say anywhere what the bolus actually does? That
might be something, ‘cause I was thinking I don’t really
know. I clocked that the idea is to reduce it but not actually
what it does
P13, mother, non-bereavedI just wondered if the 20ml has to be given over a certain
amount of time?
P17, mother, bereavedNot voicing concerns I think generally . . . your child’s ill, somebody takes them
off you and knows what they’re doing, you just kind of let
them deal with it. You don’t get too involved other than
just asking how they’re doing, but you don’t necessarily
voice concerns
P5, mother, non-bereavedI don’t think it would be at the forefront of what’s going on
to question the doctor
P11, mother, non-bereaved
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National Institute for Health Research, EvaluatioExample quotationsApproaching non-
bereaved parents for a
RWPC discussionTiming I think it’d be very much dependent on the actual time . . .
if I was asked this once my child was stable, I’d know . . .
he’s OK . . . before that point I’d have probably found it
quite hard to make any decisions
P5, mother, non-bereavedBeing in that stressful situation, I don’t think it would
benefit the parent or the staff that are having to ask these
questions . . . Once a parent’s a bit calmer, it literally will
open up a whole different world to you guys
P11, mother, non-bereavedThe real first 24 hours might be too soon possibly, because
emotions are running high and you know, there’s a lot of
new, strange things happening. It might be a little bit much
to ask at that point
P7, father, non-bereavedGauge on a case-by-case
basisI think that’s probably where it would be down to each
individual, you know, case by case . . . it’s always going to
be a difficult position but people react completely different
to their child being in that sort of environment . . . So I think
it would be about the timing, and some degree of
judgement on behalf of the medical staff to actually ask,
‘Can this person reasonably given consent at this time?’
P10, mother, non-bereavedApproaching bereaved
parents for a RWPC
discussionPrepare for parental concerns
about RWPCI think probably my only concern is, as a bereaved parent,
you are always looking for a reason as to why it happened.
And it possibly would lay the door open for people to go
‘You did it wrong, you shouldn’t have done that.’ That’s my
only concern. It gives you angle – it’s the doctor’s fault
because they did this and they didn’t ask me
P21, mother, bereavedRWPC is acceptable as a way
to help othersIf it helps one other family, it’s fine by us. At the end of the
day that’s what it’s about. We can’t bring our [child] back
and if this helps one other child not go through the
suffering, the pain, that’s fine by us. I would just say just
get on with it. Just do it
P14, father, bereavedTo be honest, I am so desperate to help, or if [child’s name]
information can be used in any way . . . If it could help stop
it happening to someone else, or help understand why,
I would be happy for them to use it for research without
confirming it first. For me, I can’t think of any negatives
P19, mother, bereavedDo not approach in hospital I don’t think you should do it straight away. I don’t think it
should be done in hospital. It’s just an overwhelming
experience is all I can say. And then to have that, you won’t
take it in, you won’t understand. You’ll be more angry that
your child is dead and they did this and they didn’t tell you
P21, mother, bereavedOn the day, I think you’re more likely to get parents who
will want to opt out. And I think that you will get more of
an opt-out the earlier that you do it
P17, mother, bereavedAcceptability of postal contact
and ‘opt-out’ approachI think a letter is the right way round but with a lot of
sensitivity in the way it’s worded because it will come as a
shock to families
P18, father, bereavedt al. under the terms of a commissioning contract issued by the Secretary of State for
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associated with any form of advertising. Applications for commercial reproduction should
n, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
97
APPENDIX 4
N
98ThemeIHR Journals Library www.journSubthemealslibrary.nihr.ac.ukExample quotations
I think the opt-out rather than the opt-in is fair because I
think if it’s an opt-in situation, you’re going to lose the
data. And I think by opting-out you give the people, if they
have strong feelings the other way, you give them
that option
P16, father, bereavedCould you make that in like bold or underlined or
something, that they will be included? Because it’s quite
often that when you receive something like that you’re like,
well, if you don’t get in touch then that’s it, you don’t get
included. Whereas you’re saying actually if we don’t get in
touch with you, you are being included in it. And I think,
yeah maybe that little bit could be highlighted
P15, mother, bereavedImportance of
parent–practitioner
relationshipsDepending on your stay, you become quite familiar with
certain nurses and you do have a rapport with them. And I
think some, from our point of view, some nurses we would
definitely have accepted letters from them probably a bit
better than from other nurses
P15, mother, bereavedPatient-centred
outcomes(1) ‘Getting better’
(e.g. looking and behaving
more like their normal selves)Actually, when she was in the PICU, one of the things for
me, being not medical, was looking more like herself, if
that makes sense. To me that was the big measure of she
was getting better
P13, mother, non-bereaved(2) Survival Well I guess for me he was in a critical situation, so it was
just about getting him to survive at that stage
P10, mother, non-bereaved(3) Organ/physiological
functioning (e.g. blood
pressure, temperature and
heart rate)Temperature was always a big one. It showed that he was
getting better to me
P21, mother, bereaved(4) Long-term effects
(e.g. disabilities, long-term
health and development)The fact there would be no problems in the future because
that’s what you worry about, the long-term future things.
So, whether there’ve been any other repercussions because
of the infection is a big thing I think
P4, mother non-bereaved(5) Time spent on machines
and medicationsBy the third or fourth day all her drugs were getting
reduced and she was slowly coming off the machines,
so sort of we knew then that she was making a recovery.
So maybe how long they’re on a machine
P3, mother, non-bereaved
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admission experiencel
l
l
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l
l
l
l
l
l
l
l
l
HMSO
ay be
wled
ry, NaSo just to get a background of what happened, what first prompted you to seek medical help
when your child became unwell? (Prompt: explore what happened, how they were admitted
to hospital)
In which hospital did your child receive treatment in the FiSh pilot trial? (If not already stated)
Did the doctor tell you what had caused the illness? (Prompt: diagnosis)FiSh pilot trial
consent processWould you mind if I start by getting an overall picture of what happened when you first heard
about the FiSh pilot trial . . . could you tell me a bit about that?
Could you tell me what the nurse or doctor explained to you about the FiSh pilot trial?
Was there anything that you found: (a) unclear; (b) surprising?
Could you tell me about any written information you were given by a nurse or doctor about
the pilot trial?Consent in the
emergency settingDuring the actual treatment in the room where your child was in the ED, did you ask any
questions about the study?
What did you think when you found out that your child had already been entered into the
pilot trial before you were approached by the doctor or nurse about your consent?
Did you have any concerns about this method? If so, could you tell me a little bit more about
these? (Prompt: did you raise these concerns with a practitioner? If so, were they addressed/
alleviated and how? If not, why?)
Did you have any concerns about your child taking part?Decision-making Is there anything that sticks out in your mind about the discussion? (Prompt: was the research
discussion the first mention of the word sepsis or septic shock? How did that make you feel?)
This is a question I ask all parents and it’s not a test, but just so we can gauge whether the
pilot trial is being explained clearly enough, I wanted to know whether you could you tell me
what the FiSh pilot trial was looking at?
Did a doctor or nurse explain to you what a fluid bolus was? Again, this is not a test, but from
these conversations, how did you understand, or how can you best explain, what a fluid
bolus is?
Would you mind telling me what were your reasons for (providing consent/not
providing consent)?Decision-making
(those who did
not consent to
participate in the
FiSh trial)Would you mind telling me your reason for saying no to the pilot trial?
Did you worry about how the doctor or nurse would respond?
How did they respond?Outcome measures Thinking about your experience of your child being admitted for a severe infection – what
would you hope the fluid bolus would do to help your child? (Prompt: what effect would the
treatment have to be useful?)
What would you be looking for as an indicator that your child was getting better?Child assent (not for
bereaved parents)Did the nurse or doctor explain the FiSh pilot trial to your child and give them an information
sheet to seek their permission to take part? (Prompts if yes: could you tell me a bit more about
that? Do you think they understood the information they were given? Did they give their
permission to take part? Did they ask any questions?)
Did the nurse/doctor give you an information sheet to help you discuss the trial with your child
when you got home? (Prompts if yes: did you discuss the FiSh pilot trial with your child? Could
you tell me about that?)2018. This work was produced by Inwald et al. under the terms of a commissioning contract issued by the Secretary of State for
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only(If received letter in post)l
l
l
l
l
l
rnalsHow long after leaving hospital did you receive the letter about the FiSh pilot trial?
How did you feel when you first read the letter about the FiSh pilot trial?
Was this the first time you had heard about the pilot trial?
Do you think that it is OK for doctors to send a letter to bereaved parents about their child’s
involvement in a trial, or would you have preferred to have been told about the trial before
you left hospital?
What advice would you give doctors and nurses on how to go about approaching bereaved
parents to discuss FiSh before they leave hospital?
When do you think is the best time for doctors and nurses to approach bereaved parents for
deferred consent?
How do you think this should be done? [Prompt: explore response and options including letter
(explore time frame), in person (who) and telephone call]llibrary.nihr.ac.uk
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HMSO
ay be
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ry, NaWho did you receive your FiSh site training from? 1: trial team, 2: PI or member of your site
team, 3: both
Do you think the FiSh site training prepared you for recruitment and consent in FiSh?
1: yes, 2: no
What could be improved if we went to a larger study?
Did you use any additional training or resources to prepare for FiSh?Screening When do you start screening? (Prompt: do you start during admission phone call?)
Do you screen patients you may have missed?
Do you think the screening process could be improved? 1: yes, 2: no (Prompt: discuss
potential challenges to screening or systems that have been put in place to assist screening)Randomisation Overall, how do you think the randomisation process has been going so far? Any problems?
Where do you open envelopes? (Prompt: explore: is this in view of parents? If no, why?)
Have any parents asked about FiSh in resus? If yes, what questions have parents asked in
resus? If yes, could you tell me what happened? (Prompt: explore whether or not parents
directed to poster/leaflets)
Do you think the randomisation process could be improved? 1: yes, 2: no. (Prompt: discuss
potential challenges to the randomisation process or anything that has been put in places to
assist randomisation)Protocol deviations Have you experienced any difficulties in adhering to the protocol? 1: yes, 2: no
What is your understanding of the inclusion/exclusion criteria?
Have you experienced difficulties with applying the inclusion/exclusion criteria? (Prompt:
if yes, could you tell me a bit more about what the major barriers have been? Are they clear,
too broad, too restrictive?)
When was the first study fluid bolus delivered in relation to the time of randomisation? What
was the time that shock was (re-)confirmed? (Prompt: explore minimum and maximum
time frames)
Have there been any barriers to delivering the intervention? (Prompt: explore lack of equipoise,
inadequate training, protocol or CRF overly complex or difficult to follow)Recruitment and
consent in the
FiSh trialBefore FiSh, did you have any experience of RWPC? 1: yes, 2: no
Have your views about RWPC changed over time? 1: yes, 2: no. (Prompt: if yes, could you tell
me a bit more about that? At what point did they change before/after SIV? After experience
of RWPC?)
How have parents reacted to finding out that their child has been entered into a clinical trial
without their prior consent? Have any parents been angry/upset etc. – what happened?
Is there anything that you find particularly difficult about explaining FiSh to parents?Completing forms Is the CRF easy to use? 1: yes, 2: no. (Prompt: How can it be improved? Explore layout, data
points, who completed it, i.e. front-line staff prospectively or research team retrospectively
or both)
Is the consent form easy to use? 1: yes, 2: no. (Prompt: how can it be improved?)lresus, resuscitation; SIV, site initiation visit.
Note
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